adenosine diphosphate has been researched along with clopidogrel in 425 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (0.94) | 18.7374 |
| 1990's | 26 (6.12) | 18.2507 |
| 2000's | 187 (44.00) | 29.6817 |
| 2010's | 182 (42.82) | 24.3611 |
| 2020's | 26 (6.12) | 2.80 |
| Authors | Studies |
|---|---|
| Combalbert, J; Defreyn, G; Delebassee, D; Dol, F; Herbert, JM; Maffrand, JP; Pflieger, AM; Savi, P | 1 |
| Colman, RF; Colman, RW; Freedman, MD; Grana, G; Hu, CJ; Mills, DC; Minniti, C; Puri, R | 1 |
| Maruyama, S; Uchiyama, S; Yamazaki, M | 1 |
| Anderson, HV; Benedict, CR; Buja, LM; Campbell, WB; Cui, K; Maffrand, JP; McNatt, J; Ober, JC; Rosolowsky, M; Yao, SK | 1 |
| Cazenave, JP; Defreyn, G; Driot, F; Gachet, C; Maffrand, JP; Savi, P | 1 |
| Bouloux, C; Cazenave, JP; Gachet, C; Lanza, F; Maffrand, JP; Ohlmann, P; Stierlé, A | 1 |
| Chap, H; Defreyn, G; Delebassée, D; Douste-Blazy, L; Féliste, R; Maffrand, JP; Simon, MF; Vallée, E | 1 |
| Bernat, A; Cazenave, JP; Defreyn, G; Delebassée, D; Gordon, JL; Maffrand, JP | 1 |
| Bernat, A; Gordon, JL; Maffrand, JP; Vallee, E | 1 |
| Chap, H; Defreyn, G; Douste-Blazy, L; Feliste, R; Maffrand, JP; Simon, MF | 1 |
| Berger, Y; Combalbert, J; Gaich, C; Herbert, JM; Maffrand, JP; Rouchon, MC; Savi, P | 1 |
| Herbert, JM; Laplace, MC; Savi, P | 1 |
| Aït-Chek, L; Bernat, A; Dumas, A; Herbert, JM; Savi, P | 1 |
| Herbert, JM; Laplace, MC; Maffrand, JP; Savi, P | 1 |
| Anderson, HV; Buja, LM; Cui, K; Maffrand, JP; McNatt, J; Willerson, JT; Yao, SK | 1 |
| Cassel, D; Cattaneo, M; Cazenave, JP; Chevalier, J; Gachet, C; Hechler, B; Lecchi, A; Mannucci, PM; Ohlmann, P | 1 |
| Ishihara, H; Nakashima, M; Umemura, K | 1 |
| Bihour, C; Heilmann, E; Herbert, JM; Humbert, M; Kunicki, TJ; Nurden, AT; Nurden, P; Pasquet, JM; Savi, P; Winckler, J | 1 |
| Artçanuthurry, V; Bornia, J; Grelac, F; Herbert, JM; Levy-Toledano, S; Maclouf, J; Savi, P | 1 |
| Beauverger, P; Delfaud, M; Herbert, JM; Kaghad, M; Labouret, C; Salel, V; Savi, P | 1 |
| Cazenave, JP; Eckly, A; Gachet, C; Hechler, B; Ohlmann, P | 1 |
| Schrör, K | 1 |
| Reimann, S; Schrör, K; Weber, AA | 1 |
| Dol-Gleizes, F; Herbert, JM; Marés, AM; Savi, P | 1 |
| D'Sa, S; Machin, SJ | 1 |
| Caplain, H; Cariou, R; D'Honneur, G | 1 |
| Brich, J; Eigenthaler, M; Geiger, J; Herbert, JM; Hönig-Liedl, P; Schanzenbächer, P; Walter, U | 1 |
| Herbert, JM; Savi, P | 3 |
| Fitzgerald, DJ; Quinn, MJ | 1 |
| David, JL; Limet, R | 1 |
| Asai, F; Inoue, T; Koike, H; Ogawa, T; Sugidachi, A | 1 |
| Gebauer, MU; Haeberli, A; Julmy, F; Meyer, BJ; Moshfegh, K; Redondo, M; Wuillemin, WA | 1 |
| Fiore, L; Hasbargen, JA; Kaufman, JS; O'Connor, TZ; Perdriset, G | 1 |
| Badimon, JJ; Chesebro, JH; Farkouh, ME; Fuster, V; Helft, G; Lev, EI; Osende, JI; Rodriguez, OJ; Worthley, SG; Zaman, AG | 1 |
| Braun, M; Hermann, A; Rauch, BH; Schrör, K; Weber, AA | 1 |
| Maayani, S; Martinez, R; Schwarz, T; Tagliente, TM | 1 |
| Delesque, N; Guette, F; Herbert, JM; Labouret, C; Lupker, J; Savi, P | 1 |
| Abbondanzo, SJ; Agans, JM; Bayne, ML; Chintala, MS; Cook, DN; Foster, CJ; Gustafson, E; Lachowicz, JE; Lira, SA; Monsma, FJ; Prosser, DM; Smith, MD; Wiekowski, MT; Zhai, Y; Zhang, FL | 1 |
| Gershlick, A; Hogrefe, K; Stephens Lloyd, A; Swanson, N | 1 |
| Alcala, C; Craddock-Royal, B; Maayani, S; Marrero, G; Martinez, R; Schwarz, T; Tagliente, TM | 1 |
| Braun, M; Hohlfeld, T; Schrör, K; Schwippert, B; Tschöpe, D; Weber, AA | 1 |
| Guile, SD; Ince, F; Ingall, AH; Kindon, ND; Meghani, P; Mortimore, MP | 1 |
| Albertson, CM; Fink, LM; Hauer-Jensen, M; Herbert, JM; Wang, J; Zheng, H | 1 |
| Dörr, G; Fleck, E; Gräfe, M; Regitz-Zagrosek, V; Schmidt, G | 1 |
| Hermann, A; Schrör, K; Weber, AA | 1 |
| Bosmans, JM; Claeys, MJ; Dilling, D; Michiels, JJ; Van Der Planken, MG; Vertessen, F; Vrints, CJ | 1 |
| Heptinstall, S; Judge, HM; Storey, RF; Wilcox, RG | 1 |
| Heptinstall, S; Storey, RF; Wilcox, RG | 1 |
| Bryckaert, M; Contreres, JO; Dupuy, E; Habib, A; Herbert, JM; Job, B; Levy-Toledano, S; Rosa, JP; Savi, P; Simoneau, G | 1 |
| Andrié, R; Bauriedel, G; Jabs, A; Lüderitz, B; Schneider, M; Skowasch, D | 1 |
| Besta, F; Gawaz, M; Massberg, S; Müller, I; Schönig, A; Schulz, C | 1 |
| Bliden, KP; Gurbel, PA; Hiatt, BL; O'Connor, CM | 1 |
| Cazenave, JP; Freund, M; Gachet, C; Lenain, N; Léon, C | 1 |
| Herbert, JM; Lalé, A; Savi, P | 1 |
| Jin, J; Kim, S; Kunapuli, SP | 1 |
| Behan, MW; Fox, SC; Heptinstall, S | 1 |
| Berneman, ZN; Bosmans, JM; Claeys, MJ; Dilling, D; Michiels, JJ; Van der Planken, MG; Vertessen, FJ; Vrints, C | 1 |
| Inchiosa, MA; Nagappala, B; Pothula, S; Sanchala, VT | 1 |
| Mousa, SA | 1 |
| Mikhailidis, DP; Shenton, BK; Smout, JD; Stansby, G | 1 |
| Bae, HR; Cha, JK; Ho, JM; Jo, WS; Kim, JW; Shin, HC | 1 |
| Elisaf, M; Goudevenos, JA; Mitsios, JV; Papathanasiou, AI; Rodis, FI; Tselepis, AD | 1 |
| Bliden, KP; Gurbel, PA; Samara, WM | 1 |
| Geroulakos, G; Jagroop, IA; Matsagas, MI; Mikhailidis, DP | 1 |
| Alfonso, F; Angiolillo, DJ; Bañuelos, C; Bernardo, E; Escaned, J; Fernandez-Ortiz, A; Hernández-Antolín, R; Macaya, C; Moreno, R; Ramírez, C; Sabaté, M | 1 |
| Alfonso, F; Angiolillo, DJ; Bernardo, E; Fernández, C; Fernandez-Ortiz, A; Macaya, C; Pignatti, PF; Sabaté, M; Stranieri, C; Trabetti, E | 1 |
| Théroux, P; Xiao, Z | 1 |
| Beinart, R; Bienart, R; Goldenberg, I; Guetta, V; Hod, H; Matetzky, S; Novikov, I; Pres, H; Savion, N; Shechter, M; Shenkman, B; Varon, D | 1 |
| Angiolillo, DJ; Bernardo, E; Escaned, J; Fernandez-Ortiz, A; Hernández-Antolin, R; Macaya, C; Moreno, R; Pignatti, PF; Ramírez, C; Sabaté, M; Trabetti, E | 1 |
| Pongrácz, E | 1 |
| Domanovits, H; Frossard, M; Fuchs, I; Hsieh, K; Jilma, B; Laggner, AN; Leitner, JM; Losert, H; Schreiber, W; Vlcek, M | 1 |
| Martus, P; Piorkowski, M; Rauch, U; Schultheiss, HP; Schwimmbeck, PL; Weikert, U | 1 |
| Kelly, AB; Levy, JH; Szlam, F; Tanaka, KA; Vega, JD | 1 |
| Hjemdahl, P; Hu, H; Li, N; Perneby, C; Wallén, NH | 1 |
| Badimon, L; Salas, E; Segalés, E; Vilahur, G | 1 |
| Hua, WY; Wang, FX; Wang, X; Wang, ZY; Yang, J | 1 |
| Bliden, KP; Gurbel, PA; Samara, WM; Tantry, US | 1 |
| Bonz, A; Eigenthaler, M; Grossmann, R; Lengenfelder, B; Obergfell, A; Porsche, C; Schnurr, A; Sokolova, O; Walter, U | 1 |
| Bauersachs, J; Bonz, A; Ertl, G; Grossmann, R; Obergfell, A; Strotmann, J; Walter, U | 1 |
| Aleil, B; Cazenave, JP; Gachet, C; Heitz, A; Ravanat, C; Rochoux, G | 1 |
| Greinacher, A; Raschke, R; Rosenblood, GS; Schmidt, CO; Selleng, K; Selleng, S; Warkentin, TE | 1 |
| Baxi, SM; Gould, WR; Leadley, RJ; Peng, YW; Perrin, LA; Peterson, JT; Schroeder, R | 1 |
| Eichinger, M; Kastrati, A; Koch, W; Schömig, A; von Beckerath, N; von Beckerath, O | 1 |
| Andris, K; Bestehorn, HP; Blanke, P; Büttner, HJ; Fischer, B; Frundi, D; Hochholzer, W; Neumann, FJ; Trenk, D | 1 |
| Diodati, JG; Nguyen, TA; Pharand, C | 1 |
| Mustard, JF; Packham, MA | 1 |
| Cattaneo, M; Gachet, C; Hechler, B | 1 |
| Gachet, C; Hechler, B | 1 |
| Asai, F; Jakubowski, JA; Niitsu, Y; Sugidachi, A | 1 |
| Bliden, KP; Gurbel, PA; Hayes, KM; Herzog, WR; Tantry, US; Yoho, JA | 1 |
| Baumann, PQ; Schneider, DJ; Sobel, BE; Whitaker, DA | 1 |
| Feijge, MA; Giesen, PL; Heemskerk, JW; Huijberts, M; van der Meijden, PE; van Raak, LP | 1 |
| Elisaf, M; Goudevenos, JA; Mitsios, JV; Papathanasiou, AI; Tselepis, AD | 1 |
| Almsherqi, ZA; Deng, Y; McLachlan, C; Mossop, PJ | 1 |
| Harder, S; Klinkhardt, U | 1 |
| Brannath, W; Graff, J; Heinrich, W; Klinkhardt, U; Krischek, B; Nemeh, A; Schenk, J; Wenzel, E; Wenzel, T; Wieding, U | 1 |
| Golubeva, MG; Grigoreva, ME; Smirnova, MP | 1 |
| Harder, S; Klinkhardt, U; Wenzel, E | 1 |
| Barden, A; Claxton, A; Eikelboom, JW; Gilmore, G; Hankey, GJ; Norman, PE; Staton, J; Thom, J; Yi, Q | 1 |
| Alfonso, F; Angiolillo, DJ; Bañuelos, C; Bass, TA; Bernardo, E; Costa, MA; Escaned, J; Fernandez-Ortiz, A; Hernández, R; Jimenez-Quevedo, P; Macaya, C; Moreno, R; Ramírez, C; Sabaté, M | 1 |
| Dokainish, H; Gonzales, R; Gonzalez, R; Lakkis, N; Patel, P | 1 |
| Binkley, PF; Bray, PF; Cooke, GE; Ferketich, AK; Frid, DJ; Goldschmidt-Clermont, PJ; Liu-Stratton, Y; Magorien, RD; Moeschberger, ML | 1 |
| Atar, D; Defranco, A; Mahmud, E; Malinin, A; Pokov, A; Schwartz, D; Schwartz, K; Serebruany, V; Spergling, M | 1 |
| Borgdorff, P; Tangelder, GJ | 1 |
| Bauriedel, G; Lüderitz, B; Nickenig, G; Schneider-Schmitt, M; Skowasch, D; Viktor, A | 1 |
| Kastrati, A; Schömig, A; Sibbing, D; von Beckerath, N; von Beckerath, O | 3 |
| Harrison, P; Pidcock, M | 1 |
| Barnard, MR; Fox, ML; Frelinger, AL; Furman, MI; Li, Y; Linden, MD; Michelson, AD | 1 |
| Bono, F; Culouscou, JM; Delesque-Touchard, N; Ferrara, P; Herbert, JM; Hervé, C; Labouret, C; Pereillo, JM; Savi, P; Uzabiaga, MF; Zachayus, JL | 1 |
| Bal-dit-Sollier, C; Beygui, F; Collet, JP; Drouet, L; Henry, P; Lellouche, N; Meuleman, C; Milleron, O; Montalescot, G; Sideris, G; Slama, M; Steg, PG | 1 |
| Barnard, MR; Fox, ML; Frelinger, AL; Furman, MI; Lau, WC; Li, Y; Linden, MD; McLaughlin, TJ; Michelson, AD | 1 |
| Bliden, KP; Gurbel, PA; Tantry, US | 1 |
| Dong, XC; Wang, YL; Yang, J; Zhan, C | 1 |
| Badimon, JJ; Choi, BG; Fuster, V; Vilahur, G; Viles-Gonzalez, JF; Vorchheimer, DA; Zafar, MU | 1 |
| Anders, N; Gawaz, M; Geisler, T; Herdeg, C; Langer, H; Lindemann, S; May, AE; Paterok, M; Stellos, K | 1 |
| Angiolillo, DJ; Bass, TA; Bernardo, E; Charlton, RK; Costa, MA; Desai, B; Guzman, LA; Shoemaker, SB; Yuan, H; Zenni, MM | 1 |
| Alessi, MC; Bonnet, JL; Camoin, L; Cuisset, T; Frere, C; Juhan-Vague, I; Lambert, M; Morange, PE; Quilici, J; Romero-Barra, M; Saut, N | 1 |
| Alessi, MC; Bali, L; Bonnet, JL; Cuisset, T; Frere, C; Lambert, M; Mielot, C; Morange, PE; Nait-Saidi, L; Quilici, J | 1 |
| Bareiss, P; Chauvin, M; Desprez, D; Faure, A; Grunebaum, L; Jesel, L; Morel, O; Ohlmann, P; Roul, G; Viellard, C | 1 |
| Bliden, KP; Etherington, A; Gurbel, PA; Tantry, US | 1 |
| Hackeng, CM; Kleibeuker, M; Mieremet, N; ten Berg, JM; van Werkum, JW | 1 |
| Brandt, JT; Farid, NA; Jakubowski, JA; Lachno, DR; Li, YG; Naganuma, H; Payne, CD; Weerakkody, GJ; Winters, KJ | 1 |
| Bostwick, JS; Hua, J; Ogletree, ML; Price, LA; Rehfuss, RP; Schumacher, WA; Steinbacher, TE; Stewart, AB; Wong, PC | 1 |
| Fitzgerald, DJ; Maree, AO | 1 |
| Asai, F; Hagihara, K; Hashimoto, M; Jakubowski, JA; Kurihara, A; Niitsu, Y; Ogawa, T; Sugidachi, A | 1 |
| Bliden, KP; Gurbel, P; Tantry, U | 1 |
| Angioï, M; Hacquard, M; Lecompte, T; Vigneron, C | 1 |
| Bostwick, JS; Crain, EJ; Hua, J; Jiang, X; Ogletree, ML; Rehfuss, R; Schumacher, WA; Watson, CA; Wong, PC | 1 |
| Cha, JK; Jeon, HW | 1 |
| Abbate, R; Antoniucci, D; Buonamici, P; Gensini, GF; Giglioli, C; Gori, AM; Marcucci, R; Paniccia, R | 1 |
| Biernat, M; Dropinski, J; Dziedzina, S; Jakiela, B; Plutecka, H; Sanak, M; Szczeklik, A; Wegrzyn, W | 1 |
| Dick, R; Hiscock, M; Oqueli, E | 1 |
| Buffa, M; Clerico, A; De Filippis, R; Della Pina, F; Gianetti, J; Rizza, A; Sbrana, S | 1 |
| Akers, WS; Charnigo, R; Ferraris, S; Oestreich, JH; Oh, JJ; Steinhubl, SR | 1 |
| Goodall, AH; Hayes, PD; Jones, CI; Naylor, AR; Payne, DA | 1 |
| Eder, C; Funke, U; Lutze, G; Prasse, T; Schulze, M; Töpfer, G; Zimmermann, M | 1 |
| Brandt, JT; Jakubowski, JA; Naganuma, H; Payne, CD; Weerakkody, GJ; Winters, KJ | 1 |
| Alfonso, F; Angiolillo, DJ | 1 |
| Alessi, MC; Bonnet, JL; Camoin, L; Carvajal, J; Cuisset, T; Frere, C; Juhan-Vague, I; Lambert, M; Morange, PE; Quilici, J | 1 |
| Bigalke, B; Dietz, K; Drosch, T; Gawaz, M; Geisler, T; Grass, D; Herdeg, C; Stellos, K | 1 |
| Brandt, JT; Ernest, CS; Farid, NA; Jakubowski, JA; Li, YG; Payne, CD; Salazar, DE; Small, DS; Winters, KJ | 1 |
| Hjemdahl, P; Hofman-Bang, C; Ivert, T; Li, N; Perneby, C; Tornvall, P; Wallén, NH | 1 |
| Blindt, R; de Taeye, A; Hoffmann, R; Kelm, M; Kiefer, P; Müller, R; Stellbrink, K; Weber, C; Yagmur, E | 1 |
| Einav, Y; Fefer, P; Hod, H; Lubetsky, A; Matetzky, S; Savion, N; Shenkman, B; Varon, D | 1 |
| Lindhoff-Last, E; Linnemann, B; Mani, H; Prochnow, S; Schwonberg, J | 1 |
| Braun, S; Jawansky, S; Kastrati, A; Mehilli, J; Schömig, A; Sibbing, D; Vogt, W; von Beckerath, N | 1 |
| Alfonso, F; Angiolillo, DJ; Bass, TA; Bernardo, E; Desai, B; Fernandez-Ortiz, A; Guzman, LA; Hernández-Antolin, R; Macaya, C; Palazuelos, J; Weisberg, I; Zenni, MZ | 1 |
| Bestehorn, HP; Büttner, HJ; Frundi, D; Hochholzer, W; Neumann, FJ; Stratz, C; Trenk, D; Valina, CM | 1 |
| Brandt, JT; Farid, NA; Jakubowski, JA; Li, YG; Payne, CD; Salazar, DE; Small, DS; Winters, KJ | 2 |
| Abraham, P; Custaud, MA; Fromy, B; Godon, A; Rousseau, P; Saumet, JL; Tartas, M | 1 |
| Engelhardt, A; Lask, S; Mügge, A; Neubauer, H | 1 |
| Bareiss, P; Bernhard, N; Desprez, D; Freyssinet, JM; Grunebaum, L; Morel, O; Toti, F | 1 |
| Brandt, JT; Farid, NA; Li, YG; Payne, CD; Salazar, DE; Small, DS; Weerakkody, GJ; Winters, KJ | 1 |
| Chen, BL; Fan, L; He, YJ; Li, Q; Li, YL; Liu, ZQ; Wang, LS; Zhang, W; Zhou, HH | 1 |
| Alessi, MC; Bonnet, JL; Camoin-Jau, L; Cuisset, T; Faille, D; Frere, C; Juhan-Vague, I; Lambert, M; Morange, PE; Quilici, J; Saut, N | 1 |
| Braun, S; Busch, G; Jawansky, S; Kastrati, A; Ott, I; Schömig, A; Sibbing, D; von Beckerath, N | 1 |
| Cho, YH; Choi, TY; Ki, CS; Kim, YH; Lee, YK; Lee, YW; Na, JS; Shin, HB | 1 |
| Dovlatova, NL; Heptinstall, S; Jakubowski, JA; Sugidachi, A | 1 |
| Diodati, JG; Lordkipanidzé, M; Nguyen, TA; Pharand, C; Schampaert, E | 1 |
| Dovlatova, N; Heptinstall, S; Johnson, A | 1 |
| Schneider, DJ; Sobel, BE | 1 |
| Fukushima, K; Iwata, Y; Kitahara, H; Kobayashi, Y; Komuro, I; Kuroda, N; Nakayama, T; Nomura, F; Ooyama, M | 1 |
| Antonino, MJ; Bailey, WL; Baker, BA; Bliden, KP; Dichiara, J; Gurbel, PA; Lawal, L; Singla, A; Tantry, US | 1 |
| Bagatini, MD; Battisti, V; dos Santos, RB; Gasparetto, D; Gonçalves, JF; Martins, CC; Morsch, VM; Rosa, CS; Schetinger, MR; Spanevello, RM | 1 |
| D'Amico Oblak, T; Ku, CJ; Spence, DM | 1 |
| Price, MJ; Teirstein, PS | 1 |
| Kristensen, SR; Madsen, EH; Maurer-Spurej, E; Schmidt, EB | 1 |
| Dieplinger, B; Haltmayer, M; Mueller, T; Poelz, W | 1 |
| Berndt, MC; Dicker, P; Foley, DP; Kenny, D; Peace, AJ; Tedesco, AF | 1 |
| Bauersachs, J; Eigenthaler, M; Ertl, G; Flierl, U; Schäfer, A; Störk, S; Walter, U; Weinberger, S | 1 |
| Béres, BJ; Kerecsen, G; Kiss, RG; László, A; Masszi, T; Préda, I; Tóth-Zsámboki, E; Vargová, K | 1 |
| Bali, L; Bonnet, JL; Cuisset, T; Frere, C; Gaborit, B; Lambert, M; Morange, PE; Moro, PJ; Mouret, JP; Quilici, J; Uhry, S | 1 |
| Farhan, S; Glogar, D; Gyöngyösi, M; Hemetsberger, H; Hemetsberger, R; Huber, K; Pavo, I; Petrasi, Z; Posa, A; Sperker, W; Strehblow, C | 1 |
| Fu, W; Guo, H; Huang, J; Huang, L; Jian, Z; Li, A; Li, J; Qian, D; Song, Y | 1 |
| Dale, GL; Hann, CL; Hennebry, TA; Norgard, NB; Saya, S; Schechter, E | 1 |
| Cha, JK; Jeon, HW; Kang, MJ | 1 |
| Shen, J; Zhang, Q; Zhang, RY | 1 |
| Storey, RF | 1 |
| Crain, EJ; Hua, J; Rehfuss, R; Schumacher, WA; Watson, CA; Wong, PC | 1 |
| Bal Dit Sollier, C; Berge, N; Boval, B; Drouet, L; Hovsepian, L | 1 |
| Lip, GY; Shantsila, E | 1 |
| Abbate, R; Antoniucci, D; Antonucci, E; Buonamici, P; Fedi, S; Gensini, GF; Giusti, B; Gori, AM; Marcucci, R; Paniccia, R | 1 |
| Campbell, CL; Oestreich, JH; Smyth, SS | 1 |
| Gremmel, T; Kopp, CW; Koppensteiner, R; Panzer, S; Seidinger, D; Steiner, S | 6 |
| Antonino, MJ; Bassi, AK; Bliden, KP; DiChiara, J; Gesheff, TB; Gurbel, PA; Hennebry, TA; Herzog, WR; Mahla, E; Saucedo, JF; Singla, A; Suarez, TA; Tantry, US | 1 |
| Diodati, JG; Lordkipanidzé, M; Palisaitis, DA; Pharand, C; Schampaert, E | 3 |
| Husted, S | 1 |
| Akers, WS; Campbell, CL; Charnigo, R; Dunn, SP; Holt, J; Oestreich, JH; Smyth, SS; Steinhubl, SR | 1 |
| Goto, S; Serebruany, V | 1 |
| Braun, S; Hadamitzky, M; Kastrati, A; Morath, T; Schömig, A; Sibbing, D; Stegherr, J; Vogt, W; von Beckerath, N | 1 |
| Angiolillo, DJ; Antman, EM; Braunwald, E; Downey, WE; Frelinger, AL; Jakubowski, JA; Li, Y; McCabe, CH; Michelson, AD; Murphy, SA; Qin, J; Wiviott, SD; Xenopoulos, NP | 1 |
| Fox, SC; Heptinstall, S; May, JA; Neubert, U; Shah, A | 1 |
| Ahn, JH; Kang, W; Kim, EY; Kim, MJ; Kim, SD; Kim, SW; Lee, HW; Na, HJ; Nam, HS; Park, DJ; Yoon, YR | 1 |
| Carrié, D; Garcia, C; Gratacap, MP; Payrastre, B; Sié, P; Voisin, S | 1 |
| Gorog, DA; Saraf, S; Sharma, S; Wellsted, D | 1 |
| Bjessmo, S; Lindvall, B; Lindvall, G; Sartipy, U; Svenarud, P; van der Linden, J | 1 |
| Bjørnsen, S; Brosstad, F; Erikssen, G; Meen, Ø; Pedersen, TM | 1 |
| Bilkova, D; Hajkova, J; Kala, P; Kvasnicka, J; Marinov, I; Motovska, Z; Petr, R; Simek, S; Widimsky, P | 1 |
| Akao, M; Horiuchi, H; Hoshino, K; Jinnai, T; Kimura, T; Kita, T; Makiyama, T; Naruse, Y; Ono, K; Tada, T; Takahashi, K; Tazaki, J; Watanabe, H | 1 |
| Husted, S; van Giezen, JJ | 1 |
| Giurgea, GA; Gremmel, T; Kopp, CW; Koppensteiner, R; Panzer, S; Seidinger, D; Steiner, S | 1 |
| Armstrong, M; Cannon, CP; Emanuelsson, H; Heptinstall, S; Husted, S; Lawrance, R; Melissa Thornton, S; Storey, RF; Wickens, M | 1 |
| Gouya, G; Jilma, B; Siller-Matula, JM; Wolzt, M | 1 |
| Ak, K; Arsan, S; Eksioglu-Demiralp, E; Iqbal, O; Isbir, S; Tetik, S; Yardimci, T | 1 |
| Abbate, R; Bandinelli, B; Cecchi, E; Gensini, GF; Giglioli, C; Lazzeri, C; Mannini, L; Marcucci, R; Paniccia, R; Valente, S | 1 |
| Alessi, MC; Bali, L; Bonnet, JL; Cayla, G; Cuisset, T; Frere, C; Gaborit, B; Morange, PE; Poyet, R; Quilici, J | 1 |
| Alessi, MC; Bali, L; Bonnet, JL; Castelli, C; Cuisset, T; Frere, C; Gaborit, B; Morange, PE; Poyet, R; Quilici, J | 1 |
| Berg, JM; Bouman, HJ; Elsenberg, EH; Hackeng, CM; van de Wal, RM; van Werkum, JW; Verheugt, FW; Zomer, AC | 1 |
| Banks, P; Curzen, NP; Hobson, AR; Qureshi, Z | 1 |
| Carneiro, FS; Giachini, FR; Inscho, EW; Lima, VV; Osmond, DA; Tostes, RC; Webb, RC; Zhang, S | 1 |
| Antonino, MJ; Bliden, KP; Conley, PB; Gretler, DD; Gurbel, PA; Jurek, MM; Pakyz, RE; Shuldiner, AR; Stephens, G; Tantry, US | 1 |
| Braun, S; Jawansky, S; Kastrati, A; Morath, T; Schömig, A; Sibbing, D; Vogt, W; von Beckerath, N | 1 |
| Klauss, V; Krötz, F; Nagel, J; Schuhmann, CG; Sohn, HY; Spannagl, M | 1 |
| Suttorp, MJ; van Werkum, JW; Zomer, AC; Zwart, B | 1 |
| Braun, S; Kastrati, A; Mehilli, J; Morath, T; Schömig, A; Schulz, S; Sibbing, D; Stegherr, J; von Beckerath, N | 1 |
| del Río, A; Heras, M | 1 |
| Bouman, HJ; Breet, NJ; Hackeng, CM; Parlak, E; Taubert, D; ten Berg, JM; ten Cate, H; van Werkum, JW | 1 |
| Braun, S; Kastrati, A; Mehilli, J; Morath, T; Schömig, A; Sibbing, D; Stegherr, J; Vogt, W; von Beckerath, N | 1 |
| Bal dit Sollier, C; Barthélémy, O; Beygui, F; Cohen, R; Collet, JP; Drouet, L; Henry, P; Lim, P; Luo, J; Marshall, D; Meuleman, C; Montalescot, G; Petitjean, H; Sideris, G | 1 |
| Brunner, KP; Kobsar, AL; Koessler, J; Rajkovic, MS; Steigerwald, U; Walter, U | 1 |
| Fukushima, K; Iwata, Y; Kitahara, H; Kobayashi, Y; Komuro, I; Kuroda, N; Kuwabara, Y; Nomura, F; Ooyama, M | 1 |
| Badimon, JJ; Burg, MM; Chaplin, W; Davidson, KW; Fuster, V; Paz-Yepes, M; Shimbo, D; Vilahur, G; Zafar, MU | 1 |
| Hwang, JY; Hwang, SJ; Jeong, YH; Kim, IS; Kwak, CH; Lee, SW; Park, SW; Park, Y | 1 |
| Alessi, MC; Barbato, E; Bartunek, J; Bonnet, JL; Cuisset, T; Delrue, M; Eijgelsheim, M; Frère, C; Hamilos, M; Saut, N; Verhamme, K; Wijns, W | 1 |
| Bolliger, D; Levy, JH; Rumph, B; Szlam, F; Tanaka, KA | 1 |
| Alessi, MC; Bali, L; Bonnet, JL; Brissy, O; Cuisset, T; Frere, C; Gaborit, B; Lambert, M; Morange, PE; Poyet, R; Quilici, J | 1 |
| Braun, S; Kastrati, A; Mehilli, J; Morath, T; Sarafoff, N; Schömig, A; Schulz, S; Sibbing, D; Stegherr, J; von Beckerath, N | 1 |
| Bal-Dit-Sollier, C; Barthélémy, O; Bellemain-Appaix, A; Beygui, F; Collet, JP; Drouet, L; Ducrocq, G; Henry, P; Lellouche, N; Meuleman, C; Milleron, O; Montalescot, G; Sideris, G; Silvain, J; Slama, M | 1 |
| Gao, P; Gao, R; Hu, SS; Li, L; Xiong, H; Zheng, Z | 1 |
| Antonijević, N; Antović, J; Baskot, B; Djenić, N; Dopudja, M; Gligić, B; Grdenić, A; Jovelić, A; Miković, D; Obradović, S; Salinger, S; Subota, V; Vukotić, S | 1 |
| Jakubowski, JA; Li, YG; Luo, J; Payne, CD; Small, DS; Tomlin, ME; Winters, KJ | 1 |
| Buckland, RJ; Jakubowski, JA; Judge, HM; Patil, SB; Storey, RF | 1 |
| Fukushima, K; Iwata, Y; Kitahara, H; Kobayashi, Y; Komuro, I; Kuroda, N; Nomura, F; Ooyama, M | 1 |
| Brainard, BM; Budsberg, SC; Kleine, SA; Papich, MG | 1 |
| Calatzis, A; Gremmel, T; Kaider, A; Kopp, CW; Koppensteiner, R; Panzer, S; Seidinger, D; Steiner, S | 1 |
| Neubauer, M; Neumeister, P; Quehenberger, F; Rainer, F; Robier, C; Sternad, H | 1 |
| Aradi, D; Komócsi, A; Magyarlaki, T; Rideg, O; Tokés-Füzesi, M; Vorobcsuk, A | 1 |
| Angiolillo, DJ; Vivas, D | 1 |
| Bal Dit Sollier, C; Berge, N; Boval, B; Drouet, L; Dubar, M | 1 |
| Braun, S; Byrne, RA; Kastrati, A; Massberg, S; Mehilli, J; Morath, T; Schömig, A; Schulz, S; Sibbing, D | 1 |
| Lindhoff-Last, E; Mani, H; Wolf, Z | 1 |
| Barnard, MR; Fox, ML; Frelinger, AL; Michelson, AD | 1 |
| Nathisuwan, S; Panomvana, D; Sansanayudh, N; Siriswangvat, S | 1 |
| Hwang, JY; Hwang, SJ; Jeong, YH; Kang, MK; Kim, IS; Kim, S; Koh, EH; Koh, JS; Kwak, CH; Park, JR; Park, KS; Park, Y | 1 |
| Angiolillo, DJ; Becker, R; Bhatt, DL; Blindt, R; Bonello, L; Cattaneo, M; Collet, JP; Cuisset, T; Gachet, C; Gurbel, PA; Jennings, LK; Kereiakes, D; Marcucci, R; Montalescot, G; Paganelli, F; Price, MJ; Sibbing, D; Tantry, US; Trenk, D; Van Werkum, JW; Waksman, R | 1 |
| Bernlochner, I; Braun, S; Jaitner, J; Kastrati, A; Mehilli, J; Morath, T; Schömig, A; Sibbing, D; Stegherr, J; Steinhubl, S; von Beckerath, N | 1 |
| Dicker, P; Foley, DP; Kenny, D; Mangiacapra, F; Mylotte, D; Peace, AJ; Tedesco, AT | 1 |
| Cattaneo, M | 2 |
| Lecka, J; Rana, MS; Sévigny, J | 1 |
| Bernlochner, I; Braun, S; Jaitner, J; Kastrati, A; Morath, T; Schömig, A; Sibbing, D; Stegherr, J | 1 |
| Bhavaraju, K; Gartner, TK; Georgakis, A; Jin, J; Kunapuli, SP; Nurden, A; Nurden, P; Tomiyama, Y | 1 |
| Hwang, JY; Hwang, SJ; Jeong, YH; Kang, MK; Kim, IS; Koh, JS; Kwak, CH; Park, Y | 1 |
| Grbac, L; Ledinsky, M; Rincić, G; Stancić, N; Stancić, V; Vuk, A | 1 |
| Jilma, B; Siller-Matula, JM | 1 |
| Abbate, R; Antonucci, E; Gori, AM; Maggini, N; Marcucci, R; Miranda, M; Paniccia, R; Prisco, D; Romano, E | 1 |
| Bongard, V; Carrié, D; Lhermusier, T; Sié, P; Tidjane, MA; Voisin, S | 1 |
| Deguchi, I; Dembo, T; Fukuoka, T; Furuya, D; Horiuchi, Y; Kato, Y; Maruyama, H; Nagoya, H; Takeda, H; Tanahashi, N | 1 |
| Brasseur, D; Bremond, N; Delesque Touchard, N; Hurbin, F; Lavisse, M; Rouchon, MC; Roy, S; Savi, P; Schofield, J; Sultan, E; Tuffal, G | 1 |
| Hwang, JY; Hwang, SJ; Jeong, YH; Kim, IS; Kim, S; Koh, EH; Kwak, CH; Park, JR; Park, KS; Park, Y; Yun, SE | 1 |
| Anzaha, G; Barthélémy, O; Bellemain-Appaix, A; Beygui, F; Caron, C; Cayla, G; Chastre, T; Collet, JP; Galier, S; Gallois, V; Hulot, JS; Montalescot, G; Pena, A; Silvain, J; Vignalou, JB | 1 |
| Behr, T; Behr, W; Kuch, B; von Scheidt, W | 1 |
| Gremmel, T; Panzer, S | 1 |
| Andreotti, F; Bielis, L; Boinska, J; Grabczewska, Z; Kozinski, M; Kubica, A; Kubica, J; Marciniak, A; Navarese, EP; Rosc, D; Siller-Matula, JM; Stolarek, W; Wisniewska-Szmyt, J | 1 |
| Archan, S; Drexler, C; Macher, S; Mahla, E; Prüller, F; Raggam, RB | 1 |
| Antman, EM; Braunwald, E; Costigan, TM; Frelinger, AL; Jakubowski, JA; McCabe, CH; Michelson, AD; Miller, DL; Neumann, FJ; Trenk, D; Wiviott, SD | 1 |
| Bergougnan, L; Bhatt, DL; Dubar, M; Farenc, C; Hurbin, F; Lacreta, F; Pearson, K; Perrin, L; Simon, T; Vicaut, E | 1 |
| Bertin, R; Caparrotta, L; Dorigo, P; Froldi, G; Montopoli, M | 1 |
| Gaglia, MA; Kent, KM; Mahmoudi, M; Pakala, R; Pichard, AD; Sardi, G; Satler, LF; Suddath, WO; Torguson, R; Waksman, R; Xue, Z | 1 |
| Dimitriou, AA; Goudevenos, JA; Kalantzi, KI; Tselepis, AD | 1 |
| Antonino, MJ; Bliden, KP; Cummings, CC; Dubois, BV; Gesheff, T; Gurbel, PA; Herzog, WR; Tantry, US | 1 |
| Kafian, S; Kalani, M; Mobarrez, F; Samad, BA; Wallén, H | 1 |
| Alessi, MC; Bonnet, JL; Cuisset, T; Fourcade, L; Gaborit, B; Grosdidier, C; Molines, L; Morange, PE; Pankert, M; Quilici, J | 1 |
| Abbate, R; Antoniucci, D; Buonamici, P; Gensini, GF; Giusti, B; Gori, AM; Marcucci, R; Migliorini, A; Parodi, G; Valenti, R | 1 |
| Babin, J; Bonnefoy, A; Bryckaert, M; Labarthe, B; Théroux, P | 1 |
| De Mey, JG; Feijge, MA; Heemskerk, JW; Kuijpers, MJ; Megens, RT; Nikookhesal, E; oude Egbrink, MG; van Giezen, JJ | 1 |
| Bonneau, D; Boulenc, X; Cheng, S; Daskalakis, N; Farenc, C; Hurbin, F; Lacreta, F; Sultan, E; Taylor, T | 1 |
| Bouman, HJ; de Maat, MP; Hackeng, CM; Leebeek, FW; Rudež, G; ten Berg, JM; ten Cate, H; van Werkum, JW | 1 |
| Chen, X; Ge, CJ; Lü, SZ; Meng, K; Song, XT; Zhu, HG | 1 |
| Castriota, F; Grzesk, E; Grzesk, G; Kozinski, M; Krzyzanowski, M; Kubica, A; Kubica, J; Navarese, EP; Siller-Matula, JM | 1 |
| Eikelboom, JW; Hirsh, J; Johnston, MA; Li, C; Xie, C | 1 |
| Cortese-Hassett, A; Grate, S; Lee, JS; Lemieux, N; Marroquin, OC; Moguilanski, D; Mulukutla, S; Rao, SV; Semaan, RW; Toma, C; Zahr, F | 1 |
| Bosticco, B; Brizzio, ME; Collins, M; Grau, JB; Mak, AW; Shaw, RE; Zapolanski, A | 1 |
| Grgurevich, S; Jacoski, MV; Jennings, LK; Li, JS; Michelson, AD; Tyagi, A | 1 |
| Desta, Z; Flockhart, DA; Jin, Y; Kovacs, R; Kreutz, RP; Kreutz, Y; Miao, J; Nystrom, P | 1 |
| Abbate, R; Antoniucci, D; Gensini, GF; Giglioli, C; Giusti, B; Gori, AM; Marcucci, R; Paniccia, R; Parodi, G; Saracini, C; Valente, S | 1 |
| Ahn, JH; Bliden, KP; Gho, EH; Gurbel, PA; Hwang, JY; Hwang, SJ; Jeong, YH; Kim, S; Kwak, CH; Kwon, TJ; Park, JR; Park, Y; Tantry, US | 1 |
| Chan, MY; Cornel, JH; Erlinge, D; Goodman, SG; Gurbel, PA; Huber, K; Jakubowski, JA; Ohman, EM; Roe, MT; Shah, S; Tantry, US | 1 |
| Bauersachs, J; Flierl, U; Fraccarollo, D; Lausenmeyer, E; Massberg, S; Rosenstock, T; Schäfer, A; Schulz, C | 1 |
| Bakdash, S; Bhatt, DL; Depta, JP; Fowler, J; Katzan, I; Kottke-Marchant, K; Novak, E | 1 |
| Kim, MH; Yu, LH; Zhang, HZ | 1 |
| Eikelboom, JW; Hirsh, J; Johnston, M; Li, C; Liang, Y; Mehta, S; Pare, G; Sloane, D; Teo, KK; Yi, Q; Zhu, J | 1 |
| Ge, J; Qian, J; Sun, A; Wang, Q; Wu, H | 1 |
| Collins, L; Conley, PB; Craft, CS; Deng, H; Eagleton, MC; Floyd, DH; Grabowska, D; Heller, E; Hirbe, AC; Hughes, A; Hurchla, MA; Novack, DV; Piwnica-Worms, D; Rogers, M; Schneider, JG; Steinberg, TH; Su, X; Townsley, S; Uluckan, O; Weilbaecher, KN; Wu, K; Xiang, J; Zou, W | 1 |
| Bobbert, P; Bobbert, T; Rauch, U; Schultheiss, HP; Schütte, C; Steffens, D; Stellbaum, C | 1 |
| Baeriswyl, G; Cook, S; Goy, JJ; Lehmann, S; Lehner, C; Oberhänsli, M; Puricel, S; Stauffer, JC; Togni, M | 1 |
| Curzen, N; Radhakrishnan, A; Sambu, N | 1 |
| Butler, K; Maya, J; Teng, R | 1 |
| Cano, P; Carrillo, P; Consuegra-Sánchez, L; Kaski, JC; López-Palop, R; Picó, F; Sanchis, J; Villegas, M | 1 |
| Badr Eslam, R; Kaider, A; Lang, IM; Panzer, S | 1 |
| He, BS; Tan, J; Yang, J; Zhou, JS; Zou, JJ | 1 |
| Akkawat, B; Buddhari, W; Chaipromprasit, J; Jirapattrathamrong, S; Lertsuwunseri, V; Rojnuckarin, P; Srimahachota, S; Udayachalerm, W | 1 |
| Basset, T; Delavenne, X; Garcin, A; Garnier, P; Laporte, S; Magnin, M; Mallouk, N; Mismetti, P; Piot, M; Ressnikoff, D | 1 |
| Chen, J; Chen, SY; Lian, JJ; Luo, TC; Zeng, XQ | 1 |
| Abadilla, KA; Gurbel, PA; Hwang, JY; Jeong, YH; Koh, JS; Kwak, CH; Park, Y; Tantry, US | 1 |
| Ding, YL; Gu, ZQ; Tan, J; Yang, J; Zhao, HD; Zou, JJ | 1 |
| Deguchi, I; Fukuoka, T; Hayashi, T; Horiuchi, Y; Kato, Y; Maruyama, H; Nagoya, H; Ohe, Y; Tanahashi, N | 1 |
| Abd Elhamid, S; Abulata, N; El Sobky, M; Khafagy, D; Mostafa, A; Zoheir, N | 1 |
| Conyers, JL; Dong, JF; Fu, Y; Li, M; Liu, L; Liu, X; Yang, X; Zaske, AM; Zhang, J; Zhang, Y; Zhou, Z | 1 |
| Altamirano, AV; Callender, RA; Cattano, D; Mukalel, J; Pivalizza, EG | 1 |
| Beynon, C; Jakobs, M; Jung, C; Sakowitz, OW; Scherer, M; Unterberg, AW | 1 |
| Bagoly, Z; Csiba, L; Kappelmayer, J; Magyar, T; Muszbek, L; Pongrácz, E; Sarkady, F | 1 |
| Al Ghumlas, AK; Gader, AG | 1 |
| Ahn, YS; Bidot, C; Horstman, LL; Johansen, ME; Jy, W | 1 |
| Kakouros, N; Kickler, TS; Laws, KM; Rade, JJ | 1 |
| Albertsson, P; Åström-Olsson, K; Dellborg, M; Hansson, EC; Hesse, C; Jeppsson, A; Shams Hakimi, C; Wallén, H | 1 |
| Neubauer, M; Robier, C; Stettin, M | 1 |
| Chakrabarty, D; Chanda, C; Sarkar, A; Sistla, S | 1 |
| Dhillon, K; Dovlatova, N; Fox, SC; Glenn, JR; Heptinstall, S; White, AE | 1 |
| Barbieri, L; Cassetti, E; De Luca, G; Galasso, G; Marino, P; Piccolo, R; Schaffer, A; Sinigaglia, F; Verdoia, M | 1 |
| Bauersachs, J; Flierl, U; Fraccarollo, D; Hildemann, SK; Massberg, S; Pelisek, J; Schäfer, A; Schöpp, C; Schulz, C; Wissel, K | 1 |
| Gremmel, T; Kopp, CW; Koppensteiner, R; Panzer, S; Steiner, S; Xhelili, E | 1 |
| Grybauskas, P; Gustiene, O; Jankauskiene, L; Kupstyte, N; Lesauskaite, V; Skipskis, V; Tatarunas, V | 1 |
| Dalén, M; Holm, M; Ivert, T; Lindvall, G; van der Linden, J | 1 |
| Akdeniz, B; Aytemiz, F; Badak, O; Barış, N; Göldeli, O; Ozpelit, E; Uzel, H | 1 |
| Espinosa, EV; Karim, ZA; Khasawneh, FT; Lin, OA; Vemana, HP | 1 |
| Chen, SL; Fan, HW; He, BS; Tan, J; Xie, HG; Zou, JJ | 1 |
| Cho, JY; Chu, K; Hong, KS; Jang, IJ; Ji, SC; Jung, KH; Lee, H; Lee, S; Lim, KS; Oh, J; Shin, D; Shin, KH; Yoon, SH; Yu, KS | 1 |
| Choi, JL; Han, JY; Kim, BR; Kim, JE; Kim, JM; Kim, KH; Kim, MH; Woo, KS | 1 |
| Dalén, M; Holm, M; Tornvall, P; van der Linden, J | 1 |
| Chowdhury, M; Leyvi, G; Mais, AM; Shore-Lesserson, L | 1 |
| Giachini, FR; Inscho, EW; Leite, R; Lima, VV; Osmond, DA; Tostes, RC; Webb, RC | 1 |
| Curzen, N; Englyst, N; Hobson, A; Khanna, V; Mikael, R; Sambu, N | 1 |
| Asher, E; Beigel, R; Fefer, P; Hod, H; Matetzky, S; Savion, N; Shechter, M; Shenkman, B; Varon, D | 1 |
| Arroyo, AB; Bernal, A; Guiú, IS; Iniesta, JA; Jover, E; Lozano, ML; Martínez, C; Rivera, J; Rodríguez, JM; Vicente, V | 1 |
| Durstberger, M; Eichelberger, B; Gremmel, T; Kopp, CW; Koppensteiner, R; Panzer, S | 1 |
| Bacchi Reggiani, ML; Dall'Ara, G; Gallo, P; Ghetti, G; Marrozzini, C; Marzocchi, A; Moretti, C; Palmerini, T; Rapezzi, C; Saia, F; Taglieri, N | 1 |
| Duraj, L; Fedor, M; Fedorová, J; Kovář, F; Kubisz, P; Mokáň, M; Samoš, M; Šimonová, R; Škorňová, I; Staško, J | 1 |
| Abendschein, D; Broekman, MJ; Chen, R; Drosopoulos, JH; Jeong, SS; Marcus, AJ; Moeckel, D; Nguyen, A; Robson, SC; Sun, X | 1 |
| Andruszkiewicz, A; Fabiszak, T; Kasprzak, M; Koziński, M; Kubica, A; Kubica, J; Obońska, K; Paciorek, P; Pio Navarese, E; Siller-Matula, J; Swiątkiewicz, I; Sztuba, B | 1 |
| Franskavichene, LV; Golukhova, EZ; Serebruany, VL; Syvolap, VV | 1 |
| Galuszka, J; Hlusi, A; Hutyra, M; Indrak, K; Indrakova, J; Krcova, V; Slavik, L; Ulehlova, J | 1 |
| Hunnangkul, S; Kamkaew, R; Likidlilid, A; Poldee, S; Suktitipat, B; Tassaneetrithep, B; Tresukosol, D | 1 |
| Deguchi, I; Fukuoka, T; Hayashi, T; Horiuchi, Y; Kato, Y; Maruyama, H; Nagamine, Y; Ohe, Y; Sano, H; Sehara, Y; Tanahashi, N | 1 |
| Chen, H; Wang, H; Wu, HX; Wu, XY | 1 |
| Fabiszak, T; Grześk, G; Kasprzak, M; Koziński, M; Kubica, A; Kubica, J; Laskowska, E; Navarese, EP; Obońska, K; Świątkiewicz, I; Sztuba, B | 1 |
| Assinger, A; Kral, JB; Scharbert, G; Schrottmaier, WC; Weber, T; Wetzel, L | 1 |
| Cong, YL; Dong, M; Li, J; Sun, B; Wu, C; Yang, L; Zhu, L | 1 |
| Cao, Y; He, Y; Hu, H; Sun, C; Yao, Y; Zeng, Z; Zhang, S | 1 |
| Yang, J; Yang, ZH; Zhang, YD; Zhao, HD; Zhao, YX; Zhou, JS; Zou, JJ | 1 |
| Durstberger, M; Eichelberger, B; Gremmel, T; Koppensteiner, R; Panzer, S | 1 |
| Brun, C; Gowda, A; Hah, JM; Noon, K | 1 |
| Fiedler, AK; Kastrati, A; Martischnig, AM; Massberg, S; Mayer, K; Mehilli, J; Petzold, T; Pollak, J; Sarafoff, N; Schulz-Schüpke, S; Sibbing, D | 1 |
| Gick, M; Hochholzer, W; Kirtane, AJ; Leggewie, S; Neumann, FJ; Nührenberg, TG; Stone, GW; Stratz, C; Trenk, D; Valina, CM | 1 |
| Banya, W; Booth, J; Dalby, M; Davidson, SJ; Droppa, M; Flather, M; Gawaz, M; Geisler, T; Karathanos, A; Müller, K; Stables, RH; Tavlaki, E; Yanez-Lopez, M; Zaman, A | 1 |
| Gierlotka, M; Kaczmarski, J; Kim, MH; Kuliczkowski, W; Serebruany, V; Sliwka, J; Steter, D; Zembala, M; Zysko, D | 1 |
| Anderson, RA; Freeman, PM; Hinz, C; James, PE; Kinnaird, TD; Moschonas, KE; O'Donnell, VB | 1 |
| Barbieri, L; Bellomo, G; De Luca, G; Marino, P; Nardin, M; Pergolini, P; Rolla, R; Schaffer, A; Suryapranata, H; Verdoia, M | 2 |
| An, LX; Dong, Q; Guan, YT; Han, Y; Jiang, JM; Li, L; Li, SX; Liu, X; Luo, Z; Lv, HH; Wu, S; Xu, JF; Yang, XL; Zheng, SL | 1 |
| Eichelberger, B; Gremmel, T; Kopp, CW; Koppensteiner, R; Panzer, S; Xhelili, E | 1 |
| Bode, C; Diehl, P; Meyer, M; Moser, M; Olivier, CB; Weber, S; Weik, P; Zhou, Q | 1 |
| Alexopoulos, D; Andonopoulos, AP; Daoussis, D; Davlouros, P; Filippopoulou, A; Gkizas, V; Ntelis, K | 1 |
| Fawcett, JP; Gu, J; Liu, M; Meng, X; Su, C; Wang, H; Xu, X; Yang, Y; Yang, Z; Zhao, X | 1 |
| Bernlochner, I; Gross, L; Jaitner, J; Kastrati, A; Laugwitz, KL; Mayer, K; Morath, T; Orban, M; Rössner, L; Sibbing, D | 1 |
| Anstrom, KJ; Effron, MB; Faries, DE; Federspiel, JJ; Mauri, L; McCoy, LA; Peterson, ED; Wang, TY; Xian, Y; Yeh, RW; Zettler, M | 1 |
| Dong, T; Jin, L; Liao, H; Yan, H; Yu, H; Zhang, B; Zou, X | 1 |
| Barbieri, L; Bellomo, G; Daffara, V; De Luca, G; Marino, P; Nardin, M; Pergolini, P; Rolla, R; Sartori, C; Schaffer, A; Suryapranata, H; Verdoia, M | 1 |
| Cheng, C; Guo, H; Li, B; Liu, Y; Liu, YJ; Xu, J; Zhang, R; Zhao, Y; Zhou, C | 1 |
| Harris, SP; Ho, V; Li, RH; Stern, JA; Tablin, F | 1 |
| Gao, RL; He, C; Liu, R; Ma, YL; Meng, XM; Song, L; Song, Y; Tang, XF; Wang, M; Xu, JJ; Yao, Y; Yuan, JQ; Zhang, JH | 1 |
| den Toom, ML; Szatmári, V; Teske, E; van Leeuwen, MW | 1 |
| Eichelberger, B; Fedrizzi, S; Gremmel, T; Panzer, S; Weigel, G | 1 |
| Anstrom, KJ; Baker, BA; Cohen, DJ; Effron, MB; Henry, TD; McCoy, LA; Messenger, JC; Peterson, ED; Wang, TY; Zettler, ME | 1 |
| Cao, Y; Dong, K; Liu, L; Rao, Z; Wang, A; Wang, F; Wang, Y; Zhao, X; Zheng, H | 1 |
| Alotti, N; Aradi, D; Barabás, E; Dézsi, DA; Faluközy, J; Merkely, B; Skopál, J; Várnai, K; Veress, G | 1 |
| Gremmel, T; Kopp, CW; Koppensteiner, R; Lang, IM; Lee, S; Panzer, S; Pultar, J; Wadowski, PP; Weikert, C | 1 |
| Chen, J; Gao, LJ; Gao, RL; Gao, Z; Qiao, SB; Tang, XF; Xu, B; Xu, JJ; Yang, YJ; Yuan, JQ; Zhang, Y; Zhu, P | 1 |
| Ferenc, M; Hochholzer, W; Löffelhardt, N; Mashayekhi, K; Neumann, FJ; Nührenberg, T; Stratz, C; Trenk, D; Valina, CM | 1 |
| Li, L; Li, Y; Lu, N; Meng, F; Wei, Q; Xu, Y; Yuan, J; Zhang, S; Zheng, X | 1 |
| Chen, S; Li, S; Xie, W; Yin, Q; Zhang, M | 1 |
| Brunner, S; Hamm, W; Lackermair, K; Mehr, M; Rizas, K | 1 |
| Choi, SY; Kim, MH | 1 |
| Barbato, E; Bartunek, J; Bressi, E; Bruyne, B; Di Gioia, G; Di Serafino, L; Mangiacapra, F; Morisco, C; Peace, AJ; Pellicano, M; Wijns, W | 1 |
| Aradi, D; Dézsi, DA; Freynhofer, MK; Geisler, T; Gross, L; Haller, PM; Hein-Rothweiler, R; Huber, K; Huczek, Z; Massberg, S; Orban, M; Sibbing, D; Toth-Gayor, GG; Trenk, D | 1 |
| Eikelboom, JW; Fan, Y; Li, C; Li, J; Mei, L; Niles, K; Wang, F; Xu, K; Yang, L; Zhang, J; Zhang, S; Zhu, H; Zou, F | 1 |
| Knych, HK; Kozikowski, TA; Norris, JW; Tablin, F; Watson, JL | 1 |
| Ge, JB; Qian, JY; Wang, QB; Wu, HY; Zhang, C; Zhao, X | 1 |
| Gager, GM; Hengstenberg, C; Jilma, B; Kolesnik, E; Lang, IM; Prüller, F; Siller-Matula, JM; Toma, A; von Lewinski, D; Wallner, M; Winter, MP | 1 |
| Ferraris, VA | 1 |
| Enomoto, Y; Ishida, H; Kitano, K; Matsubara, H; Omori, Y; Sakayori, T; Uematsu, K | 1 |
| Gremmel, T; Hoberstorfer, T; Kopp, CW; Lee, S; Panzer, S; Pultar, J; Wadowski, PP; Weikert, C | 1 |
| Bokemeyer, C; Fiehler, J; Frölich, AM; Haddad, M; Holst, B; Holstein, K; Janjetovic, S; Langer, F; Renné, T; Rolling, CC; Rolling, T; Tomada, J; Voigtländer, M | 1 |
| Chen, J; Li, X; Lv, Q; Wang, Z; Wu, H; Xue, Y | 1 |
| Li, Q; Tu, C; Ye, Y; Zeng, Y; Zhao, X | 1 |
| Eichinger, S; Kaider, A; Kollars, M; Kyrle, PA; Siller-Matula, JM; Steinbrecher, O; Traby, L; Wolzt, M | 1 |
| Ishigaku, Y; Itabashi, R; Kamada, A; Maeda, T; Narumi, S; Natori, T; Oi, K; Oura, K; Shimizu, M; Terayama, Y; Tsuda, K; Yoshida, M | 1 |
| Che, J; Chen, K; Dou, S; Liu, H; Liu, X; Wang, W; Wang, X; Zhang, X; Zhou, X | 1 |
| Battaglia, E; Bruni, A; Caracciolo, M; Franco, G; Garofalo, E; Labate, D; Lascala, S; Longhini, F; Macheda, S; Marano, G; Polimeni, N; Rovida, S; Squillaci, R; Tescione, M; Vadalà, E | 1 |
| Bliden, KP; Dahlen, J; Fisher, R; Gurbel, PA; Speros, PC; Sukavaneshvar, S; Tantry, US | 1 |
| Fang, L; Jiao, KL; Lin, YJ; Liu, B; Meng, S | 1 |
| Friebel, J; Hassanein, A; Jakobs, K; Landmesser, U; Puccini, M; Rauch, C; Rauch, U | 1 |
| Aguiar, MO; Azevedo, L; Baracioli, LM; Berwanger, O; Chiang, HP; Dalcoquio, TF; de Luca, F; Ferrari, AG; Furtado, RHM; Giugliano, RP; Goodman, S; Lima, FG; Matthias, W; Menezes, FR; Nicolau, JC; Scanavini-Filho, MA | 1 |
| Li, X; Lv, Q; Wang, Z; Xia, L; Yao, Y; Ye, Y; Zou, Y | 1 |
| Han, X; He, M; Kong, Y; Li, Y; Liu, G; Ren, J; Shi, J; Yan, W; Zhang, Y; Zhao, Z | 1 |
| Li, X; Sun, Y; Tian, WJ; Wang, DL; Wang, L; Wang, RN; Xia, XS | 1 |
| Hu, X; Liu, C; Zhang, M; Zhang, W | 1 |
| Barrs, VR; Griebsch, C; Hall, E | 1 |
| Angiolillo, DJ; Been, L; Franchi, F; Galli, M; Rollini, F; Zenni, MM | 1 |
| Han, K; Huang, X; Ma, M; Sun, T; Yang, S; Zhao, Z; Zhou, Y | 1 |
| Bode, C; Diehl, P; Gjermeni, D; Hesselbarth, D; Moser, M; Olivier, CB; Siegel, PM; Szabo, S | 1 |
| Ding, LP; Do, HP; Ge, WH; Li, YC; Liu, T; Shao, TF; Wang, R; Xu, MM; Yi, MM; Zhuang, Z | 1 |
| Baron, SJ; Dani, SS; Ganatra, S; Ijaz, SH; Kulbak, G; Levy, M; Resnic, F; Shahnawaz, A | 1 |
29 review(s) available for adenosine diphosphate and clopidogrel
| Article | Year |
|---|---|
Clinical pharmacology of the adenosine diphosphate (ADP) receptor antagonist, clopidogrel.
Topics: Adenosine Diphosphate; Animals; Arteriosclerosis; Aspirin; Clopidogrel; Humans; Platelet Activation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Rats; Receptors, Purinergic P2; Signal Transduction; Thrombosis; Ticlopidine | 1998 |
Ticlopidine and clopidogrel.
Topics: Adenosine Diphosphate; Adenylyl Cyclase Inhibitors; Adenylyl Cyclases; Angina, Unstable; Aspirin; Bone Marrow Diseases; Carbamazepine; Cardiovascular Diseases; Clopidogrel; Combined Modality Therapy; Coronary Disease; Drug Interactions; Hemorrhage; Humans; Myocardial Infarction; Peripheral Vascular Diseases; Phenytoin; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Safety; Stents; Theophylline; Thrombolytic Therapy; Ticlopidine | 1999 |
The medicinal chemistry of the P2 receptor family.
Topics: Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate; Animals; Arteriosclerosis; Cloning, Molecular; Clopidogrel; Cystic Fibrosis; Humans; Ophthalmic Solutions; Polyphosphates; Receptors, Purinergic P2; Structure-Activity Relationship; Ticlopidine; Tissue Distribution; Uracil Nucleotides | 2001 |
Highlights of latest advances in antithrombotics.
Topics: Adenosine Diphosphate; Animals; Blood Platelets; Clopidogrel; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thromboembolism; Ticlopidine | 2004 |
P2Y12, a new platelet ADP receptor, target of clopidogrel.
Topics: Adenosine Diphosphate; Angina, Unstable; Animals; Blood Platelets; Clopidogrel; Down-Regulation; Humans; Membrane Proteins; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Stroke; Ticlopidine | 2003 |
Resistance to clopidogrel: a review of the evidence.
Topics: Adenosine Diphosphate; Clopidogrel; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Resistance; Humans; Individuality; Membrane Proteins; Platelet Activation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Ticlopidine; Up-Regulation | 2005 |
Platelet aggregation and adenosine diphosphate/adenosine triphosphate receptors: a historical perspective.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Adenylyl Cyclases; Animals; Calcium; Calcium Signaling; Clopidogrel; Cyclic AMP; Drug Resistance; Hemorrhagic Disorders; Hemostasis; Humans; Mice; Mice, Knockout; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Second Messenger Systems; Thrombosis; Ticlopidine | 2005 |
The P2 receptors in platelet function.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Adenylyl Cyclases; Blood Vessels; Cell Shape; Clopidogrel; Cytoplasmic Granules; Fibrinolytic Agents; Humans; Ion Transport; Membrane Proteins; Models, Biological; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Receptor Cross-Talk; Receptors, Purinergic P2; Receptors, Purinergic P2X; Receptors, Purinergic P2Y1; Receptors, Purinergic P2Y12; Signal Transduction; Stress, Mechanical; Thrombosis; Ticlopidine | 2005 |
The platelet P2 receptors in thrombosis.
Topics: Adenosine Diphosphate; Animals; Blood Vessels; Clinical Trials as Topic; Clopidogrel; Fibrinolytic Agents; Hemorrhagic Disorders; Humans; Membrane Proteins; Mice; Mice, Knockout; Platelet Aggregation Inhibitors; Pyridines; Receptors, Purinergic P2; Receptors, Purinergic P2X; Receptors, Purinergic P2Y1; Receptors, Purinergic P2Y12; Thrombosis; Ticlopidine | 2005 |
Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis.
Topics: Adenosine Diphosphate; Animals; Arteriosclerosis; Aspirin; Clinical Trials as Topic; Clopidogrel; Cohort Studies; Double-Blind Method; Drug Resistance; Fibrinolytic Agents; Forecasting; Humans; Membrane Proteins; Meta-Analysis as Topic; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Pyridines; Randomized Controlled Trials as Topic; Rats; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thrombophilia; Thrombosis; Ticlopidine | 2005 |
Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity.
Topics: Adenosine Diphosphate; Adult; Animals; Aspirin; Biotransformation; Clinical Trials, Phase I as Topic; Clopidogrel; Collagen; Drug Evaluation, Preclinical; Drug Synergism; Fibrinolytic Agents; Hemostasis; Humans; Male; Membrane Proteins; Molecular Structure; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Pyridines; Rats; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thiophenes; Thrombin; Thrombosis; Ticlopidine | 2005 |
Prasugrel.
Topics: Adenosine Diphosphate; Animals; Aspirin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Clopidogrel; Collagen; Coronary Disease; Drug Evaluation, Preclinical; Drug Resistance; Drug Synergism; Drug Therapy, Combination; Drugs, Investigational; Humans; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Pyridines; Rats; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine | 2006 |
Variable platelet response to aspirin and clopidogrel in atherothrombotic disease.
Topics: Adenosine Diphosphate; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atherosclerosis; Biomarkers; Biotransformation; Blood Coagulation Tests; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Drug Interactions; Drug Resistance; Hemorrhage; Humans; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Receptors, Purinergic P2Y1; Receptors, Purinergic P2Y12; Thrombosis; Thromboxane A2; Thromboxane B2; Ticlopidine; Treatment Failure | 2007 |
Clopidogrel resistance.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Clopidogrel; Cytochrome P-450 Enzyme System; Drug Resistance; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Receptors, Purinergic P2; Ticlopidine; Treatment Failure | 2007 |
Greater inhibition of platelet aggregation and reduced response variability with prasugrel versus clopidogrel: an integrated analysis.
Topics: Adenosine Diphosphate; Adolescent; Adult; Aged; Bayes Theorem; Clinical Trials, Phase I as Topic; Clopidogrel; Databases, Factual; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Treatment Outcome | 2007 |
Unmet needs in oral antiplatelet therapy with ADP receptor blocking agents.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Administration, Oral; Clinical Trials as Topic; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine | 2009 |
Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Animals; Atherosclerosis; Clinical Trials as Topic; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine; Vasoconstriction | 2009 |
Update on antiplatelet therapy in acute coronary syndromes: what do new drugs bring into clinical practice?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Clopidogrel; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Pyridines; Thiophenes; Ticagrelor; Ticlopidine | 2009 |
Platelet P2Y₁₂ receptor inhibition: an update on clinical drug development.
Topics: Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Drug Design; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Pyridines; Receptors, Purinergic P2Y12; Ticlopidine | 2010 |
[Significance of platelet function tests].
Topics: Adenosine Diphosphate; Arachidonic Acid; Aspirin; Blood Platelet Disorders; Clopidogrel; Collagen; Hemorrhagic Disorders; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Prognosis; Ristocetin; Ticlopidine | 2010 |
The platelet P2Y₁₂ receptor for adenosine diphosphate: congenital and drug-induced defects.
Topics: Adenosine; Adenosine Diphosphate; Animals; Blood Platelet Disorders; Blood Platelets; Clopidogrel; Female; Hemorrhage; Humans; Male; Mice; Mutation; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Signal Transduction; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
Ticagrelor: from discovery to Phase III clinical trial.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Clinical Trials, Phase III as Topic; Clopidogrel; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine | 2010 |
Bleeding manifestations of congenital and drug-induced defects of the platelet P2Y12 receptor for adenosine diphosphate.
Topics: Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Animals; Clinical Trials, Phase III as Topic; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
Clinical, genetic and confounding factors determine the dynamics of the in vitro response/non response to clopidogrel.
Topics: Adenosine Diphosphate; Clopidogrel; Drug Interactions; Drug Resistance; Female; Humans; In Vitro Techniques; Male; Pharmacogenetics; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticlopidine | 2011 |
Translational platelet research in patients with coronary artery disease: what are the major knowledge gaps?
Topics: Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Biomarkers, Pharmacological; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Humans; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Ticlopidine; Translational Research, Biomedical; Treatment Outcome | 2012 |
Pharmacodynamic impacts of proton pump inhibitors on the efficacy of clopidogrel in vivo--a systematic review.
Topics: Adenosine Diphosphate; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Drug Interactions; Drug Resistance; Gastrointestinal Diseases; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Receptors, Purinergic P2Y12; Ticlopidine | 2013 |
Benefits from new ADP antagonists as compared with clopidogrel in patients with stable angina or acute coronary syndrome undergoing invasive management: a meta-analysis of randomized trials.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Angina, Stable; Case Management; Clopidogrel; Endpoint Determination; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticlopidine; Treatment Outcome | 2014 |
Risk of stroke in patients with high on-clopidogrel platelet reactivity to adenosine diphosphate after percutaneous coronary intervention.
Topics: Adenosine Diphosphate; Blood Platelets; Clopidogrel; Dose-Response Relationship, Drug; Global Health; Humans; Incidence; Myocardial Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Postoperative Period; Risk Factors; Stroke; Ticlopidine | 2014 |
Utilization Trends In Platelet Adenosine Diphosphate P2Y12 Receptor Inhibitor and Cost Among Medicare Beneficiaries.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Clopidogrel; Humans; Medicare; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; United States | 2023 |
123 trial(s) available for adenosine diphosphate and clopidogrel
| Article | Year |
|---|---|
Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase.
Topics: Adenosine; Adenosine Diphosphate; Adenylyl Cyclase Inhibitors; Adult; Binding Sites; Blood Platelets; Clopidogrel; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Membrane Glycoproteins; Receptors, Purinergic; Thionucleotides; Thrombin; Ticlopidine | 1992 |
Prolonged heparin administration during clopidogrel treatment in healthy subjects.
Topics: Adenosine Diphosphate; Administration, Oral; Adult; Clopidogrel; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Heparin; Humans; Infusions, Intravenous; Male; Partial Thromboplastin Time; Ticlopidine | 1999 |
Antiplatelet activity of clopidogrel in coronary artery bypass graft surgery patients.
Topics: Adenosine Diphosphate; Adult; Bleeding Time; Clopidogrel; Coronary Artery Bypass; Female; Humans; Male; Middle Aged; Patient Compliance; Platelet Aggregation; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Ticlopidine; Treatment Outcome | 1999 |
Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: enhanced inhibitory effects of combination therapy.
Topics: Adenosine Diphosphate; Adult; Aged; Antigens, CD; Aspirin; Blood; Clopidogrel; Collagen; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dual Specificity Phosphatase 2; Humans; Middle Aged; Myocardial Infarction; P-Selectin; Peptide Fragments; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Membrane Glycoproteins; Prospective Studies; Protein Phosphatase 2; Protein Tyrosine Phosphatases; Tetraspanin 30; Ticlopidine | 2000 |
Acute antithrombotic effect of a front-loaded regimen of clopidogrel in patients with atherosclerosis on aspirin.
Topics: Adenosine Diphosphate; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Drug Therapy, Combination; Fibrinogen; Fibrinolytic Agents; Humans; Perfusion; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticlopidine; Time Factors | 2000 |
Recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers.
Topics: Adenosine Diphosphate; Adult; Binding, Competitive; Blood Platelets; Clopidogrel; Flow Cytometry; Humans; Male; P-Selectin; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticlopidine; Time Factors | 2001 |
Effects of combined therapy with clopidogrel and acetylsalicylic acid on platelet glycoprotein expression and aggregation.
Topics: Adenosine Diphosphate; Aged; Aspirin; Clopidogrel; Coronary Disease; Drug Synergism; Drug Therapy, Combination; Dual Specificity Phosphatase 2; Female; Humans; Male; P-Selectin; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Protein Phosphatase 2; Protein Tyrosine Phosphatases; Ticlopidine | 2002 |
Clopidogrel inhibits platelet adhesion and platelet-dependent mitogenesis in vascular smooth muscle cells.
Topics: Adenosine Diphosphate; Adult; Animals; Blood Platelets; Cattle; Cell Culture Techniques; Cell Division; Clopidogrel; Culture Media, Conditioned; DNA Replication; Fibrinogen; Humans; Male; MAP Kinase Signaling System; Muscle, Smooth, Vascular; Paracrine Communication; Platelet Adhesiveness; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticlopidine | 2002 |
Comparison of antiplatelet effect of loading dose of clopidogrel versus abciximab during coronary intervention.
Topics: Abciximab; Adenosine Diphosphate; Aged; Aged, 80 and over; Angina Pectoris; Antibodies, Monoclonal; Aspirin; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Stents; Ticlopidine; Treatment Outcome | 2002 |
Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Ischemia; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2 Receptor Antagonists; Ticlopidine | 2002 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Resistance; Female; Flow Cytometry; Genetic Variation; Humans; Male; P-Selectin; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Ticlopidine | 2003 |
The effect of preoperative antiplatelet/anticoagulant prophylaxis on postoperative blood loss in cardiac surgery.
Topics: Adenosine Diphosphate; Aged; Anticoagulants; Body Temperature; Cardiac Surgical Procedures; Clopidogrel; Coronary Artery Bypass; Double-Blind Method; Female; Fibrinogen; Hemostasis; Heparin; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Premedication; Prospective Studies; Purinergic P2 Receptor Antagonists; Ticlopidine | 2004 |
Combination antiplatelet therapy in patients with peripheral vascular bypass grafts.
Topics: Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Blood Vessel Prosthesis; Clopidogrel; Drug Therapy, Combination; Female; Flow Cytometry; Graft Occlusion, Vascular; Humans; Male; Middle Aged; Peripheral Vascular Diseases; Platelet Activation; Platelet Aggregation Inhibitors; Ticlopidine | 2004 |
Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes.
Topics: Acute Disease; Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; CD40 Ligand; Clopidogrel; Combined Modality Therapy; Coronary Disease; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Administration Schedule; Drug Interactions; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inactivation, Metabolic; Male; Middle Aged; P-Selectin; Peptide Fragments; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Stents; Ticlopidine; Treatment Outcome | 2004 |
Failure of clopidogrel to reduce platelet reactivity and activation following standard dosing in elective stenting: implications for thrombotic events and restenosis.
Topics: Adenosine Diphosphate; Aged; Aged, 80 and over; Clopidogrel; Coronary Restenosis; Female; Humans; Male; Middle Aged; Platelet Activation; Platelet Aggregation; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Thrombosis; Ticlopidine; Time Factors; Treatment Failure | 2004 |
The effect of clopidogrel, aspirin and both antiplatelet drugs on platelet function in patients with peripheral arterial disease.
Topics: Adenosine Diphosphate; Aged; Arteriosclerosis; Aspirin; Blood Platelets; Cell Shape; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; P-Selectin; Peripheral Vascular Diseases; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet-Derived Growth Factor; Serotonin; Ticlopidine | 2004 |
Is a 300 mg clopidogrel loading dose sufficient to inhibit platelet function early after coronary stenting? A platelet function profile study.
Topics: Adenosine Diphosphate; Clopidogrel; Coronary Vessels; Female; Fibrinogen; Flow Cytometry; Humans; Male; Middle Aged; P-Selectin; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Glycoprotein GPIIb-IIIa Complex; Premedication; Stents; Thrombosis; Ticlopidine; von Willebrand Factor | 2004 |
Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome.
Topics: Adenosine Diphosphate; Aspirin; Blood Platelets; CD40 Ligand; Clopidogrel; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Humans; Leukocytes; Male; Middle Aged; Myocardial Infarction; P-Selectin; Peptide Fragments; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2004 |
Measurement of platelet aggregation during antiplatelet therapy in ischemic stroke.
Topics: Adenosine Diphosphate; Adult; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Collagen; Epinephrine; Female; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Reference Values; Ticlopidine | 2004 |
ADP induced platelet degranulation in healthy individuals is reduced by clopidogrel after pretreatment with atorvastatin.
Topics: Adenosine Diphosphate; Adolescent; Adult; Atorvastatin; Cell Degranulation; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Fibrinogen; Heptanoic Acids; Humans; Middle Aged; P-Selectin; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Pyrroles; Ticlopidine | 2004 |
Prothrombotic responses to exercise are little influenced by clopidogrel treatment.
Topics: Adenosine Diphosphate; Adult; Blood Platelets; Cell Adhesion; Clopidogrel; Cross-Over Studies; Exercise; Humans; Leukocytes; Male; P-Selectin; Platelet Aggregation; Platelet Aggregation Inhibitors; Thrombophilia; Thromboxane B2; Ticlopidine | 2004 |
The difference between clopidogrel responsiveness and posttreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Function Tests; Predictive Value of Tests; Prognosis; Risk; Stents; Thrombosis; Ticlopidine | 2005 |
Variable extent of clopidogrel responsiveness in patients after coronary stenting.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Cell Adhesion Molecules; Clopidogrel; Drug Therapy, Combination; Female; Flow Cytometry; GTP-Binding Protein alpha Subunits, Gi-Go; Heart Diseases; Humans; Male; Membrane Proteins; Microfilament Proteins; Middle Aged; Phosphoproteins; Phosphorylation; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Stents; Ticlopidine; Treatment Outcome | 2004 |
Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention.
Topics: Adenosine Diphosphate; Aged; Cardiac Catheterization; Clopidogrel; Cohort Studies; Drug Interactions; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pharmacokinetics; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticlopidine; Time Factors | 2005 |
The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting.
Topics: Adenosine Diphosphate; Aged; Clopidogrel; Coronary Stenosis; Dose-Response Relationship, Drug; Female; Humans; Incidence; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Postoperative Complications; Stents; Ticlopidine; Treatment Outcome | 2005 |
Enhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: a randomized crossover trial.
Topics: Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Biomarkers; Clopidogrel; Collagen; Cross-Over Studies; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Nephelometry and Turbidimetry; Peripheral Vascular Diseases; Platelet Activation; Platelet Aggregation Inhibitors; Ticlopidine | 2005 |
Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination.
Topics: Adenosine Diphosphate; Antigens, Human Platelet; Aspirin; Blood Platelets; Clopidogrel; Collagen; Coronary Artery Disease; Cytoplasmic Granules; Epinephrine; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polymorphism, Genetic; Ticlopidine | 2006 |
Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study.
Topics: Adenosine Diphosphate; Adult; Aged; Alprostadil; Blood Platelets; Clopidogrel; Coronary Disease; Female; Humans; Male; Middle Aged; Monitoring, Physiologic; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Purinergic P2 Receptor Agonists; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y1; Stents; Thrombosis; Ticlopidine | 2007 |
Diabetes mellitus and platelet function after administration of aspirin and a single 600 mg dose of clopidogrel.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Collagen; Coronary Artery Disease; Diabetes Complications; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Male; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Receptors, Thrombin; Thrombosis; Ticlopidine | 2006 |
A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) t
Topics: Acute Disease; Adenosine Diphosphate; Aged; Biomarkers; Clopidogrel; Dose-Response Relationship, Drug; Electrocardiography; Female; Humans; Inflammation; Male; Middle Aged; Myocardial Infarction; Myocardium; Necrosis; Platelet Aggregation; Platelet Aggregation Inhibitors; Single-Blind Method; Ticlopidine; Troponin I | 2006 |
Evidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance'.
Topics: Adenosine Diphosphate; Adult; Aspirin; Bayes Theorem; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; Drug Resistance; Female; Humans; Male; Middle Aged; Models, Cardiovascular; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Reference Values; Severity of Illness Index; Ticlopidine; Time Factors | 2007 |
Normalization of platelet reactivity in clopidogrel-treated subjects.
Topics: Adenosine Diphosphate; Adult; Arachidonic Acid; Aspirin; Blood Platelets; Clopidogrel; Collagen; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fibrinogen; Humans; Male; Pilot Projects; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Platelet Transfusion; Platelet-Rich Plasma; Postoperative Hemorrhage; Receptors, Thrombin; Recovery of Function; Reference Values; Ticlopidine; Time Factors | 2007 |
Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Humans; Male; Middle Aged; Pilot Projects; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Ticlopidine | 2007 |
Lack of association between the 807 C/T polymorphism of glycoprotein Ia gene and post-treatment platelet reactivity after aspirin and clopidogrel in patients with acute coronary syndrome.
Topics: Acute Disease; Adenosine Diphosphate; Aged; Aspirin; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Cytosine; Female; France; Genotype; Humans; Integrin alpha2; Male; Microfilament Proteins; Middle Aged; Myocardial Ischemia; P-Selectin; Phosphoproteins; Phosphorylation; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymorphism, Single Nucleotide; Prospective Studies; Syndrome; Thymine; Ticlopidine; Treatment Outcome | 2007 |
Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects.
Topics: Adenosine Diphosphate; Adolescent; Adult; Aspirin; Bleeding Time; Clopidogrel; Collagen; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Male; Middle Aged; Peptide Fragments; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2007 |
The additive antiplatelet action of clopidogrel in patients with coronary artery disease treated with aspirin.
Topics: Adenosine Diphosphate; Adult; Aged; Aspirin; Biomarkers; Case-Control Studies; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Drug Resistance; Drug Synergism; Drug Therapy, Combination; Flow Cytometry; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticlopidine; Treatment Outcome | 2007 |
Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Adolescent; Adult; Clopidogrel; Cyclooxygenase Inhibitors; Female; Humans; Male; Middle Aged; P-Selectin; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Ticlopidine | 2008 |
Therapeutic benefit of low-dose clopidogrel in patients undergoing carotid surgery is linked to variability in the platelet adenosine diphosphate response and patients' weight.
Topics: Adenosine Diphosphate; Aspirin; Blood Platelets; Body Weight; Clopidogrel; Endarterectomy, Carotid; Humans; Placebos; Platelet Activation; Platelet Aggregation Inhibitors; Postoperative Complications; Statistics as Topic; Thrombosis; Ticlopidine | 2007 |
Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel.
Topics: Adenosine Diphosphate; Adult; Area Under Curve; Blood Platelets; Clopidogrel; Cross-Over Studies; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2007 |
Effect of clopidogrel treatment on stress-induced platelet activation and myocardial ischemia in aspirin-treated patients with stable coronary artery disease.
Topics: Adenosine Diphosphate; Aged; Aspirin; Blood Platelets; C-Reactive Protein; CD40 Ligand; Clopidogrel; Collagen; Coronary Artery Disease; Double-Blind Method; Drug Therapy, Combination; Electrocardiography, Ambulatory; Exercise Test; Flow Cytometry; Heart Rate; Humans; Interleukin-6; Leukocytes; Male; Middle Aged; Myocardial Ischemia; P-Selectin; Platelet Activation; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Research Design; Stress, Physiological; Thrombin; Ticlopidine; Treatment Outcome | 2007 |
The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cell Adhesion Molecules; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; Female; Flow Cytometry; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Phosphorylation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Prospective Studies; Reproducibility of Results; Research Design; Risk Assessment; Risk Factors; ROC Curve; Sensitivity and Specificity; Stents; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2007 |
Variable responsiveness to clopidogrel and aspirin among patients with acute coronary syndrome as assessed by platelet function tests.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Adult; Aged; Arachidonic Acid; Aspirin; Clopidogrel; Female; Humans; Male; Middle Aged; Nephelometry and Turbidimetry; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet-Rich Plasma; ROC Curve; Sensitivity and Specificity; Ticlopidine | 2008 |
Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment.
Topics: Adenosine Diphosphate; Aged; Clopidogrel; Electrodes; Female; Humans; Light; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Reproducibility of Results; Ticlopidine; Time Factors | 2008 |
Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Florida; Humans; Male; Middle Aged; Pilot Projects; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Research Design; Spain; Stents; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2008 |
Impact of cytochrome P450 3A4-metabolized statins on the antiplatelet effect of a 600-mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Cohort Studies; Coronary Disease; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Female; Flow Cytometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Pyrroles; Simvastatin; Stents; Ticlopidine; Time Factors; Treatment Outcome | 2008 |
A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry.
Topics: Adenosine Diphosphate; Adult; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Flow Cytometry; Humans; Light; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Phosphorylation; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Reproducibility of Results; Thiophenes; Ticlopidine; Time Factors | 2008 |
Platelet inhibition by low-dose aspirin but not by clopidogrel reduces the axon-reflex current-induced vasodilation in humans.
Topics: Acetylcholine; Adenosine Diphosphate; Adult; Aspirin; Axons; Blood Platelets; Clopidogrel; Electric Stimulation; Endothelium, Vascular; Female; Humans; Iontophoresis; Laser-Doppler Flowmetry; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Prostaglandin-Endoperoxide Synthases; Signal Transduction; Ticlopidine; Vasodilation; Vasodilator Agents | 2008 |
Residual prothrombotic status in low responder patients to clopidogrel identified by Vasodilator-Stimulated Phosphoprotein Phosphorylation (VASP) analysis?
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Aged, 80 and over; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Drug Resistance; Female; Humans; Male; Microfilament Proteins; Middle Aged; Myocardial Ischemia; P-Selectin; Phosphoproteins; Phosphorylation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIb-IX Complex; Recurrence; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2008 |
Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Diphosphate; Adolescent; Adult; Aged; Area Under Curve; Biological Availability; Clopidogrel; Cross-Over Studies; Drug Interactions; Female; Humans; Lansoprazole; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Thiophenes; Ticlopidine | 2008 |
Impact of bivalirudin or unfractionated heparin on platelet aggregation in patients pretreated with 600 mg clopidogrel undergoing elective percutaneous coronary intervention.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel; Double-Blind Method; Female; Heparin; Hirudins; Humans; Male; Peptide Fragments; Perioperative Care; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Premedication; Recombinant Proteins; Ticlopidine | 2008 |
Assessment of VerifyNow P2Y12 assay accuracy in evaluating clopidogrel-induced platelet inhibition.
Topics: Adenosine Diphosphate; Adult; Alprostadil; Clopidogrel; Double-Blind Method; Female; Humans; Male; Peptide Fragments; Platelet Aggregation; Platelet Aggregation Inhibitors; Point-of-Care Systems; Prospective Studies; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Sample Size; Ticlopidine | 2008 |
Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects.
Topics: Adenosine Diphosphate; Adult; Aspirin; Clopidogrel; Drug-Related Side Effects and Adverse Reactions; Female; Hemorrhage; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2008 |
Effect of 150-mg vs 300-mg loading doses of clopidogrel on platelet function in Japanese patients undergoing coronary stent placement.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Asian People; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Dose-Response Relationship, Drug; Female; Humans; Japan; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Stents; Ticlopidine; Time Factors; Treatment Outcome | 2008 |
Effects of aspirin and clopidogrel in healthy men measured by platelet aggregation and PFA-100.
Topics: Adenosine Diphosphate; Adolescent; Adult; Arachidonic Acid; Aspirin; Clopidogrel; Collagen; Cross-Over Studies; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Resistance; Epinephrine; Humans; Male; Middle Aged; Nephelometry and Turbidimetry; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Reference Values; Ticlopidine | 2008 |
ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay.
Topics: Adenosine Diphosphate; Aged; Aspirin; Blood Platelets; Clopidogrel; Comorbidity; Coronary Artery Disease; Drug Resistance; Female; Flow Cytometry; Humans; Incidence; Male; P-Selectin; Platelet Aggregation; Platelet Aggregation Inhibitors; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Signal Transduction; Ticlopidine | 2008 |
Effect of increased aspirin dose after stenting in association with ClOpidogrel: the FIASCO randomized study.
Topics: Adenosine Diphosphate; Aged; Angina Pectoris; Arachidonic Acid; Aspirin; Blood Platelets; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prospective Studies; Ticlopidine; Time Factors; Treatment Outcome | 2009 |
Comparison of collagen versus adenosine diphosphate in detecting antiplatelet effect in patients with coronary artery disease.
Topics: Adenosine Diphosphate; Aged; Aspirin; Clopidogrel; Collagen; Coronary Artery Disease; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Prospective Studies; Ticlopidine; Treatment Outcome | 2009 |
Clopidogrel attenuates coated-platelet production in patients undergoing elective coronary catheterization.
Topics: Adenosine Diphosphate; Aged; Aged, 80 and over; Blood Platelets; Cardiac Catheterization; Clopidogrel; Coronary Angiography; Crotalid Venoms; Female; Fibrinolytic Agents; Humans; Lectins, C-Type; Male; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thrombin; Ticlopidine | 2008 |
[Impact of statins on clopidogrel platelet inhibition in patients with acute coronary syndrome or stable angina].
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angina Pectoris; Atorvastatin; Clopidogrel; Drug Interactions; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Pravastatin; Prospective Studies; Pyrroles; Ticlopidine | 2008 |
Functional variability of platelet response to clopidogrel correlates with P2Y(12) receptor occupancy.
Topics: Adenosine Diphosphate; Adolescent; Adult; Binding Sites; Blood Platelets; Clopidogrel; Double-Blind Method; Drug Resistance; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Ticlopidine; Young Adult | 2009 |
Thrombotic events in high risk patients are predicted by evaluating different pathways of platelet function.
Topics: Adenosine Diphosphate; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Arachidonic Acid; Aspirin; Clopidogrel; Collagen; Drug Resistance; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Likelihood Functions; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Point-of-Care Systems; Predictive Value of Tests; Prospective Studies; Reproducibility of Results; Risk Assessment; Risk Factors; ROC Curve; Thrombosis; Ticlopidine | 2008 |
Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Cell Adhesion Molecules; Clopidogrel; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Phosphorylation; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Reproducibility of Results; Sensitivity and Specificity; Stents; Ticlopidine | 2009 |
Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with Eptifibatide to
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Blood Coagulation; Blood Platelets; Clopidogrel; Collagen; Drug Therapy, Combination; Eptifibatide; Female; Hemorheology; Hirudins; Humans; Male; Middle Aged; Myocardial Infarction; Peptide Fragments; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Receptors, Thrombin; Recombinant Proteins; Stents; Thrombelastography; Ticlopidine | 2009 |
Considerable variability in platelet activity among patients with coronary artery disease in response to an increased maintenance dose of clopidogrel.
Topics: Adenosine Diphosphate; Aged; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Ticlopidine; Time Factors | 2009 |
Insights into the interpretation of light transmission aggregometry for evaluation of platelet aggregation inhibition by clopidogrel.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Ticlopidine | 2009 |
Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Cell Adhesion Molecules; Clopidogrel; Female; Humans; Male; Microfilament Proteins; Middle Aged; Myocardial Infarction; Phosphoproteins; Phosphorylation; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2009 |
Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects.
Topics: Adenosine Diphosphate; Administration, Oral; Adult; Area Under Curve; Chromatography, High Pressure Liquid; Clopidogrel; Cross-Over Studies; Humans; Korea; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Salts; Tandem Mass Spectrometry; Therapeutic Equivalency; Ticlopidine; Young Adult | 2009 |
Assessment of platelet response to clopidogrel through measurement of ADP-induced Akt phosphorylation.
Topics: Adenosine Diphosphate; Aged; Blood Platelets; Clopidogrel; Female; Humans; Male; Methods; Middle Aged; Phosphorylation; Proto-Oncogene Proteins c-akt; Ticlopidine | 2009 |
High loading dose of clopidogrel is unable to satisfactorily inhibit platelet reactivity in patients with glycoprotein IIIA gene polymorphism: a genetic substudy of PRAGUE-8 trial.
Topics: Adenosine Diphosphate; Aged; Antigens, Human Platelet; Clopidogrel; Coronary Artery Disease; Female; Humans; Integrin beta3; Male; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Ticlopidine; Time Factors | 2009 |
Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3.
Topics: Adenosine; Adenosine Diphosphate; Area Under Curve; Atherosclerosis; Clopidogrel; Dose-Response Relationship, Drug; Humans; Integrin beta3; Pharmacogenetics; Platelet Aggregation; Polymorphism, Single Nucleotide; Receptors, Purinergic P2; Receptors, Purinergic P2Y1; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine | 2009 |
Cross validation of the Multiple Electrode Aggregometry. A prospective trial in healthy volunteers.
Topics: Adenosine Diphosphate; Adult; Alprostadil; Arachidonic Acid; Aspirin; Clopidogrel; Electrodes; Female; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Ticlopidine; Time Factors; Young Adult | 2009 |
Clopidogrel provides significantly greater inhibition of platelet activity than aspirin when combined with atorvastatin after coronary artery bypass grafting: a prospective randomized study.
Topics: Adenosine Diphosphate; Aged; Aspirin; Atorvastatin; Clopidogrel; Comorbidity; Coronary Artery Bypass; Coronary Disease; Drug Therapy, Combination; Female; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipoproteins, LDL; Male; Middle Aged; P-Selectin; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Complications; Prospective Studies; Pyrroles; Ticlopidine | 2010 |
The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients.
Topics: Adenosine Diphosphate; Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Blood Coagulation; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Collagen; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Drug Therapy, Combination; Female; Gene Frequency; Genotype; Humans; Male; Microfilament Proteins; Middle Aged; Phenotype; Phosphoproteins; Phosphorylation; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Purinergic P2 Receptor Antagonists; Quinazolinones; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Stents; Sulfonamides; Thrombelastography; Ticlopidine | 2010 |
Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Blood Coagulation Tests; Clopidogrel; Drug Monitoring; Drug Resistance; Drug-Eluting Stents; Female; Germany; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Point-of-Care Systems; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Risk Assessment; Risk Factors; ROC Curve; Thrombosis; Ticlopidine; Time Factors; Treatment Failure | 2010 |
Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Clopidogrel; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Paris; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome | 2010 |
Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patie
Topics: Adenosine Diphosphate; Aged; Aspirin; Blood Platelets; Blood Vessel Prosthesis Implantation; Cells, Cultured; Chemotherapy, Adjuvant; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Activation; Platelet Aggregation Inhibitors; Prospective Studies; Stents; Tetrazoles; Ticlopidine | 2010 |
Differential sensitivity and kinetics of response of different ex vivo tests monitoring functional variability of platelet response to clopidogrel.
Topics: Adenosine Diphosphate; Adult; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Double-Blind Method; Flow Cytometry; Humans; Kinetics; Male; Microfilament Proteins; Nephelometry and Turbidimetry; P-Selectin; Phosphoproteins; Phosphorylation; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Receptors, Purinergic P2Y12; Sensitivity and Specificity; Thionucleotides; Thrombelastography; Ticlopidine; Young Adult | 2010 |
The Platelet Activity After Clopidogrel Termination (PACT) study.
Topics: Adenosine Diphosphate; Adult; Aged; Blood Platelets; CD40 Ligand; Clopidogrel; Double-Blind Method; Female; Humans; Male; Middle Aged; P-Selectin; Platelet Activation; Platelet Glycoprotein GPIIb-IIIa Complex; Ticlopidine; Withholding Treatment | 2010 |
Comparison between the effect of omeprazole and rabeprazole on the antiplatelet action of clopidogrel.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Diphosphate; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Interactions; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Omeprazole; Platelet Aggregation; Platelet Aggregation Inhibitors; Rabeprazole; Ticlopidine; Treatment Outcome | 2010 |
Cytochrome 2C19 polymorphism and response to adjunctive cilostazol versus high maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention.
Topics: Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Blood Platelets; Chemotherapy, Adjuvant; Cilostazol; Clopidogrel; Codon, Nonsense; Cytochrome P-450 CYP2C19; DNA Mutational Analysis; Humans; Ischemia; Platelet Aggregation; Polymorphism, Genetic; Receptors, Purinergic P2Y12; Tetrazoles; Ticlopidine | 2010 |
Stability of the high on-treatment platelet reactivity phenotype over time in clopidogrel-treated patients.
Topics: Adenosine Diphosphate; Clopidogrel; Double-Blind Method; Drug Monitoring; Humans; Phenotype; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticlopidine; Time | 2011 |
Antagonism of P2Y₁₂ reduces physiological thromboxane levels.
Topics: Adenosine Diphosphate; Adolescent; Adult; Animals; Blood Platelets; Clopidogrel; Female; Humans; Male; Mice; Mice, Knockout; Middle Aged; Pilot Projects; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Thromboxanes; Ticlopidine; Young Adult | 2010 |
Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Chi-Square Distribution; Cilostazol; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Female; Genotype; Humans; Korea; Liver; Male; Middle Aged; Myocardial Infarction; Phenotype; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Regression Analysis; Risk Assessment; Risk Factors; Tetrazoles; Thrombosis; Ticlopidine; Treatment Outcome | 2011 |
High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2).
Topics: Adenosine Diphosphate; Adult; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Bypass; Cross-Over Studies; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Drug; Drug Resistance; Female; France; Gene Dosage; Heterozygote; Homozygote; Humans; Male; Middle Aged; Myocardial Infarction; Phenotype; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Prospective Studies; Registries; Risk Assessment; Risk Factors; Ticlopidine; Treatment Outcome | 2011 |
Low platelet reactivity is recovered by transfusion of stored platelets: a healthy volunteer in vivo study.
Topics: Adenosine Diphosphate; Aryl Hydrocarbon Hydroxylases; Austria; Blood Platelets; Blood Transfusion, Autologous; Cell Adhesion Molecules; Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Microfilament Proteins; Phosphoproteins; Phosphorylation; Pilot Projects; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Platelet Transfusion; Polymorphism, Single Nucleotide; Ticlopidine | 2011 |
Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44.
Topics: Adenosine Diphosphate; Aged; Clopidogrel; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Platelet Activating Factor; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine | 2011 |
Genetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects.
Topics: Adenosine Diphosphate; Adult; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cross-Over Studies; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Ticlopidine; Young Adult | 2011 |
Clopidogrel pharmacodynamics and pharmacokinetics in the fed and fasted state: a randomized crossover study of healthy men.
Topics: Adenosine Diphosphate; Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Breakfast; Clopidogrel; Cross-Over Studies; Cytochrome P-450 CYP2C19; Diet, High-Fat; Food-Drug Interactions; Genotype; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticlopidine; Young Adult | 2012 |
Use of tailored loading-dose clopidogrel in patients undergoing selected percutaneous coronary intervention based on adenosine diphosphate-mediated platelet aggregation.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Ticlopidine | 2010 |
Reversal of the anti-platelet effects of aspirin and clopidogrel.
Topics: Adenosine Diphosphate; Adult; Arachidonic Acid; Aspirin; Biomarkers; Blood Platelets; Clopidogrel; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Ontario; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Transfusion; Recovery of Function; Thromboxane B2; Ticlopidine; Time Factors | 2012 |
Pharmacodynamic effects of clopidogrel in pediatric cardiac patients: a comparative study of platelet aggregation response.
Topics: Adenosine Diphosphate; Adult; Arteries; Blood Platelets; Child, Preschool; Clopidogrel; Double-Blind Method; Female; Fetal Blood; Heart; Heart Diseases; Humans; Infant; Infant, Newborn; Male; Peptide Fragments; Placebos; Platelet Aggregation; Platelet Aggregation Inhibitors; Thrombosis; Ticlopidine | 2012 |
Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study.
Topics: Adenosine Diphosphate; Aspirin; Atorvastatin; Calcium Channel Blockers; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP3A; Drug Substitution; Drug Therapy, Combination; Female; Fluorobenzenes; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Ticlopidine | 2012 |
Relation between clopidogrel active metabolite levels and different platelet aggregation methods in patients receiving clopidogrel and aspirin.
Topics: Adenosine Diphosphate; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prodrugs; Ticlopidine; Time Factors | 2012 |
A randomized comparison of platelet reactivity in patients after treatment with various commercial clopidogrel preparations: the CLO-CLO trial.
Topics: Adenosine Diphosphate; Aged; Aged, 80 and over; Clopidogrel; Cross-Over Studies; Drugs, Generic; Female; Humans; Male; Middle Aged; Myocardial Ischemia; Patient Selection; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Single-Blind Method; Stents; Therapeutic Equivalency; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome | 2012 |
A randomized crossover study comparing the antiplatelet effect of plavix versus generic clopidogrel.
Topics: Adenosine Diphosphate; Adult; Clopidogrel; Cross-Over Studies; Drugs, Generic; England; Humans; Male; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Prospective Studies; Therapeutic Equivalency; Thrombelastography; Ticlopidine; Time Factors | 2012 |
Paraoxonase-1 Q192R polymorphism is not associated with clopidogrel response in Chinese stroke patients.
Topics: Adenosine Diphosphate; Adolescent; Adult; Aged; Aryldialkylphosphatase; Asian People; Clopidogrel; Female; Genotype; Humans; Linear Models; Male; Mass Spectrometry; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Stroke; Ticlopidine; Young Adult | 2012 |
Comparison of original and generic clopidogrel 600 mg loading dose in the patients who planned undergoing coronary angiography.
Topics: Adenosine Diphosphate; Clopidogrel; Coronary Angiography; Drugs, Generic; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticlopidine | 2012 |
Investigation of drug-drug interactions between clopidogrel and fluoxetine.
Topics: Adenosine Diphosphate; Adult; Area Under Curve; Cell Adhesion Molecules; Clopidogrel; Cross-Over Studies; Drug Interactions; Flow Cytometry; Fluoxetine; Humans; Male; Microfilament Proteins; Phosphoproteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Selective Serotonin Reuptake Inhibitors; Ticlopidine; Young Adult | 2013 |
Dual antiplatelet therapy clopidogrel with low-dose cilostazol intensifies platelet inhibition in patients with ischemic stroke.
Topics: Adenosine Diphosphate; Aged; Aryl Hydrocarbon Hydroxylases; Brain Ischemia; Cilostazol; Clopidogrel; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Drug; Drug Resistance; Drug Synergism; Female; Humans; Male; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Receptors, Purinergic P2Y12; Risk Factors; Tetrazoles; Ticlopidine | 2013 |
Aspirin decreases systemic exposure to clopidogrel through modulation of P-glycoprotein but does not alter its antithrombotic activity.
Topics: Adenosine Diphosphate; Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; Aspirin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Fibrinolytic Agents; Genotype; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; RNA, Messenger; Ticlopidine | 2014 |
Monitoring the efficacy of ADP inhibitor treatment in patients with acute STEMI post-PCI by VASP-P flow cytometry assay.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Female; Flow Cytometry; Follow-Up Studies; Humans; Male; Microfilament Proteins; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Phosphoproteins; Platelet Activation; Platelet Aggregation Inhibitors; Prospective Studies; Ticlopidine | 2015 |
Switching from generic to brand clopidogrel in male patients after ST-elevated myocardial infarction.
Topics: Adenosine Diphosphate; Aspirin; Clopidogrel; Drug Substitution; Drug Therapy, Combination; Drugs, Generic; Epinephrine; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Ticlopidine | 2014 |
Relationship between smoking and responsiveness to clopidogrel in non-cardiogenic ischemic stroke patients.
Topics: Adenosine Diphosphate; Aged; Blood Coagulation Tests; Clopidogrel; Drug Resistance; Female; Humans; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Risk Factors; Smoking; Stroke; Ticlopidine | 2014 |
A randomized controlled trial of adjunctive Bunchang Naoxintong Capsule (步长脑心通胶囊) versus maintenance dose clopidogrel in patients with CYP2C19*2 polymorphism.
Topics: Adenosine Diphosphate; Clopidogrel; Cytochrome P-450 CYP2C19; Drugs, Chinese Herbal; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Maintenance Chemotherapy; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymorphism, Genetic; Ticlopidine; Treatment Outcome | 2014 |
Comparison of patient intake of ticagrelor, prasugrel, or clopidogrel on restoring platelet function by donor platelets.
Topics: Adenosine; Adenosine Diphosphate; Aged; Blood Platelets; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Female; Flow Cytometry; Half-Life; Humans; Male; Middle Aged; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Transfusion; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2015 |
Impact of Dabigatran versus Phenprocoumon on ADP Induced Platelet Aggregation in Patients with Atrial Fibrillation with or without Concomitant Clopidogrel Therapy (the Dabi-ADP-1 and Dabi-ADP-2 Trials).
Topics: Adenosine Diphosphate; Administration, Oral; Aged; Aged, 80 and over; Atrial Fibrillation; Clopidogrel; Dabigatran; Female; Follow-Up Studies; Humans; Male; Middle Aged; Phenprocoumon; Platelet Aggregation; Ticlopidine | 2015 |
Temporal variability in the antiplatelet effects of clopidogrel and aspirin after elective drug-eluting stent implantation. An ADAPT-DES substudy.
Topics: Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Blood Vessel Prosthesis Implantation; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Elective Surgical Procedures; Female; Germany; Humans; Male; Middle Aged; Observer Variation; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Receptors, Purinergic P2Y12; Ticlopidine | 2015 |
High Platelet Reactivity in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Randomised Controlled Trial Comparing Prasugrel and Clopidogrel.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Blood Platelets; Clopidogrel; Female; Follow-Up Studies; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticlopidine; Treatment Outcome | 2015 |
Clopidogrel treatment may associate with worsening of endothelial function and development of new digital ulcers in patients with systemic sclerosis: results from an open label, proof of concept study.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Animals; Clopidogrel; Endothelium, Vascular; Female; Fingers; Humans; Male; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Proof of Concept Study; Purinergic P2Y Receptor Antagonists; Scleroderma, Systemic; Serotonin; Skin Ulcer; Ticlopidine; Vascular Cell Adhesion Molecule-1 | 2016 |
Ticagrelor versus prasugrel in patients with high on-clopidogrel treatment platelet reactivity after PCI: The ISAR-ADAPT-PF study.
Topics: Adenosine; Adenosine Diphosphate; Aged; Blood Platelets; Clopidogrel; Comorbidity; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
The Prognostic Value of ADP-Induced Platelet Aggregation for Bleeding Complications in Low - Intermediate Risk Patients with Acute Coronary Syndrome Taking Clopidogrel After Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Clopidogrel; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Prognosis; Risk Factors; Ticlopidine | 2017 |
Effects of clopidogrel therapy on whole blood platelet aggregation, the Plateletworks® assay and coagulation parameters in cats with asymptomatic hypertrophic cardiomyopathy: a pilot study.
Topics: Adenosine Diphosphate; Animals; Asymptomatic Diseases; Blood Coagulation; Cardiomyopathy, Hypertrophic; Cat Diseases; Cats; Clopidogrel; Double-Blind Method; Female; Male; Pilot Projects; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Ticlopidine | 2017 |
Impact of Reticulated Platelets on the Antiplatelet Effect of the Intravenous P2Y12-Receptor Inhibitor Cangrelor.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Administration, Oral; Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Flow Cytometry; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thienopyridines; Ticagrelor | 2018 |
Platelet reactivity and coronary microvascular impairment after percutaneous revascularization in stable patients receiving clopidogrel or prasugrel.
Topics: Adenosine Diphosphate; Aged; Blood Platelets; Clopidogrel; Double-Blind Method; Female; Humans; Male; Microcirculation; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Pyridines; Troponin T | 2018 |
Diurnal Variability of On-Treatment Platelet Reactivity in Clopidogrel versus Prasugrel Treated Acute Coronary Syndrome Patients: A Pre-Specified TROPICAL-ACS Sub-Study.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Aspirin; Blood Platelets; Circadian Rhythm; Clopidogrel; Double-Blind Method; Drug Administration Schedule; Drug Delivery Systems; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Receptors, Purinergic P2Y12; Time Factors | 2019 |
Reversal of the antiplatelet effect of ticagrelor by simulated platelet transfusion.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Female; Healthy Volunteers; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Transfusion; Ticagrelor; Young Adult | 2019 |
Pharmacokinetics and competitive pharmacodynamics of ADP-induced platelet activation after oral administration of clopidogrel to horses.
Topics: Adenosine Diphosphate; Administration, Oral; Animals; Area Under Curve; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Female; Horses; Male; Microfilament Proteins; Phosphoproteins; Phosphorylation; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors | 2019 |
Differential Effects of Clopidogrel With or Without Aspirin on Platelet Reactivity and Coagulation Activation: A Randomized Trial in Healthy Volunteers.
Topics: Adenosine Diphosphate; Adult; Arachidonic Acid; Aspirin; beta-Thromboglobulin; Blood Coagulation; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Drug Therapy, Combination; Healthy Volunteers; Humans; Male; Microfilament Proteins; P-Selectin; Phosphoproteins; Platelet Aggregation Inhibitors; Thromboxane B2; Whole Blood Coagulation Time; Young Adult | 2021 |
CD36+/CD61+ Microparticles Correlate with the Risk of Percutaneous Cardiac Interventions in Coronary Artery Disease Patients and the Effects of Ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Clopidogrel; Coronary Artery Disease; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor | 2022 |
Antiplatelet and myocardial protective effect of Shexiang Tongxin Dropping Pill in patients undergoing percutaneous coronary intervention: A randomized controlled trial.
Topics: Adenosine Diphosphate; Angina, Unstable; Animals; Biomarkers; Clopidogrel; Cytochrome P-450 CYP2C19; Drugs, Chinese Herbal; Galectin 3; Humans; Intercellular Adhesion Molecule-1; Male; Mice; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Vascular Cell Adhesion Molecule-1 | 2022 |
Effects of Ticagrelor and Clopidogrel on Coronary Microcirculation in Patients with Acute Myocardial Infarction.
Topics: Adenosine Diphosphate; Clopidogrel; Humans; Microcirculation; Myocardial Infarction; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Ticagrelor | 2022 |
Effects of ticagrelor monotherapy vs. clopidogrel monotherapy on platelet reactivity: a randomized, crossover clinical study (SINGLE study).
Topics: Adenosine; Adenosine Diphosphate; Aspirin; Blood Platelets; Clopidogrel; Cross-Over Studies; Epinephrine; Fibrinolytic Agents; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2022 |
Impact of diabetes mellitus on the pharmacodynamic effects of prasugrel and ticagrelor after switching from clopidogrel in patients with coronary artery disease.
Topics: Adenosine; Adenosine Diphosphate; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Diabetes Mellitus; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Ticagrelor | 2022 |
273 other study(ies) available for adenosine diphosphate and clopidogrel
| Article | Year |
|---|---|
Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel.
Topics: Adenosine Diphosphate; Animals; Choledochostomy; Clopidogrel; Dose-Response Relationship, Drug; Female; Hepatectomy; Intestinal Mucosa; Liver; Perfusion; Platelet Aggregation; Platelet Aggregation Inhibitors; Rats; Rats, Inbred Strains; Ticlopidine | 1992 |
[Antiplatelet effect of clopidogrel].
Topics: Adenosine Diphosphate; Adolescent; Adult; Animals; Bleeding Time; Clopidogrel; Disease Models, Animal; Dogs; Drug Evaluation; Female; Humans; Intracranial Embolism and Thrombosis; Male; Platelet Adhesiveness; Platelet Aggregation Inhibitors; Rabbits; Rats; Thrombosis; Ticlopidine | 1992 |
ADP plays an important role in mediating platelet aggregation and cyclic flow variations in vivo in stenosed and endothelium-injured canine coronary arteries.
Topics: Adenosine Diphosphate; Animals; Apyrase; Bridged Bicyclo Compounds, Heterocyclic; Clopidogrel; Coronary Circulation; Coronary Disease; Coronary Vessels; Dogs; Endothelium, Vascular; Fatty Acids, Unsaturated; Female; Hydrazines; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Serotonin; Thromboxane A2; Ticlopidine | 1992 |
Ticlopidine and clopidogrel (SR 25990C) selectively neutralize ADP inhibition of PGE1-activated platelet adenylate cyclase in rats and rabbits.
Topics: Adenosine Diphosphate; Adenylyl Cyclases; Alprostadil; Animals; Blood Platelets; Clopidogrel; Enzyme Activation; Female; In Vitro Techniques; Platelet Aggregation Inhibitors; Rabbits; Rats; Rats, Inbred Strains; Stereoisomerism; Ticlopidine | 1991 |
The thienopyridine PCR 4099 selectively inhibits ADP-induced platelet aggregation and fibrinogen binding without modifying the membrane glycoprotein IIb-IIIa complex in rat and in man.
Topics: Adenosine Diphosphate; Animals; Clopidogrel; Female; Fibrinogen; Humans; Immunoelectrophoresis, Two-Dimensional; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Membrane Glycoproteins; Precipitin Tests; Rats; Rats, Inbred Strains; Ticlopidine | 1990 |
Broad spectrum anti-platelet activity of ticlopidine and PCR 4099 involves the suppression of the effects of released ADP.
Topics: Adenosine Diphosphate; Animals; Blood Platelets; Calcimycin; Clopidogrel; Diglycerides; Female; Platelet Aggregation Inhibitors; Rats; Serotonin; Tetradecanoylphorbol Acetate; Thrombin; Ticlopidine; Type C Phospholipases | 1987 |
ADP plays a key role in thrombogenesis in rats.
Topics: Adenosine Diphosphate; Animals; Clopidogrel; Cyclooxygenase Inhibitors; Disease Models, Animal; Female; In Vitro Techniques; Ketanserin; Platelet Aggregation; Rats; Rats, Inbred Strains; Serotonin; Thrombosis; Ticlopidine | 1988 |
The role of platelets and ADP in experimental thrombosis induced by venous stasis in the rat.
Topics: Adenosine Diphosphate; Animals; Blood Platelets; Blood Transfusion; Clopidogrel; Male; Platelet Count; Platelet Transfusion; Rats; Thrombocytopenia; Thrombophlebitis; Ticlopidine | 1988 |
Effect of PCR 4099 on ADP-induced calcium movements and phosphatidic acid production in rat platelets.
Topics: Adenosine Diphosphate; Animals; Blood Platelets; Calcium; Clopidogrel; Fibrinogen; In Vitro Techniques; Phosphatidic Acids; Platelet Aggregation; Rats; Ticlopidine; Type C Phospholipases | 1988 |
The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A.
Topics: Adenosine Diphosphate; Animals; Biotransformation; Chromatography, High Pressure Liquid; Clopidogrel; Cytochrome P-450 Enzyme System; Female; Isoenzymes; Microsomes, Liver; Platelet Aggregation; Platelet Aggregation Inhibitors; Rats; Rats, Sprague-Dawley; Ticlopidine | 1994 |
Evidence for the existence of two different ADP-binding sites on rat platelets.
Topics: Adenosine Diphosphate; Adenylyl Cyclases; Animals; Binding Sites; Blood Platelets; Clopidogrel; Female; Platelet Aggregation; Rats; Rats, Sprague-Dawley; Signal Transduction; Ticlopidine | 1994 |
Effect of aspirin and clopidogrel on platelet-dependent tissue factor expression in endothelial cells.
Topics: Adenosine Diphosphate; Animals; Aorta; Aspirin; Blood Platelets; Cattle; Clopidogrel; Endothelium, Vascular; Female; Ligation; Platelet Aggregation Inhibitors; Rats; Rats, Sprague-Dawley; Stimulation, Chemical; Thionucleotides; Thrombin; Thromboplastin; Thrombosis; Ticlopidine; Vena Cava, Inferior | 1994 |
Binding of [3H]-2-methylthio ADP to rat platelets--effect of clopidogrel and ticlopidine.
Topics: Adenosine Diphosphate; Adenylyl Cyclases; Animals; Binding Sites; Blood Platelets; Clopidogrel; Female; In Vitro Techniques; Platelet Aggregation Inhibitors; Rats; Rats, Sprague-Dawley; Receptors, Purinergic P2; Thionucleotides; Ticlopidine | 1994 |
Combined ADP and thromboxane A2 antagonism prevents cyclic flow variations in stenosed and endothelium-injured arteries in nonhuman primates.
Topics: Adenosine Diphosphate; Animals; Clopidogrel; Constriction, Pathologic; Coronary Vessels; Dogs; Endothelium, Vascular; Female; Femoral Artery; Hemodynamics; Humans; In Vitro Techniques; Papio; Platelet Aggregation; Regional Blood Flow; Thromboxane A2; Ticlopidine | 1993 |
Purinoceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptors.
Topics: Adenosine Diphosphate; Animals; Blood Platelets; Clopidogrel; Female; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Rats; Rats, Wistar; Receptors, Purinergic P2; Thionucleotides; Ticlopidine | 1995 |
Anti-platelet effects of clopidogrel in rat middle cerebral artery thrombosis model.
Topics: Adenosine Diphosphate; Analysis of Variance; Animals; Clopidogrel; Intracranial Embolism and Thrombosis; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Rats; Rats, Wistar; Thrombin; Ticlopidine | 1995 |
Ultrastructural studies of platelet aggregates from human subjects receiving clopidogrel and from a patient with an inherited defect of an ADP-dependent pathway of platelet activation.
Topics: Adenosine Diphosphate; Adult; Antigens, Human Platelet; Blood Platelets; Clopidogrel; Flow Cytometry; Humans; Immunohistochemistry; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Signal Transduction; Ticlopidine | 1996 |
Effect of clopidogrel treatment on ADP-induced phosphorylations in rat platelets.
Topics: Adenosine Diphosphate; Animals; Blood Platelets; Clopidogrel; Female; Phosphorylation; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Rats; Rats, Sprague-Dawley; Thionucleotides; Ticlopidine | 1997 |
Role of P2Y1 purinoceptor in ADP-induced platelet activation.
Topics: Adenosine Diphosphate; Animals; Calcium; Clopidogrel; Humans; In Vitro Techniques; Platelet Activation; Platelet Aggregation Inhibitors; Polymerase Chain Reaction; Rabbits; Receptors, Purinergic P2; Receptors, Purinergic P2Y1; Ticlopidine | 1998 |
The P2Y1 receptor, necessary but not sufficient to support full ADP-induced platelet aggregation, is not the target of the drug clopidogrel.
Topics: Adenosine Diphosphate; Adenylyl Cyclases; Animals; Calcium; Clopidogrel; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Rats; Rats, Wistar; Receptors, Purinergic P2; Receptors, Purinergic P2Y1; Ticlopidine | 1998 |
Specific inhibition of ADP-induced platelet aggregation by clopidogrel in vitro.
Topics: Adenosine Diphosphate; Alprostadil; Apyrase; Blood Platelets; Clopidogrel; Cyclic AMP; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Serum Albumin; Stereoisomerism; Ticlopidine; Time Factors | 1999 |
Relaxant effect of 2-methyl-thio-adenosine diphosphate on rat thoracic aorta: effect of clopidogrel.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Animals; Aorta, Thoracic; Clopidogrel; Endothelium, Vascular; In Vitro Techniques; Isometric Contraction; Male; NG-Nitroarginine Methyl Ester; Phenylephrine; Platelet Aggregation Inhibitors; Rats; Receptors, Purinergic; Ticlopidine; Uridine Triphosphate; Vasodilation | 1999 |
Clopidogrel: a novel antiplatelet agent.
Topics: Adenosine Diphosphate; Aspirin; Clopidogrel; Humans; Ischemia; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine; Vascular Diseases | 1999 |
Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel.
Topics: Adenosine Diphosphate; Adult; Alprostadil; Blood Platelets; Calcium; Clopidogrel; Cyclic AMP; Epinephrine; Female; Humans; Male; Middle Aged; Phosphoproteins; Phosphorylation; Platelet Aggregation Inhibitors; Ticlopidine; Vasodilator Agents | 1999 |
Non-specific inhibition of ADP-induced platelet antiaggregation by clopidogrel in vitro.
Topics: Adenosine Diphosphate; Cells, Cultured; Clopidogrel; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticlopidine | 1999 |
The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties.
Topics: Adenosine Diphosphate; Administration, Oral; Animals; Arteriovenous Shunt, Surgical; Binding, Competitive; Bleeding Time; Blood Platelets; Clopidogrel; Collagen; Cyclic AMP; Disease Models, Animal; Dose-Response Relationship, Drug; Fibrinolytic Agents; Male; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Rats; Rats, Sprague-Dawley; Receptors, Purinergic P2; Thionucleotides; Thiophenes; Thrombin; Thrombosis; Ticlopidine; Time Factors; Tritium | 2000 |
A pharmacodynamic study of clopidogrel in chronic hemodialysis patients.
Topics: Adenosine Diphosphate; Arterial Occlusive Diseases; Chronic Disease; Clopidogrel; Dose-Response Relationship, Drug; Hemostasis; Humans; Pilot Projects; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Renal Dialysis; Renal Insufficiency; Thrombosis; Ticlopidine | 2000 |
Platelet CD40 ligand (CD40L)--subcellular localization, regulation of expression, and inhibition by clopidogrel.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Adenosine Diphosphate; Adult; Antigens, CD; Blood Platelets; Calcimycin; Calcium; CD40 Ligand; Cells, Cultured; Clopidogrel; Collagen; Cytoplasmic Granules; Cytoskeleton; Gene Expression Regulation; Humans; Ionophores; Male; P-Selectin; Peptide Fragments; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Membrane Glycoproteins; Subcellular Fractions; Tetradecanoylphorbol Acetate; Tetraspanin 30; Thrombin; Ticlopidine | 2001 |
Activation of Gi-coupled receptors releases a tonic state of inhibited platelet aggregation.
Topics: Adaptation, Physiological; Adenosine Diphosphate; Adenosine Monophosphate; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Adult; Clopidogrel; Epinephrine; Female; GTP-Binding Protein alpha Subunits, Gi-Go; GTP-Binding Protein alpha Subunits, Gq-G11; Heterotrimeric GTP-Binding Proteins; Hirudins; Humans; Male; Membrane Proteins; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Agonists; Receptor, Serotonin, 5-HT2A; Receptors, Adrenergic, alpha-2; Receptors, Purinergic P2; Receptors, Purinergic P2Y1; Receptors, Purinergic P2Y12; Receptors, Serotonin; Recombinant Proteins; Serotonin; Serotonin Receptor Agonists; Ticlopidine | 2001 |
P2y(12), a new platelet ADP receptor, target of clopidogrel.
Topics: Adenosine Diphosphate; Adenylyl Cyclases; Animals; Blood Platelets; CHO Cells; Clopidogrel; Cricetinae; Down-Regulation; Humans; Kinetics; Receptors, Purinergic P2; Ticlopidine; Transfection | 2001 |
Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs.
Topics: Adenosine Diphosphate; Adenylyl Cyclases; Animals; Bleeding Time; Blood Coagulation; Blood Platelets; Cells, Cultured; Clopidogrel; Fibrinolytic Agents; Gene Targeting; Kinetics; Membrane Proteins; Mice; Mice, Knockout; Platelet Aggregation; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Ticlopidine | 2001 |
Current perspectives on British use of adjunctive therapies during coronary interventions.
Topics: Abciximab; Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Clopidogrel; Combined Modality Therapy; Coronary Disease; Heparin; Humans; Immunoglobulin Fab Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Patterns, Physicians'; Ticlopidine; United Kingdom | 2001 |
Deaggregation is an integral component of the response of platelets to ADP in vitro: kinetic studies of literature and original data.
Topics: Adenosine Diphosphate; Binding, Competitive; Blood Platelets; Clopidogrel; Dose-Response Relationship, Drug; Humans; Kinetics; Membrane Proteins; Models, Theoretical; Nephelometry and Turbidimetry; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y1; Receptors, Purinergic P2Y12; Signal Transduction; Ticlopidine | 2001 |
Short-term inhibition of ADP-induced platelet aggregation by clopidogrel ameliorates radiation-induced toxicity in rat small intestine.
Topics: Adenosine Diphosphate; Animals; Chemotaxis, Leukocyte; Clopidogrel; Collagen; Endothelium, Vascular; Enteritis; Extracellular Matrix; Fibrosis; Gastrointestinal Hemorrhage; Intestine, Small; Male; Muscle, Smooth; Neutrophils; Platelet Aggregation; Platelet Aggregation Inhibitors; Radiation Injuries, Experimental; Rats; Rats, Sprague-Dawley; RNA, Messenger; Ticlopidine; Time Factors; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2002 |
Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Aspirin; Blood Platelets; Cell Adhesion; Clopidogrel; Drug Therapy, Combination; Female; Humans; Leukocytes; Male; Membrane Proteins; Middle Aged; Myocardial Ischemia; P-Selectin; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Stents; Ticlopidine | 2002 |
Effect of clopidogrel administration to healthy volunteers on platelet phosphorylation events triggered by ADP.
Topics: Adenosine Diphosphate; Adolescent; Adult; Benzylamines; Blood Platelets; Clopidogrel; Electrophoresis, Polyacrylamide Gel; Humans; Male; Membrane Proteins; Phosphorylation; Piperidines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Receptors, Purinergic P2; Receptors, Purinergic P2Y1; Receptors, Purinergic P2Y12; Serine; Signal Transduction; Thiazoles; Thionucleotides; Threonine; Ticlopidine; Tyrosine | 2003 |
Antiplatelet effects of angiotensin-converting enzyme inhibitors compared with aspirin and clopidogrel: a pilot study with whole-blood aggregometry.
Topics: Adenosine Diphosphate; Adult; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Case-Control Studies; Clopidogrel; Coronary Disease; Female; Humans; Hypertension; Male; Middle Aged; Pilot Projects; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Ticlopidine | 2003 |
Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement.
Topics: Adenosine Diphosphate; Aged; Angina Pectoris; Clopidogrel; Drug Resistance; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Predictive Value of Tests; Prevalence; Prosthesis Implantation; Stents; Thrombosis; Ticlopidine | 2003 |
Inhibition of localized thrombosis in P2Y1-deficient mice and rodents treated with MRS2179, a P2Y1 receptor antagonist.
Topics: Adenosine Diphosphate; Animals; Clopidogrel; Disease Models, Animal; Drug Interactions; Mesenteric Arteries; Mice; Mice, Mutant Strains; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y1; Thromboplastin; Thrombosis; Ticlopidine; Vena Cava, Inferior | 2003 |
The antiaggregating activity of clopidogrel is not affected by N-acetyl L-cysteine.
Topics: Acetylcysteine; Adenosine Diphosphate; Animals; Blood Platelets; Cells, Cultured; Clopidogrel; Drug Interactions; Female; Humans; Male; Membrane Proteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Rats; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Ticlopidine | 2003 |
Akt activation in platelets depends on Gi signaling pathways.
Topics: Adenosine Diphosphate; Animals; Blood Platelets; Clopidogrel; Enzyme Activation; GTP-Binding Protein alpha Subunits, Gi-Go; Humans; In Vitro Techniques; Mice; Mice, Knockout; Oligopeptides; Peptide Fragments; Phosphorylation; Protein Kinase C; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Receptors, Purinergic P2; Receptors, Purinergic P2Y1; Signal Transduction; Thrombin; Ticlopidine | 2004 |
Inhibition of ADP-induced intracellular Ca2+ responses and platelet aggregation by the P2Y12 receptor antagonists AR-C69931MX and clopidogrel is enhanced by prostaglandin E1.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Alprostadil; Calcium; Calcium Signaling; Clopidogrel; Cytoplasm; Dose-Response Relationship, Drug; Drug Synergism; Humans; Membrane Proteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Ticlopidine; Time Factors | 2004 |
Comparison of turbidimetric aggregation and in vitro bleeding time (PFA-100) for monitoring the platelet inhibitory profile of antiplatelet agents in patients undergoing stent implantation.
Topics: Abciximab; Adenosine Diphosphate; Aged; Angina Pectoris; Antibodies, Monoclonal; Aspirin; Bleeding Time; Clopidogrel; Collagen; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Nephelometry and Turbidimetry; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Stents; Ticlopidine; Time Factors | 2003 |
Increased platelet CD63 and P-selectin expression persist in atherosclerotic ischemic stroke.
Topics: Adenosine Diphosphate; Aged; Anticoagulants; Antigens, CD; Aspirin; Blood Platelets; Brain Ischemia; Clopidogrel; Collagen; Female; Flow Cytometry; Heparin; Humans; Intracranial Arteriosclerosis; Lipids; Male; Middle Aged; P-Selectin; Patient Selection; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Glycoprotein GPIb-IX Complex; Platelet Membrane Glycoproteins; Stroke; Tetraspanin 30; Ticlopidine; Time Factors | 2004 |
PlA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation.
Topics: Abciximab; Adenosine Diphosphate; Aged; Amino Acid Substitution; Antibodies, Monoclonal; Aspirin; Blood Platelets; Clopidogrel; Coronary Thrombosis; Dose-Response Relationship, Drug; Female; Gene Expression Regulation; Heterozygote; Homozygote; Humans; Immunoglobulin Fab Fragments; Integrin beta3; Male; Middle Aged; P-Selectin; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polymorphism, Genetic; Stents; Ticlopidine; Treatment Outcome | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Coronary Artery Disease; Coronary Restenosis; Coronary Thrombosis; Drug Resistance; Drug Therapy, Combination; Epinephrine; Eptifibatide; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Prodrugs; Prospective Studies; Purinergic P2 Receptor Antagonists; Recurrence; Risk; Smoking; Stents; Ticlopidine; Treatment Outcome | 2004 |
807 C/T Polymorphism of the glycoprotein Ia gene and pharmacogenetic modulation of platelet response to dual antiplatelet treatment.
Topics: Adenosine Diphosphate; Aged; Clopidogrel; Collagen; Coronary Disease; Female; Humans; Integrin alpha2; Male; Middle Aged; Pharmacogenetics; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Stents; Thrombosis; Ticlopidine | 2004 |
Platelet function predicts myocardial damage in patients with acute myocardial infarction.
Topics: Abciximab; Adenosine Diphosphate; Aged; Antibodies, Monoclonal; Anticoagulants; Aspirin; Cardiovascular Agents; Clopidogrel; Collagen; Comorbidity; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Leukocyte Count; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Myocardium; Necrosis; Peptides; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Prospective Studies; Ticlopidine; Tirofiban; Tyrosine; von Willebrand Factor | 2004 |
Clopidogrel (Plavix) and cardiac surgical patients: implications for platelet function monitoring and postoperative bleeding.
Topics: Adenosine; Adenosine Diphosphate; Aged; Aged, 80 and over; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Function Tests; Postoperative Hemorrhage; Purinergic P2 Receptor Antagonists; Retrospective Studies; Thrombelastography; Ticlopidine; Time Factors | 2004 |
Effects of a novel platelet nitric oxide donor (LA816), aspirin, clopidogrel, and combined therapy in inhibiting flow- and lesion-dependent thrombosis in the porcine ex vivo model.
Topics: Adenosine Diphosphate; Amino Acids; Animals; Aspirin; Benzoates; Blood Pressure; Clopidogrel; Collagen; Cyclooxygenase Inhibitors; Drug Evaluation; Drug Therapy, Combination; Fibrinolytic Agents; Free Radical Scavengers; Guanylate Cyclase; Heart Rate; Hemorheology; Imidazoles; Membrane Proteins; Nitric Oxide; Nitric Oxide Donors; Nitroso Compounds; Oxadiazoles; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Quinoxalines; Random Allocation; Receptors, Purinergic P2Y12; rhoA GTP-Binding Protein; Sus scrofa; Thrombosis; Ticlopidine | 2004 |
Design, synthesis, and inhibition of platelet aggregation for some 1-o-chlorophenyl-1,2,3,4-tetrahydroisoquinoline derivatives.
Topics: Adenosine Diphosphate; Clopidogrel; Drug Design; Humans; Inhibitory Concentration 50; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Structure-Activity Relationship; Tetrahydroisoquinolines; Ticlopidine | 2004 |
Impaired platelet responses to clopidogrel and ticlopidine in a patient with recurrent coronary stent stenosis.
Topics: Adenosine Diphosphate; Blood Platelets; Clopidogrel; Coronary Stenosis; Cyclic AMP; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Function Tests; Stents; Ticlopidine | 2004 |
Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases.
Topics: Actins; Adenosine Diphosphate; Adenosine Monophosphate; Adult; Aged; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Dose-Response Relationship, Drug; Drug Resistance; Female; Flow Cytometry; Humans; Male; Membrane Proteins; Microfilament Proteins; Middle Aged; Myocardial Ischemia; Phosphoproteins; Phosphorylation; Platelet Aggregation; Platelet Aggregation Inhibitors; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Ticlopidine; Time Factors | 2005 |
Immune heparin-induced thrombocytopenia can occur in patients receiving clopidogrel and aspirin.
Topics: Adenosine Diphosphate; Adult; Aged; Antibodies, Monoclonal; Anticoagulants; Aspirin; Clopidogrel; Female; Heparin; Humans; Immunoenzyme Techniques; Male; Platelet Activation; Platelet Factor 4; Thrombocytopenia; Thrombolytic Therapy; Ticlopidine | 2005 |
Gas6 receptors Axl, Sky and Mer enhance platelet activation and regulate thrombotic responses.
Topics: Adenosine Diphosphate; Animals; Axl Receptor Tyrosine Kinase; Blood Platelets; c-Mer Tyrosine Kinase; Clopidogrel; Flow Cytometry; Humans; Intercellular Signaling Peptides and Proteins; Mice; Oligopeptides; Oncogene Proteins; Peptides; Platelet Activation; Platelet Aggregation; Protein Binding; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Saccharomyces cerevisiae Proteins; Signal Transduction; Thrombosis; Ticlopidine | 2005 |
P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose.
Topics: Adenosine Diphosphate; Aged; Aspirin; Clopidogrel; Coronary Disease; Female; Genotype; Haplotypes; Humans; Male; Membrane Proteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Receptors, Cell Surface; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Ticlopidine | 2005 |
Variation in the ability of glycoprotein IIb-IIIa antagonists to exert and maintain their inhibitory effects on the binding of fibrinogen.
Topics: Adenosine Diphosphate; Aged; Binding, Competitive; Blood Platelets; Clopidogrel; Coronary Artery Disease; Data Interpretation, Statistical; Eptifibatide; Fibrinogen; Flow Cytometry; Fluorescein-5-isothiocyanate; Humans; Iodine Radioisotopes; Male; Peptide Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Receptors, Thrombin; Ticlopidine; Tirofiban; Tyrosine | 2005 |
Platelet P2Y12 receptors enhance signalling towards procoagulant activity and thrombin generation. A study with healthy subjects and patients at thrombotic risk.
Topics: Adenosine Diphosphate; Adult; Aged; Blood Platelets; Calcium Signaling; Case-Control Studies; Clopidogrel; Diabetes Mellitus, Type 2; Humans; In Vitro Techniques; Membrane Proteins; Middle Aged; Phosphatidylserines; Platelet Aggregation Inhibitors; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Stroke; Thrombin; Thrombosis; Ticlopidine | 2005 |
The inhibitory potency of clopidogrel on ADP-induced platelet activation is not attenuated when it is co-administered with atorvastatin (20 mg/day) for 5 weeks in patients with acute coronary syndromes.
Topics: Acute Disease; Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Blood Platelets; CD40 Ligand; Cholesterol; Cholesterol, LDL; Clopidogrel; Coronary Disease; Drug Administration Schedule; Drug Interactions; Female; Flow Cytometry; Heptanoic Acids; Humans; Male; Middle Aged; P-Selectin; Peptide Fragments; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrroles; Ticlopidine; Triglycerides | 2005 |
Evaluation of clopidogrel resistance.
Topics: Adenosine Diphosphate; Biological Availability; Blood Platelets; Clopidogrel; Drug Resistance; Humans; In Vitro Techniques; Membrane Proteins; Mutation; Platelet Aggregation; Platelet Aggregation Inhibitors; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Ticlopidine | 2005 |
Flow cytometric measurement of platelet-leukocyte aggregates: a possible target to monitor platelet function?
Topics: Adenosine Diphosphate; Adult; Arterial Occlusive Diseases; Aspirin; Blood Platelets; Clopidogrel; Flow Cytometry; Heart Diseases; Humans; Leukocytes; Male; Monocytes; Peptide Fragments; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Risk; Ticlopidine | 2005 |
Role of the retention test Homburg in evaluating platelet hyperactivity and in monitoring therapy with antiplatelet drugs.
Topics: Abciximab; Adenosine Diphosphate; Antibodies, Monoclonal; Aspirin; Blood Platelets; Cell Shape; Clopidogrel; Collagen; Drug Monitoring; Humans; Immunoglobulin Fab Fragments; P-Selectin; Pilot Projects; Plasma; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Prostaglandins; Ristocetin; Ticlopidine | 2005 |
Correction of changes in ADP-induced platelet aggregation with vasopressin analogue desglycinamide-arginine-vasopressin.
Topics: Adenosine Diphosphate; Animals; Arginine Vasopressin; Blood Platelets; Clopidogrel; Hemostasis; Hemostatics; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Rats; Ticlopidine; Vasopressins | 2005 |
The Retention Index Test Homburg (RTH-II): Response to clopidogrel and comparison with aggregometry and CD62P-expression.
Topics: Adenosine Diphosphate; Adult; Clopidogrel; Dose-Response Relationship, Drug; Drug Monitoring; Female; Flow Cytometry; Humans; Male; P-Selectin; Platelet Activation; Platelet Aggregation; Platelet Function Tests; Reference Values; Regression Analysis; Ticlopidine | 2006 |
Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Collagen Type I; Diabetes Mellitus; Drug Resistance; Drug Therapy, Combination; Epinephrine; Female; Flow Cytometry; Humans; Male; Middle Aged; P-Selectin; Peptide Fragments; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Ticlopidine; Vasoconstrictor Agents | 2006 |
Impact of adenosine diphosphate and calcium chelation on platelet aggregation testing in patients receiving clopidogrel therapy.
Topics: Adenosine Diphosphate; Amino Acid Chloromethyl Ketones; Chelating Agents; Citrates; Clopidogrel; Coronary Disease; Cysteine Proteinase Inhibitors; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Sodium Citrate; Ticlopidine | 2006 |
Pump-induced platelet aggregation with subsequent hypotension: Its mechanism and prevention with clopidogrel.
Topics: Adenosine Diphosphate; Albumins; Animals; Cardiopulmonary Bypass; Clopidogrel; Coated Materials, Biocompatible; Heparin; Hypotension; Platelet Aggregation; Platelet Aggregation Inhibitors; Rats; Rats, Wistar; Stress, Mechanical; Ticlopidine | 2006 |
Differential antiplatelet effects of angiotensin converting enzyme inhibitors: comparison of ex vivo platelet aggregation in cardiovascular patients with ramipril, captopril and enalapril.
Topics: Adenosine Diphosphate; Aged; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Captopril; Cardiovascular Diseases; Clopidogrel; Collagen; Coronary Artery Disease; Electric Impedance; Enalapril; Female; Fibrinolytic Agents; Germany; Humans; Hypertension; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Ramipril; Ticlopidine; Treatment Outcome | 2006 |
P2Y1 gene A1622G dimorphism is not associated with adenosine diphosphate-induced platelet activation and aggregation after administration of a single high dose of clopidogrel.
Topics: Adenosine Diphosphate; Aged; Clopidogrel; Female; Genotype; Humans; Male; Middle Aged; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Receptors, Purinergic P2; Receptors, Purinergic P2Y1; Ticlopidine | 2006 |
Can the PFA-100 be modified to detect P2Y12 inhibition?
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Blood Platelets; Clopidogrel; Drug Monitoring; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y1; Receptors, Purinergic P2Y12; Ticlopidine | 2006 |
Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance.
Topics: Adenosine Diphosphate; Arachidonic Acid; Aspirin; Clopidogrel; Coronary Artery Disease; Cyclooxygenase 1; Cyclooxygenase 2; Dose-Response Relationship, Drug; Drug Resistance; Female; Flow Cytometry; Humans; Male; Middle Aged; Multivariate Analysis; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Recurrence; Signal Transduction; Thrombosis; Thromboxane B2; Ticlopidine; Time Factors; Treatment Refusal | 2006 |
The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts.
Topics: Adenosine Diphosphate; Animals; Cell Line; Chlorocebus aethiops; Clopidogrel; Humans; Membrane Microdomains; Mutation; Protein Binding; Rats; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Ticlopidine | 2006 |
Molecular modeling of purinergic receptor P2Y12 and interaction with its antagonists.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Amino Acid Sequence; Animals; Binding Sites; Clopidogrel; Computational Biology; Computer Simulation; Humans; In Vitro Techniques; Indicators and Reagents; Membrane Proteins; Models, Molecular; Molecular Sequence Data; Platelet Aggregation Inhibitors; Protein Conformation; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y1; Receptors, Purinergic P2Y12; Rhodopsin; Sequence Homology, Amino Acid; Thermodynamics; Ticlopidine | 2007 |
Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation.
Topics: Adenosine Diphosphate; Blood Platelets; Clopidogrel; Coronary Disease; Diabetic Angiopathies; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Stents; Ticlopidine | 2007 |
High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes.
Topics: Acute Disease; Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Female; France; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Odds Ratio; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Prognosis; Prospective Studies; Research Design; Risk Factors; Stents; Syndrome; Ticlopidine; Time Factors; Troponin I | 2007 |
[Platelet responsiveness to clopidogrel in patients with coronary syndrome. Comparison of platelet aggregation induced by ADP and flow cytometric analysis of intraplatelet VASP phosphorylation].
Topics: Adenosine Diphosphate; Aged; Aspirin; Blood Platelets; Blood Proteins; Cell Adhesion Molecules; Clopidogrel; Drug Resistance; Female; Flow Cytometry; Fluorescein-5-isothiocyanate; Fluorescent Dyes; Follow-Up Studies; Humans; Male; Microfilament Proteins; Myocardial Infarction; Phosphoproteins; Phosphorylation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Syndrome; Ticlopidine | 2007 |
Assessment of clopidogrel responsiveness: measurements of maximum platelet aggregation, final platelet aggregation and their correlation with vasodilator-stimulated phosphoprotein in resistant patients.
Topics: Adenosine Diphosphate; Aged; Cell Adhesion Molecules; Clopidogrel; Drug Resistance; Female; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Phosphorylation; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Ticlopidine; Time Factors | 2007 |
Evaluation of the platelet response to clopidogrel with light transmittance aggregometry: peak aggregation or late aggregation?
Topics: Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Hematologic Tests; Humans; Light; Platelet Activation; Platelet Aggregation; Platelet Function Tests; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Risk; Ticlopidine | 2007 |
Biomarker optimization to track the antithrombotic and hemostatic effects of clopidogrel in rats.
Topics: Adenosine Diphosphate; Animals; Aspirin; Biomarkers; Cell Adhesion Molecules; Clopidogrel; Dose-Response Relationship, Drug; Fibrinolytic Agents; Hemostatics; Male; Membrane Proteins; Microfilament Proteins; Phosphoproteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Rats; Rats, Sprague-Dawley; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Ticlopidine | 2007 |
The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite.
Topics: Adenosine Diphosphate; Alprostadil; Animals; Blood Platelets; Clopidogrel; Cyclic AMP; Dose-Response Relationship, Drug; Humans; In Vitro Techniques; Male; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Rats; Rats, Sprague-Dawley; Thiophenes; Ticlopidine | 2007 |
Evidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance': a rebuttal.
Topics: Adenosine Diphosphate; Blood Platelets; Clopidogrel; Drug Resistance; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 2007 |
[Interindividual variability in the laboratory response to the aspirin-clopidogrel combination: are patients with stent occlusion "resistant" to treatment?].
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Arachidonic Acid; Aspirin; Clopidogrel; Collagen; Coronary Restenosis; Drug Resistance; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Predictive Value of Tests; Ticlopidine | 2007 |
Platelet aggregometry and receptor binding to predict the magnitude of antithrombotic and bleeding time effects of clopidogrel in rabbits.
Topics: Adenosine Diphosphate; Analysis of Variance; Animals; Aspirin; Biomarkers; Bleeding Time; Blood Platelets; Carotid Artery Thrombosis; Carotid Artery, Common; Clopidogrel; Disease Models, Animal; Dose-Response Relationship, Drug; Hemostasis; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Predictive Value of Tests; Protein Binding; Rabbits; Receptors, Purinergic P2; Regional Blood Flow; Thromboxane B2; Ticlopidine | 2007 |
Factors related to progression of middle cerebral artery stenosis determined using transcranial Doppler ultrasonograhy.
Topics: Adenosine Diphosphate; Aged; Aspirin; Cerebral Angiography; Clopidogrel; Constriction, Pathologic; Disease Progression; Female; Humans; Infarction, Middle Cerebral Artery; Logistic Models; Magnetic Resonance Angiography; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Risk Assessment; Risk Factors; Severity of Illness Index; Ticlopidine; Time Factors; Treatment Outcome; Ultrasonography, Doppler, Transcranial | 2008 |
Residual platelet reactivity is associated with clinical and laboratory characteristics in patients with ischemic heart disease undergoing PCI on dual antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Arachidonic Acid; Aspirin; Blood Platelets; Clopidogrel; Female; Humans; Male; Myocardial Ischemia; Platelet Aggregation Inhibitors; Protein Isoforms; Risk Factors; Ticlopidine | 2007 |
Relationships between optical aggregometry (type born) and flow cytometry in evaluating ADP-induced platelet activation.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Dose-Response Relationship, Drug; Drug Monitoring; Drug Therapy, Combination; Dual Specificity Phosphatase 2; Female; Flow Cytometry; Humans; Image Cytometry; Male; Microfilament Proteins; Middle Aged; P-Selectin; Phosphoproteins; Phosphorylation; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Reproducibility of Results; Sensitivity and Specificity; Ticlopidine | 2008 |
Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Body Mass Index; Clopidogrel; Female; Humans; Male; Multivariate Analysis; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticlopidine | 2007 |
[Modified platelet aggregation test in patients on ASA and/or clopidogrel].
Topics: Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Clopidogrel; Collagen; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epinephrine; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Reference Values; Thrombosis; Ticlopidine | 2007 |
Platelet function testing and cardiovascular outcomes: steps forward in identifying the best predictive measure.
Topics: Adenosine Diphosphate; Cardiovascular Diseases; Clopidogrel; Flow Cytometry; Humans; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Prognosis; Pyridines; ROC Curve; Sensitivity and Specificity; Ticlopidine; Treatment Outcome | 2007 |
ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Acute Disease; Adenosine Diphosphate; Aged; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Female; Humans; Ischemia; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Phosphorylation; Platelet Aggregation; ROC Curve; Ticlopidine; Treatment Outcome | 2007 |
The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angina Pectoris; Clopidogrel; Cohort Studies; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Models, Statistical; Platelet Aggregation; Platelet Function Tests; Regression Analysis; Stents; Ticlopidine | 2008 |
Standardization of light transmittance aggregometry for monitoring antiplatelet therapy: an adjustment for platelet count is not necessary.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Algorithms; Arachidonic Acid; Aspirin; Calibration; Clopidogrel; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Nephelometry and Turbidimetry; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Platelet-Rich Plasma; Sensitivity and Specificity; Thrombophilia; Ticlopidine | 2008 |
How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.
Topics: Adenosine Diphosphate; Aged; Algorithms; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Cardiovascular Diseases; Clinical Protocols; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Drug Resistance; Feasibility Studies; Female; Humans; Male; Middle Aged; Pilot Projects; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Stents; Ticlopidine | 2008 |
Inhibition of ADP-induced platelet aggregation by clopidogrel is related to CYP2C19 genetic polymorphisms.
Topics: Adenosine Diphosphate; Adult; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Ticlopidine | 2008 |
Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Alleles; Body Mass Index; Cell Adhesion Molecules; Clopidogrel; Cytochrome P-450 Enzyme System; Drug Resistance; Female; Heterozygote; Humans; Male; Microfilament Proteins; Middle Aged; P-Selectin; Phosphoproteins; Phosphorylation; Platelet Activation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Prospective Studies; Ticlopidine | 2008 |
Aspirin non-responsiveness in Korean subjects on dual anti-platelet treatment determined by two different platelet function assays.
Topics: Adenosine Diphosphate; Adult; Aged; Arachidonic Acid; Asian People; Aspirin; Bleeding Time; Case-Control Studies; Clopidogrel; Collagen; Drug Resistance; Epinephrine; Female; Humans; Korea; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticlopidine | 2008 |
The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Blood Platelets; Cells, Cultured; Clopidogrel; Drug Interactions; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine | 2008 |
Multiple electrode aggregometry and P2Y(12) antagonists.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Anticoagulants; Clopidogrel; Dose-Response Relationship, Drug; Electrodes; Equipment Design; Hirudins; Humans; Peptide Fragments; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine | 2008 |
Lack of early augmentation of platelet reactivity after coronary intervention in patients treated with bivalirudin.
Topics: Adenosine Diphosphate; Angina Pectoris; Anticoagulants; Aspirin; Cardiac Catheterization; Clopidogrel; Elective Surgical Procedures; Hemostatics; Hirudins; Humans; Peptide Fragments; Platelet Activation; Platelet Aggregation Inhibitors; Postoperative Period; Recombinant Proteins; Thrombin; Ticlopidine; Time Factors | 2009 |
The association of cigarette smoking with enhanced platelet inhibition by clopidogrel.
Topics: Adenosine Diphosphate; Adult; Aged; Clopidogrel; Cytochrome P-450 CYP1A2; Female; Flow Cytometry; Humans; Male; Middle Aged; Multivariate Analysis; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Proportional Hazards Models; Smoking; Stents; Ticlopidine | 2008 |
Hydrolysis of adenine nucleotides in platelets from patients with acute myocardial infarction.
Topics: Adenine Nucleotides; Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate; Aspirin; Blood Platelets; Case-Control Studies; Clopidogrel; Female; Humans; Hydrolysis; Male; Middle Aged; Myocardial Infarction; Ticlopidine | 2008 |
Interactions between multiple cell types in parallel microfluidic channels: monitoring platelet adhesion to an endothelium in the presence of an anti-adhesion drug.
Topics: Adenosine Diphosphate; Animals; Blood Platelets; Cattle; Cells, Cultured; Clopidogrel; Drug Evaluation, Preclinical; Endothelium, Vascular; Microfluidic Analytical Techniques; NG-Nitroarginine Methyl Ester; Platelet Activation; Platelet Adhesiveness; Platelet Aggregation Inhibitors; Rabbits; Ticlopidine | 2008 |
Dynamics of platelet functional recovery following a clopidogrel loading dose in healthy volunteers.
Topics: Adenosine Diphosphate; Adult; Alprostadil; Blood Platelets; Clopidogrel; Drug Monitoring; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Point-of-Care Systems; Recovery of Function; Ticlopidine | 2008 |
Utility of the PFA-100 instrument and the novel multiplate analyzer for the assessment of aspirin and clopidogrel effects on platelet function in patients with cardiovascular disease.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Collagen; Electric Impedance; Epinephrine; Female; Humans; Male; Middle Aged; Nephelometry and Turbidimetry; Platelet Activation; Platelet Function Tests; Sensitivity and Specificity; Ticlopidine | 2009 |
Dual antiplatelet therapy unmasks distinct platelet reactivity in patients with coronary artery disease.
Topics: Adenosine Diphosphate; Aged; Aspirin; Case-Control Studies; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Epinephrine; Female; Humans; Male; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticlopidine | 2008 |
Analysis of platelet alpha2-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Adrenergic alpha-Antagonists; Aged; Aspirin; Blood Platelets; Clopidogrel; Collagen; Coronary Artery Disease; Drug Resistance; Drug Therapy, Combination; Female; Humans; Imidazoles; Male; Middle Aged; Norepinephrine; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Receptors, Adrenergic, alpha-2; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Ticlopidine; Treatment Failure | 2008 |
Association between the efficacy of dual antiplatelet therapy and the development of in-stent neointimal hyperplasia in porcine coronary arteries.
Topics: Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Animals; Aspirin; Cell Proliferation; Clopidogrel; Collagen; Coronary Angiography; Coronary Stenosis; Coronary Vessels; Cytokines; Disease Models, Animal; Drug Therapy, Combination; Fibrin; Hyperplasia; Inflammation Mediators; Metals; P-Selectin; Platelet Activating Factor; Platelet Aggregation; Platelet Aggregation Inhibitors; Prosthesis Design; Stents; Swine; Ticlopidine; Time Factors; Tunica Intima | 2008 |
ADP-induced platelet aggregation in acute ischemic stroke patients on aspirin therapy.
Topics: Acute Disease; Adenosine Diphosphate; Aged; Aspirin; Brain Ischemia; Clopidogrel; Drug Synergism; Drug Therapy, Combination; Endpoint Determination; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Secondary Prevention; Stroke; Ticlopidine; Treatment Outcome | 2008 |
Clopidogrel in acute coronary syndrome: to genotype or not?
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 2009 |
Clopidogrel versus prasugrel in rabbits. Effects on thrombosis, haemostasis, platelet function and response variability.
Topics: Adenosine Diphosphate; Administration, Oral; Animals; Binding, Competitive; Bleeding Time; Clopidogrel; Disease Models, Animal; Dose-Response Relationship, Drug; Fibrinolytic Agents; Hemorrhage; Hemostasis; Male; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Rabbits; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thionucleotides; Thiophenes; Thrombosis; Ticlopidine | 2009 |
Predicting thrombotic events: creating a complex approach for a complex condition.
Topics: Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Arachidonic Acid; Aspirin; Clopidogrel; Collagen; Drug Resistance; Drug Therapy, Combination; Drug-Eluting Stents; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Point-of-Care Systems; Predictive Value of Tests; Reproducibility of Results; Risk Assessment; Risk Factors; ROC Curve; Thrombosis; Ticlopidine | 2008 |
Platelet function analysis: at the edge of meaning.
Topics: Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Cell Adhesion Molecules; Clopidogrel; Drug Resistance; Humans; Microfilament Proteins; Patient Selection; Phosphoproteins; Phosphorylation; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Reproducibility of Results; Stents; Ticlopidine | 2009 |
Evaluation of the platelet count drop method for assessment of platelet function in comparison with "gold standard" light transmission aggregometry.
Topics: Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Reproducibility of Results; Ticlopidine | 2009 |
Clopidogrel and proton pump inhibitors: gastric protection at expense of vascular benefit?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Interactions; Drug Therapy, Combination; Humans; Omeprazole; Pantoprazole; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Proton Pump Inhibitors; Stents; Ticlopidine | 2009 |
Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Cross-Sectional Studies; Drug Interactions; Drug Therapy, Combination; Esomeprazole; Female; Humans; Male; Middle Aged; Multivariate Analysis; Omeprazole; Pantoprazole; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Proton Pump Inhibitors; Stents; Ticlopidine | 2009 |
Measurement of platelet P-selectin for remote testing of platelet function during treatment with clopidogrel and/or aspirin.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Aspirin; Cardiovascular Diseases; Case-Control Studies; Clopidogrel; Drug Monitoring; Female; Flow Cytometry; Humans; Male; P-Selectin; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticlopidine; Tissue Fixation | 2009 |
Shear-induced global thrombosis test of native blood: pivotal role of ADP allows monitoring of P2Y12 antagonist therapy.
Topics: Adenosine Diphosphate; Adult; Blood Coagulation; Clopidogrel; Female; Humans; Male; Monitoring, Physiologic; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Reference Values; Ticlopidine | 2009 |
Aprotinin reduces the antiplatelet effect of clopidogrel.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Aprotinin; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Interactions; Drug Therapy, Combination; Female; Hemostatics; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2009 |
Variability in aggregometry response before and after initiation of clopidogrel therapy.
Topics: Adenosine Diphosphate; Arachidonic Acid; Aspirin; Case-Control Studies; Clopidogrel; Demography; Female; Humans; Male; Middle Aged; Peptide Fragments; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Reproducibility of Results; Ticlopidine | 2009 |
Impact of CYP2C19 polymorphisms on the antiplatelet effect of clopidogrel in an actual clinical setting in Japan.
Topics: Adenosine Diphosphate; Aged; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Female; Humans; Japan; Male; Middle Aged; Pharmacogenetics; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Receptors, Purinergic P2; Ticlopidine | 2009 |
The formation of monocyte-platelet aggregates is independent of on-treatment residual agonists'-inducible platelet reactivity.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon; Angioplasty, Balloon, Coronary; Arachidonic Acid; Aspirin; Case-Control Studies; Cell Adhesion Molecules; Clopidogrel; Drug Therapy, Combination; Female; Flow Cytometry; Humans; Lipopolysaccharide Receptors; Male; Microfilament Proteins; Middle Aged; Monocytes; P-Selectin; Phosphoproteins; Phosphorylation; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIb-IX Complex; Stents; Ticlopidine | 2009 |
Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Calcium Channel Blockers; Cardiovascular Diseases; Clopidogrel; Drug Combinations; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Stents; Ticlopidine | 2010 |
Effect of blood hematocrit and erythrocyte deformability on adenosine 5'-diphosphate platelet reactivity in patients with acute coronary syndromes on dual antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Blood Viscosity; Clopidogrel; Erythrocyte Deformability; Female; Hematocrit; Humans; Male; Middle Aged; Multivariate Analysis; Platelet Aggregation Inhibitors; Ticlopidine | 2009 |
Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment?
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Biomarkers; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Female; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Intracranial Hemorrhages; Male; Microfilament Proteins; Middle Aged; Patient Discharge; Phosphoproteins; Phosphorylation; Pilot Projects; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Prospective Studies; Risk Assessment; Ticlopidine; Time Factors; Treatment Outcome | 2009 |
Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Blood Proteins; Cell Adhesion Molecules; Clopidogrel; Coronary Thrombosis; Electrocardiography; Female; Humans; Male; Microfilament Proteins; Middle Aged; Odds Ratio; Phosphoproteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Prognosis; Prospective Studies; Prosthesis Failure; Risk Factors; ROC Curve; Stents; Ticlopidine | 2009 |
The influence of clinical characteristics, laboratory and inflammatory markers on 'high on-treatment platelet reactivity' as measured with different platelet function tests.
Topics: Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Blood Platelets; Cells, Cultured; Clopidogrel; Drug Combinations; Female; Humans; Interleukin-6; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Sensitivity and Specificity; Thrombosis; Ticlopidine | 2009 |
Effects of clopidogrel on "aspirin specific" pathways of platelet inhibition.
Topics: Adenosine Diphosphate; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Aspirin; Blood Platelets; Clopidogrel; Drug Interactions; Female; Humans; Male; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticlopidine | 2009 |
Clopidogrel, independent of the vascular P2Y12 receptor, improves arterial function in small mesenteric arteries from AngII-hypertensive rats.
Topics: Acetylcholine; Adenosine Diphosphate; Angiotensin II; Animals; Blotting, Western; Clopidogrel; Dose-Response Relationship, Drug; Endothelium, Vascular; Enzyme Inhibitors; Hypertension; In Vitro Techniques; Male; Mesenteric Arteries; NG-Nitroarginine Methyl Ester; Purinergic P2Y Receptor Antagonists; Rats, Sprague-Dawley; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thionucleotides; Ticlopidine; Vasodilation; Vasodilator Agents | 2010 |
Adenosine diphosphate-inducible platelet reactivity shows a pronounced age dependency in the initial phase of antiplatelet therapy with clopidogrel.
Topics: Adenosine Diphosphate; Age Factors; Aged; Aged, 80 and over; Angioplasty, Balloon; Blood Platelets; Cardiovascular Diseases; Chi-Square Distribution; Clopidogrel; Female; Humans; Linear Models; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Prospective Studies; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Stents; Ticlopidine | 2010 |
Assessment of platelet response to clopidogrel with multiple electrode aggregometry, the VerifyNow P2Y12 analyzer and platelet Vasodilator-Stimulated Phosphoprotein flow cytometry.
Topics: Adenosine Diphosphate; Aged; Cell Adhesion Molecules; Clopidogrel; Coronary Angiography; Electric Impedance; Female; Flow Cytometry; Humans; Male; Microfilament Proteins; Middle Aged; Nephelometry and Turbidimetry; Phosphoproteins; Phosphorylation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prognosis; Protein Processing, Post-Translational; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Reproducibility of Results; Ticlopidine | 2010 |
Clinical management of clopidogrel inefficiency by point of care platelet function testing and individual adjustment of anti-platelet therapy--initial experiences.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Dose-Response Relationship, Drug; Electric Impedance; Female; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Point-of-Care Systems; Ticlopidine | 2009 |
Time does not heal every wound: coronary stent thrombosis of a bare-metal stent more than one decade after its implantation.
Topics: Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Blood Vessel Prosthesis; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Stents; Ticlopidine | 2009 |
Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Female; Germany; Hemorrhage; Humans; Logistic Models; Male; Middle Aged; Odds Ratio; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Risk Assessment; Risk Factors; ROC Curve; Severity of Illness Index; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2010 |
Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Biotransformation; Blood Platelets; Cell Adhesion Molecules; Chromatography, Liquid; Clopidogrel; Coronary Artery Disease; Drug Resistance; Female; Flow Cytometry; Humans; Linear Models; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Tandem Mass Spectrometry; Ticlopidine | 2010 |
Prostacyclin receptor stimulation facilitates detection of human platelet P2Y(12) receptor inhibition by the PFA-100 system.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Adult; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Female; Flow Cytometry; Humans; Iloprost; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Phosphorylation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Epoprostenol; Receptors, Purinergic P2Y12; Ticlopidine; Young Adult | 2010 |
Antiplatelet effect of 50-mg maintenance dose of clopidogrel compared to 200 mg ticlopidine: a preliminary study.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Asian People; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Humans; Japan; Male; Middle Aged; Pilot Projects; Platelet Aggregation; Platelet Aggregation Inhibitors; Stents; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2010 |
Anxiety is a better predictor of platelet reactivity in coronary artery disease patients than depression.
Topics: Adenosine Diphosphate; Aged; Angina, Unstable; Anxiety Disorders; Aspirin; Clopidogrel; Cross-Sectional Studies; Depressive Disorder; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Membrane Glycoproteins; Receptors, G-Protein-Coupled; Serotonin; Ticlopidine | 2010 |
Adrenergic receptor polymorphisms and platelet reactivity after treatment with dual antiplatelet therapy with aspirin and clopidogrel in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Aspirin; Cell Adhesion Molecules; Chi-Square Distribution; Clopidogrel; Drug Therapy, Combination; Female; Gene Frequency; Genotype; Humans; Linear Models; Male; Microfilament Proteins; Middle Aged; Phenotype; Phosphoproteins; Phosphorylation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymorphism, Single Nucleotide; Prospective Studies; Receptors, Adrenergic, alpha-2; Receptors, Adrenergic, beta-2; Ticlopidine; Treatment Outcome | 2010 |
In vitro effects of recombinant activated factor VIIa (NovoSeven) on clopidogrel-induced platelet inhibition.
Topics: Adenosine Diphosphate; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopidogrel; Coagulants; Collagen; Coronary Artery Disease; Factor VIIa; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Recombinant Proteins; Thrombin; Ticlopidine; Time Factors; Treatment Outcome | 2010 |
Clopidogrel response: head-to-head comparison of different platelet assays to identify clopidogrel non responder patients after coronary stenting.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Drug Resistance; Female; Humans; Linear Models; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Point-of-Care Systems; Predictive Value of Tests; Prospective Studies; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Stents; Ticlopidine | 2010 |
Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel.
Topics: Adenosine Diphosphate; Administration, Oral; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Disease; Cross-Sectional Studies; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multivariate Analysis; Phenprocoumon; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticlopidine | 2010 |
Slow response to clopidogrel predicts low response.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Biomarkers, Pharmacological; Clopidogrel; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2010 |
Evaluation of antiplatelet effects of a modified protocol by platelet aggregation in patients undergoing "one-stop" hybrid coronary revascularization.
Topics: Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Arachidonic Acid; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Artery Bypass; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Prospective Studies; Ticlopidine | 2010 |
Changes in platelets and anticoagulant protein activity during adenosine-exercise single-photon emission computed tomography stress test.
Topics: Adenosine; Adenosine Diphosphate; Adult; Aged; Antithrombins; Aspirin; beta-Thromboglobulin; Blood Coagulation; Clopidogrel; Coronary Stenosis; Epinephrine; Exercise Test; Female; Humans; Male; Middle Aged; Myocardial Perfusion Imaging; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Factor 4; Protein C; Ticlopidine; Tomography, Emission-Computed, Single-Photon; Vasodilator Agents | 2010 |
A comparison of the VerifyNow P2Y12 point-of-care device and light transmission aggregometry to monitor platelet function with prasugrel and clopidogrel: an integrated analysis.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Adult; Aged; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Databases, Factual; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Point-of-Care Systems; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2010 |
Potentiation of clopidogrel active metabolite formation by rifampicin leads to greater P2Y12 receptor blockade and inhibition of platelet aggregation after clopidogrel.
Topics: Adenosine Diphosphate; Adult; Area Under Curve; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; Drug Synergism; Humans; Male; Middle Aged; Platelet Aggregation; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Rifampin; Ticlopidine | 2010 |
Effect of 450-mg loading dose of clopidogrel on platelet function in Japanese patients undergoing coronary stent placement.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Asian People; Clopidogrel; Coronary Artery Disease; Female; Hemorrhage; Humans; Japan; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Stents; Ticlopidine; Time Factors; Treatment Outcome | 2010 |
Pharmacodynamic and pharmacokinetic evaluation of clopidogrel and the carboxylic acid metabolite SR 26334 in healthy dogs.
Topics: Adenosine Diphosphate; Animals; Blood Coagulation; Blood Platelets; Carboxylic Acids; Clopidogrel; Cytochrome P-450 Enzyme System; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Female; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Reference Values; Ticlopidine | 2010 |
Is TRAP-6 suitable as a positive control for platelet reactivity when assessing response to clopidogrel?
Topics: Adenosine Diphosphate; Aged; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Female; Humans; Male; Microfilament Proteins; Peptide Fragments; Phosphoproteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticlopidine | 2010 |
Evaluation of platelet function and pharmacological platelet inhibition in patients with myeloproliferative disorders using multiple electrode aggregometry.
Topics: Adenosine Diphosphate; Adult; Aged; Arachidonic Acid; Aspirin; Austria; Case-Control Studies; Clopidogrel; Electrodes; Female; Humans; Linear Models; Male; Middle Aged; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Polycythemia Vera; Predictive Value of Tests; Reproducibility of Results; Thrombocythemia, Essential; Thrombosis; Ticlopidine; Treatment Outcome; Young Adult | 2010 |
Comparison of conventional aggregometry with VASP for monitoring P2Y12-specific platelet inhibition.
Topics: Adenosine Diphosphate; Angina Pectoris; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Flow Cytometry; Humans; Microfilament Proteins; Middle Aged; Phosphoproteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Receptors, Purinergic P2Y12; Ticlopidine | 2010 |
Platelet response to clopidogrel and restenosis in patients treated predominantly with drug-eluting stents.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Coronary Angiography; Coronary Restenosis; Coronary Thrombosis; Drug-Eluting Stents; Female; Humans; Middle Aged; Multivariate Analysis; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Ticlopidine | 2010 |
Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.
Topics: Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Resistance; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2 Receptor Antagonists; Risk Factors; ROC Curve; Stents; Ticlopidine | 2010 |
Association between inflammatory biomarkers and platelet aggregation in patients under chronic clopidogrel treatment.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Aspirin; C-Reactive Protein; Cardiovascular Diseases; Chi-Square Distribution; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Female; Fibrinogen; Germany; Humans; Inflammation Mediators; Leukocyte Count; Linear Models; Logistic Models; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Retrospective Studies; Risk Assessment; Risk Factors; Stents; Ticlopidine; Time Factors; Treatment Outcome | 2010 |
Clopidogrel discontinuation and platelet reactivity following coronary stenting.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Arachidonic Acid; Aspirin; Clopidogrel; Collagen; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Epinephrine; Female; Humans; Ireland; Male; Middle Aged; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Prospective Studies; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2011 |
Inhibition of vascular ectonucleotidase activities by the pro-drugs ticlopidine and clopidogrel favours platelet aggregation.
Topics: 5'-Nucleotidase; Adenosine Diphosphate; Adenosine Monophosphate; Animals; Antigens, CD; Apyrase; Chlorocebus aethiops; Clopidogrel; COS Cells; Dose-Response Relationship, Drug; Endothelial Cells; Humans; Hydrolysis; Platelet Aggregation; Platelet Aggregation Inhibitors; Prodrugs; Rats; Species Specificity; Ticlopidine; Umbilical Veins | 2010 |
The cytochrome 2C19*2 and *3 alleles attenuate response to clopidogrel similarly in East Asian patients undergoing elective percutaneous coronary intervention.
Topics: Adenosine Diphosphate; Aged; Analysis of Variance; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Asian People; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Female; Gene Frequency; Genotype; Humans; Male; Middle Aged; Phenotype; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Republic of Korea; Risk Assessment; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2011 |
Nontraumatic bilateral subdural hematoma caused by antiaggregation therapy: case report and review of the literature.
Topics: Adenosine Diphosphate; Aspirin; Clopidogrel; Female; Hematoma, Subdural; Humans; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Radiography; Ticlopidine | 2010 |
Light transmittance aggregometry induced by different concentrations of adenosine diphosphate to monitor clopidogrel therapy: a methodological study.
Topics: Adenosine Diphosphate; Angioplasty; Clopidogrel; Coronary Artery Disease; Drug Monitoring; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Point-of-Care Systems; Ticlopidine | 2011 |
More on: adenosine diphosphate-inducible platelet reactivity shows a pronounced age dependency in the initial phase of antiplatelet therapy with clopidogrel.
Topics: Adenosine Diphosphate; Aged; Aged, 80 and over; Aging; Angioplasty, Balloon, Coronary; Clopidogrel; Female; Humans; Male; Platelet Activation; Platelet Aggregation Inhibitors; Prospective Studies; Ticlopidine; Time Factors | 2011 |
Evaluation of clopidogrel resistance in ischemic stroke patients.
Topics: Adenosine Diphosphate; Aged; Aged, 80 and over; Brain Ischemia; Clopidogrel; Drug Resistance; Female; Humans; In Vitro Techniques; Male; Middle Aged; Nephelometry and Turbidimetry; Platelet Aggregation; Platelet Aggregation Inhibitors; Stroke; Ticlopidine | 2011 |
An improved method for specific and quantitative determination of the clopidogrel active metabolite isomers in human plasma.
Topics: Adenosine Diphosphate; Animals; Blood Platelets; CHO Cells; Chromatography, High Pressure Liquid; Clopidogrel; Cricetinae; Cricetulus; Humans; Mass Spectrometry; Phosphorus Isotopes; Plasma; Product Surveillance, Postmarketing; Protein Binding; Receptors, Purinergic P2Y12; Sensitivity and Specificity; Stereoisomerism; Thionucleotides; Ticlopidine; Transgenes | 2011 |
Optimizing of thienopyridine therapy by multiple electrode platelet aggregometry in clopidogrel low responders undergoing PCI.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Cerebrovascular Disorders; Cilostazol; Clopidogrel; Drug Monitoring; Drug Resistance; Drug Substitution; Electrodes; Female; Germany; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Predictive Value of Tests; Prospective Studies; Risk Assessment; Risk Factors; Stents; Tetrazoles; Thiophenes; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2011 |
The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Austria; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Drug Therapy, Combination; Female; Humans; Linear Models; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Phosphorylation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Receptors, Purinergic P2Y12; Reproducibility of Results; Risk Assessment; Risk Factors; Stents; Ticlopidine; Treatment Outcome | 2011 |
Diurnal variation in platelet inhibition by clopidogrel.
Topics: Adenosine Diphosphate; Aged; Blood Platelets; Circadian Rhythm; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticlopidine | 2011 |
Endothelium-independent vasorelaxation by ticlopidine and clopidogrel in rat caudal artery.
Topics: Acetylcholine; Adenosine Diphosphate; Animals; Arteries; Cell Proliferation; Clopidogrel; Dose-Response Relationship, Drug; Endothelium, Vascular; Enzyme Inhibitors; Male; Muscle, Smooth, Vascular; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Platelet Aggregation Inhibitors; Rats; Rats, Wistar; Ticlopidine; Vasoconstriction; Vasodilator Agents | 2011 |
Relation of body mass index to on-treatment (clopidogrel + aspirin) platelet reactivity.
Topics: Adenosine Diphosphate; Aspirin; Body Mass Index; Cell Adhesion Molecules; Clopidogrel; Coronary Disease; Female; Humans; Logistic Models; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Platelet Aggregation; Platelet Function Tests; Risk Factors; Statistics, Nonparametric; Ticlopidine | 2011 |
The platelet hyporesponsiveness to clopidogrel in acute coronary syndrome patients treated with 75 mg/day clopidogrel may be overcome within 1 month of treatment.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Blood Platelets; Clopidogrel; Drug Administration Schedule; Female; Flow Cytometry; Humans; Leukocyte Count; Male; Middle Aged; Peptide Fragments; Pilot Projects; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticlopidine | 2012 |
Time dependence of clopidogrel loading effect: platelet activation versus platelet aggregation.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Annexin A5; Aspirin; Baltimore; Clopidogrel; Collagen; Coronary Artery Disease; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Stents; Ticlopidine; Time Factors; Treatment Outcome | 2012 |
Comparison of venous and arterial blood sampling for the assessment of platelet aggregation with whole blood impedance aggregometry.
Topics: Adenosine Diphosphate; Arachidonic Acid; Area Under Curve; Arteries; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Electric Impedance; Female; Humans; Male; Phlebotomy; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Research Design; Specimen Handling; Ticlopidine; Veins | 2011 |
Comparison of platelet reactivity and clopidogrel response in patients ≤ 75 Years Versus > 75 years undergoing percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Age Factors; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Resistance; Follow-Up Studies; Hemorrhage; Humans; Middle Aged; Myocardial Ischemia; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Recurrence; Stents; Ticlopidine | 2011 |
High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty; Aspirin; Clopidogrel; Death; Female; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Prognosis; Prospective Studies; Risk; Stents; Stroke; Thrombosis; Ticlopidine | 2011 |
Effects of P2Y(1) receptor antagonism on the reactivity of platelets from patients with stable coronary artery disease using aspirin and clopidogrel.
Topics: Adenosine Diphosphate; Aged; Aspirin; Blood Platelets; Clopidogrel; Collagen; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y1; Receptors, Thrombin; Thrombosis; Ticlopidine | 2012 |
Role of newly formed platelets in thrombus formation in rat after clopidogrel treatment: comparison to the reversible binding P2Y₁₂ antagonist ticagrelor.
Topics: Adenosine; Adenosine Diphosphate; Animals; Blood Platelets; Clopidogrel; Cytoprotection; Platelet Activation; Protein Binding; Purinergic P2Y Receptor Antagonists; Rats; Rats, Inbred WKY; Thrombosis; Ticagrelor; Ticlopidine | 2011 |
The relevance of P2Y(12)-receptor gene variation for the outcome of clopidogrel-treated patients undergoing elective coronary stent implantation: a clinical follow-up.
Topics: Adenosine Diphosphate; Aged; Aspirin; Clopidogrel; Female; Follow-Up Studies; Genetic Variation; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation; Polymorphism, Single Nucleotide; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Software; Stents; Ticlopidine | 2012 |
Ticagrelor, but not clopidogrel and prasugrel, prevents ADP-induced vascular smooth muscle cell contraction: a placebo-controlled study in rats.
Topics: Adenosine; Adenosine Diphosphate; Animals; Arteries; Clopidogrel; Muscle Contraction; Myocytes, Smooth Muscle; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Rats; Rats, Wistar; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
Impact of anemia on platelet response to clopidogrel in patients undergoing percutaneous coronary stenting.
Topics: Adenosine Diphosphate; Aged; Anemia; Angioplasty, Balloon, Coronary; Clopidogrel; Female; Hemoglobins; Humans; Male; Middle Aged; Multivariate Analysis; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Registries; Stents; Ticlopidine | 2012 |
Use of an objective tool to assess platelet inhibition prior to off-pump coronary surgery to reduce blood usage.
Topics: Adenosine Diphosphate; Aged; Blood Coagulation Tests; Blood Loss, Surgical; Blood Transfusion; Clopidogrel; Coronary Artery Bypass, Off-Pump; Female; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Postoperative Complications; Preoperative Care; Reoperation; Ticlopidine | 2012 |
Inhibition of platelet aggregation by prostaglandin E1 (PGE1) in diabetic patients during therapy with clopidogrel and aspirin.
Topics: Adenosine Diphosphate; Aged; Alprostadil; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Diabetes Mellitus; Female; Genotype; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Risk Factors; Ticlopidine | 2013 |
High on-treatment platelet reactivity by ADP and increased risk of MACE in good clopidogrel metabolizers.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Alleles; Aryl Hydrocarbon Hydroxylases; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Heparin; Heterozygote; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Risk; Survival Rate; Ticlopidine | 2012 |
Fractalkine activates a signal transduction pathway similar to P2Y12 and is associated with impaired clopidogrel responsiveness.
Topics: Adenosine Diphosphate; Alprostadil; Chemokine CX3CL1; Clopidogrel; Coronary Artery Disease; Humans; Phosphatidylinositol 3-Kinases; Phosphorylation; Platelet Activation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Signal Transduction; Ticlopidine | 2012 |
Clinical outcomes using a platelet function-guided approach for secondary prevention in patients with ischemic stroke or transient ischemic attack.
Topics: Adenosine Diphosphate; Aged; Arachidonic Acid; Brain Ischemia; Cerebral Hemorrhage; Clopidogrel; Female; Humans; Ischemic Attack, Transient; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Function Tests; Proportional Hazards Models; Secondary Prevention; Stroke; Survival Analysis; Ticlopidine; Treatment Outcome | 2012 |
Effect of different anticoagulants on multiple electrode platelet aggregometry after clopidogrel and aspirin administration in patients undergoing coronary stent implantation: a comparison between citrate and hirudin.
Topics: Adenosine Diphosphate; Aged; Analysis of Variance; Angioplasty, Balloon, Coronary; Anticoagulants; Arachidonic Acid; Aspirin; Citric Acid; Clopidogrel; Female; Hirudins; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Risk Factors; ROC Curve; Sensitivity and Specificity; Stents; Ticlopidine | 2013 |
Association of CYP2C19 genotype with periprocedural myocardial infarction after uneventful stent implantation in Chinese patients receiving clopidogrel pretreatment.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Aryl Hydrocarbon Hydroxylases; Asian People; Blood Platelets; Chi-Square Distribution; China; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genotype; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Pharmacogenetics; Phenotype; Platelet Aggregation; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Stents; Thrombelastography; Ticlopidine; Time Factors; Treatment Outcome | 2012 |
The ADP receptor P2RY12 regulates osteoclast function and pathologic bone remodeling.
Topics: Adenosine Diphosphate; Animals; Arthritis, Experimental; Bone Neoplasms; Bone Remodeling; Bone Resorption; Carcinoma; Cell Adhesion; Cells, Cultured; Clopidogrel; Enzyme Activation; Female; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C57BL; Mice, Knockout; Osteoclasts; Osteoporosis; Ovariectomy; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Purinergic P2Y Receptor Antagonists; rap1 GTP-Binding Proteins; Receptors, Purinergic P2Y12; Specific Pathogen-Free Organisms; Ticlopidine | 2012 |
Postmenopausal women have an increased maximal platelet reactivity compared to men despite dual antiplatelet therapy.
Topics: Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Blood Platelets; Clopidogrel; Coronary Disease; Female; Humans; Male; Middle Aged; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Postmenopause; Prospective Studies; Sex Factors; Ticlopidine | 2012 |
Evaluation of the pharmacokinetics and pharmacodynamics of ticagrelor co-administered with aspirin in healthy volunteers.
Topics: Adenosine; Adenosine Diphosphate; Adult; Aspirin; Bleeding Time; Clopidogrel; Collagen; Drug Therapy, Combination; Female; Healthy Volunteers; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine; Young Adult | 2013 |
Assessment of high on-treatment platelet reactivity in patients with ischemic heart disease: concordance between the Multiplate and VerifyNow assays.
Topics: Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Blood Platelets; Clopidogrel; Drug Resistance; Female; Humans; Male; Middle Aged; Myocardial Ischemia; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Reproducibility of Results; Spain; Ticlopidine; Treatment Outcome | 2013 |
Human platelet protease-activated receptor-1 responsiveness to thrombin related to P2Y12 inhibition.
Topics: Adenosine Diphosphate; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Models, Cardiovascular; Platelet Activation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptor, PAR-1; Receptors, Purinergic P2Y12; Thrombin; Thromboembolism; Ticlopidine; Translational Research, Biomedical | 2013 |
Obesity is associated with poor response to clopidogrel and an increased susceptibility to protease activated receptor-1 mediated platelet activation.
Topics: Adenosine Diphosphate; Aged; Angioplasty; Blood Platelets; Case-Control Studies; Cell Adhesion Molecules; Clopidogrel; Female; Humans; Male; Microfilament Proteins; Middle Aged; Obesity; P-Selectin; Phosphoproteins; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Receptor, PAR-1; Stents; Thrombosis; Ticlopidine; Translational Research, Biomedical | 2013 |
Influence of CYP2C19*2 and *3 loss-of-function alleles on the pharmacodynamic effects of standard- and high-dose clopidogrel in East Asians undergoing percutaneous coronary intervention: the results of the ACCEL-DOUBLE-2N3 study.
Topics: Adenosine Diphosphate; Adult; Aged; Alleles; Aryl Hydrocarbon Hydroxylases; Asian People; Clopidogrel; Cohort Studies; Cytochrome P-450 CYP2C19; Female; Genotype; Heterozygote; Humans; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Percutaneous Coronary Intervention; Pharmacogenetics; Pilot Projects; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymorphism, Single Nucleotide; Ticlopidine | 2013 |
CYP2C19 polymorphism and antiplatelet effects of clopidogrel in Chinese stroke patients.
Topics: Adenosine Diphosphate; Adolescent; Adult; Aged; Aryl Hydrocarbon Hydroxylases; Asian People; China; Clopidogrel; Cohort Studies; Cytochrome P-450 CYP2C19; DNA; Female; Genotype; Humans; Isoenzymes; Linear Models; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Stroke; Ticlopidine; Young Adult | 2013 |
Preserved thrombin-inducible platelet activation in thienopyridine-treated patients.
Topics: Adenosine Diphosphate; Aged; Angioplasty; Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Female; Humans; Integrin beta3; Male; Middle Aged; P-Selectin; Peptide Fragments; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Membrane Glycoprotein IIb; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Thiophenes; Thrombin; Ticlopidine | 2013 |
P2Y12 receptor gene polymorphism and antiplatelet effect of clopidogrel in patients with coronary artery disease after coronary stenting.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Adult; Aged; Blood Platelets; Clopidogrel; Female; Genotype; Humans; Male; Middle Aged; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymerase Chain Reaction; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length; Receptors, Purinergic P2Y12; Stents; Ticlopidine | 2013 |
Contact- and agonist-regulated microvesiculation of human platelets.
Topics: Adenosine Diphosphate; Aspirin; Blood Platelets; Cell Shape; Cell-Derived Microparticles; Clopidogrel; Fibrinogen; Humans; Microscopy, Atomic Force; Peptide Fragments; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticlopidine | 2013 |
Hidden implications: potential antiplatelet effects of adjuvant anaesthetic agents.
Topics: Adenosine Diphosphate; Adjuvants, Anesthesia; Aged; Aspirin; Cholecystectomy, Laparoscopic; Clopidogrel; Female; Hemorrhage; Humans; Intraoperative Complications; Platelet Aggregation; Platelet Aggregation Inhibitors; Thrombelastography; Ticlopidine | 2013 |
Initial experiences with Multiplate® for rapid assessment of antiplatelet agent activity in neurosurgical emergencies.
Topics: Adenosine Diphosphate; Aged; Aged, 80 and over; Arachidonic Acid; Aspirin; Clopidogrel; Embolization, Therapeutic; Emergencies; Emergency Medical Services; Female; Hemostatic Techniques; Humans; Intracranial Hemorrhages; Male; Middle Aged; Neurosurgical Procedures; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Transfusion; Point-of-Care Systems; Ticlopidine | 2013 |
Comparison of a new P2Y12 receptor specific platelet aggregation test with other laboratory methods in stroke patients on clopidogrel monotherapy.
Topics: Adenosine Diphosphate; Adult; Aged; Alprostadil; Blood Platelets; Cell Adhesion Molecules; Clinical Laboratory Techniques; Clopidogrel; Female; Flow Cytometry; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Phosphorylation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Reproducibility of Results; Stroke; Ticlopidine | 2013 |
Characterization of the aggregation responses of camel platelets.
Topics: Adenosine Diphosphate; Animals; Arachidonic Acid; Blood Platelets; Camelus; Clopidogrel; Collagen; Epinephrine; Female; Platelet Activation; Platelet Aggregation; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2; Ticlopidine | 2013 |
Red cell-derived microparticles (RMP) as haemostatic agent.
Topics: Adenosine Diphosphate; Animals; Bleeding Time; Blood Coagulation Disorders; Busulfan; Cell Separation; Cell-Derived Microparticles; Clopidogrel; Disease Models, Animal; Erythrocytes; Flow Cytometry; Hemostasis; Humans; Male; Platelet Aggregation; Rabbits; Rats; Rats, Sprague-Dawley; Thrombelastography; Thrombin; Thrombocytopenia; Thromboplastin; Ticlopidine | 2013 |
Hematocrit alters VerifyNow P2Y12 assay results independently of intrinsic platelet reactivity and clopidogrel responsiveness.
Topics: Adenosine Diphosphate; Aged; Blood Platelets; Clopidogrel; Female; Hematocrit; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticlopidine | 2013 |
Effects of ex vivo platelet supplementation on platelet aggregability in blood samples from patients treated with acetylsalicylic acid, clopidogrel, or ticagrelor.
Topics: Adenosine; Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Peptide Fragments; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Transfusion; Ticagrelor; Ticlopidine | 2014 |
Changes in response to antiaggregatory treatment in patients with myeloproliferative neoplasms: a sequential study using multiple electrode aggregometry.
Topics: Adenosine Diphosphate; Adult; Aged; Arachidonic Acid; Aspirin; Blood Platelets; Case-Control Studies; Clopidogrel; Electrodes; Female; Hematologic Neoplasms; Humans; Male; Middle Aged; Myeloproliferative Disorders; Platelet Aggregation; Platelet Aggregation Inhibitors; Receptors, Thrombin; Thrombosis; Ticlopidine; Treatment Outcome | 2013 |
Anti-platelet activity of a three-finger toxin (3FTx) from Indian monocled cobra (Naja kaouthia) venom.
Topics: Adenosine Diphosphate; Arachidonic Acid; Blood Platelets; Cells, Cultured; Clopidogrel; Elapid Venoms; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thrombin; Ticlopidine | 2013 |
'VASPFix' for measurement of VASP phosphorylation in platelets and for monitoring effects of P2Y12 antagonists.
Topics: Adenosine; Adenosine Diphosphate; Alprostadil; Biomarkers, Pharmacological; Blood Platelets; Bucladesine; Cell Adhesion Molecules; Cells, Cultured; Clopidogrel; Cyclic AMP; Humans; Iloprost; Microfilament Proteins; Phosphoproteins; Phosphorylation; Piperazines; Platelet Aggregation; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Reproducibility of Results; Sensitivity and Specificity; Thiophenes; Thrombophilia; Ticlopidine | 2014 |
Fractalkine promotes platelet activation and vascular dysfunction in congestive heart failure.
Topics: Adenosine Diphosphate; Animals; Aorta; Cells, Cultured; Chemokine CX3CL1; Clopidogrel; CX3C Chemokine Receptor 1; Drug Resistance; Endothelial Cells; Heart Failure; Humans; Male; Platelet Activation; Rats; Rats, Wistar; Receptors, Chemokine; Ticlopidine; Up-Regulation; Vasodilation | 2014 |
Response to antiplatelet therapy and platelet reactivity to thrombin receptor activating peptide-6 in cardiovascular interventions: Differences between peripheral and coronary angioplasty.
Topics: Adenosine Diphosphate; Aged; Angioplasty; Angioplasty, Balloon, Coronary; Arachidonic Acid; Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Monocytes; P-Selectin; Peptide Fragments; Percutaneous Coronary Intervention; Peripheral Arterial Disease; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prognosis; Stents; Ticlopidine | 2014 |
The role of clinical parameters and of CYP2C19 G681 and CYP4F2 G1347A polymorphisms on platelet reactivity during dual antiplatelet therapy.
Topics: Adenosine Diphosphate; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Cytochrome P450 Family 4; Epinephrine; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Thrombosis; Ticlopidine | 2014 |
Adenosine diphosphate-induced single-platelet count aggregation and bleeding in clopidogrel-treated patients undergoing coronary artery bypass grafting.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Anesthesia; Aspirin; Blood Transfusion; Chest Tubes; Clopidogrel; Confidence Intervals; Coronary Artery Bypass; Critical Care; Erythrocyte Count; Female; Humans; Linear Models; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Postoperative Hemorrhage; Prospective Studies; Risk Factors; Ticlopidine | 2014 |
Diagnostic accuracy of mean platelet volume in prediction of clopidogrel resistance in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Area Under Curve; Blood Platelets; Clopidogrel; Cohort Studies; Drug Resistance; Female; Humans; Male; Middle Aged; Platelet Aggregation; Predictive Value of Tests; Prospective Studies; Ticlopidine | 2014 |
The antidepressant 5-HT2A receptor antagonists pizotifen and cyproheptadine inhibit serotonin-enhanced platelet function.
Topics: Adenosine Diphosphate; Animals; Antidepressive Agents; Blotting, Western; Calcium; Carotid Artery Thrombosis; Clopidogrel; Cyproheptadine; Flow Cytometry; Hemorrhage; Humans; Immunoprecipitation; Indoles; Male; Mice; Mice, Inbred C57BL; Piperazines; Pizotyline; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Receptor, Serotonin, 5-HT2A; Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists; Ticlopidine | 2014 |
CES1A -816C as a genetic marker to predict greater platelet clopidogrel response in patients with percutaneous coronary intervention.
Topics: Adenosine Diphosphate; Aged; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cohort Studies; Cytochrome P-450 CYP2C19; Female; Genetic Markers; Genetic Variation; Genotype; Humans; Linear Models; Male; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Stents; Ticlopidine; Treatment Outcome | 2014 |
Association between the microarray-based CYP2C19 genotyping assay and the platelet function test in cardiovascular patients receiving clopidogrel.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Alleles; Asian People; Aspirin; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Gene Expression; Genotype; Humans; Isoenzymes; Microarray Analysis; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Receptors, Purinergic P2Y12; Ticlopidine | 2014 |
Point-of-care testing of clopidogrel-mediated platelet inhibition and risk for cardiovascular events after coronary angiography with or without percutaneous coronary intervention.
Topics: Adenosine Diphosphate; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Angiography; Female; Humans; Male; Middle Aged; Myocardial Infarction; Patient Readmission; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Point-of-Care Systems; Predictive Value of Tests; Prospective Studies; ROC Curve; Stents; Survival Analysis; Thrombosis; Ticlopidine | 2014 |
Thromboelastograph with Platelet Mapping(TM) predicts postoperative chest tube drainage in patients undergoing coronary artery bypass grafting.
Topics: Adenosine Diphosphate; Aged; Algorithms; Blood Transfusion; Body Mass Index; Chest Tubes; Clopidogrel; Coronary Artery Bypass; Drainage; Female; Humans; Logistic Models; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Point-of-Care Systems; Postoperative Hemorrhage; Predictive Value of Tests; Retrospective Studies; ROC Curve; Thrombelastography; Ticlopidine | 2014 |
Anti-platelet therapy with clopidogrel prevents endothelial dysfunction and vascular remodeling in aortas from hypertensive rats.
Topics: Adenosine Diphosphate; Animals; Aorta; Blood Pressure; Clopidogrel; Disease Models, Animal; Endothelium, Vascular; Gene Expression; Hypertension; Male; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Rats; Receptors, Purinergic P2Y; Thionucleotides; Ticlopidine; Vascular Remodeling; Vasoconstriction; Vasodilation | 2014 |
Does the VerifyNow P2Y12 assay overestimate "therapeutic response" to clopidogrel? Insights using short thrombelastography.
Topics: Adenosine Diphosphate; Alprostadil; Clopidogrel; Drug Synergism; Humans; Platelet Aggregation; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thrombelastography; Ticlopidine | 2014 |
Increased mean platelet volume is associated with non-responsiveness to clopidogrel.
Topics: Adenosine Diphosphate; Blood Platelets; Cells, Cultured; Clopidogrel; Coronary Artery Disease; Drug Resistance; Female; Humans; Male; Mean Platelet Volume; Middle Aged; Platelet Aggregation; Platelet Count; Platelet Function Tests; Ticlopidine | 2014 |
High on-treatment platelet reactivity in patients with ischemic cerebrovascular disease: assessment of prevalence and stability over time using four platelet function tests.
Topics: Adenosine Diphosphate; Aged; Aged, 80 and over; Blood Platelets; Cell Adhesion Molecules; Cells, Cultured; Clopidogrel; Female; Humans; Ischemic Attack, Transient; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Receptors, Purinergic P2Y12; Stroke; Ticlopidine; Time Factors | 2014 |
Human neutrophil α-defensins are associated with adenosine diphosphate-inducible neutrophil-platelet aggregate formation and response to clopidogrel in patients with atherosclerosis.
Topics: Adenosine Diphosphate; alpha-Defensins; Atherosclerosis; C-Reactive Protein; Clopidogrel; Flow Cytometry; Humans; Interleukin-6; Neutrophils; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticlopidine | 2014 |
Optimizing human apyrase to treat arterial thrombosis and limit reperfusion injury without increasing bleeding risk.
Topics: Adenosine Diphosphate; Animals; Apyrase; Clopidogrel; Coronary Circulation; Dogs; Fibrinolysis; Hemorrhage; Humans; Mice, Inbred C57BL; Myocardial Infarction; Myocardial Reperfusion Injury; Piperazines; Platelet Aggregation; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Thrombosis; Ticlopidine; Time Factors; Tissue Plasminogen Activator; Treatment Outcome; Vascular Patency | 2014 |
Evidence of platelet sensitization to ADP following discontinuation of clopidogrel therapy in patients with stable coronary artery disease.
Topics: Adenosine Diphosphate; Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticlopidine | 2015 |
Time-related changes in determinants of antiplatelet effect of clopidogrel in patients after myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Clopidogrel; Female; Follow-Up Studies; Humans; Male; Medication Adherence; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Ticlopidine; Time Factors | 2014 |
Detection of clopidogrel resistance using ADP induced aggregometry with specific inhibitor PGE1.
Topics: Adenosine Diphosphate; Adult; Aged; Alprostadil; Cardiovascular Diseases; Clopidogrel; Drug Resistance; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Ticlopidine; Treatment Outcome | 2014 |
Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Aryldialkylphosphatase; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Female; Genotype; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Ticlopidine | 2014 |
Discrepancies in assessment of adherence to antiplatelet treatment after myocardial infarction.
Topics: Adenosine Diphosphate; Clopidogrel; Female; Humans; Male; Medication Adherence; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticlopidine | 2015 |
Diversity of platelet function and genetic polymorphism in clopidogrel-treated Chinese patients.
Topics: Adenosine Diphosphate; Adult; Aged; Alleles; Blood Coagulation; Blood Platelets; China; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Female; Genotype; Humans; Ischemia; Logistic Models; Male; Middle Aged; Mutation; Percutaneous Coronary Intervention; Pharmacogenetics; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Precision Medicine; Receptors, Purinergic P2Y12; Recurrence; Thrombelastography; Ticlopidine | 2015 |
Effects of Paclitaxel on the Ability of Aspirin and Clopidogrel to Inhibit Platelet Aggregation.
Topics: Adenosine Diphosphate; Adult; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Male; Paclitaxel; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticlopidine; Young Adult | 2016 |
ABCB1 hypomethylation is associated with decreased antiplatelet effects of clopidogrel in Chinese ischemic stroke patients.
Topics: Adenosine Diphosphate; Adolescent; Adult; Aged; Asian People; ATP Binding Cassette Transporter, Subfamily B; Brain Ischemia; Clopidogrel; Cytochrome P-450 CYP2C19; DNA Methylation; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Promoter Regions, Genetic; Stroke; Ticlopidine; Young Adult | 2015 |
Calcium-Channel Blockers Attenuate the Antiplatelet Effect of Clopidogrel.
Topics: Adenosine Diphosphate; Aged; Angioplasty; Aspirin; Calcium Channel Blockers; Clopidogrel; Dihydropyridines; Drug Interactions; Female; Flow Cytometry; Humans; Male; Middle Aged; P-Selectin; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Ticlopidine | 2015 |
Management of a Patient with a Thoracic Epidural After Accidental Clopidogrel Administration.
Topics: Adenosine Diphosphate; Aged; Analgesia, Epidural; Catheters, Indwelling; Clopidogrel; Device Removal; Humans; Male; Medication Errors; Platelet Aggregation Inhibitors; Thoracotomy; Ticlopidine | 2015 |
Low platelet activity predicts 30 days mortality in patients undergoing heart surgery.
Topics: Adenosine Diphosphate; Aged; Aortic Valve; Arachidonic Acid; Area Under Curve; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Erythrocyte Transfusion; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Prognosis; Retrospective Studies; Risk Factors; Survival Analysis; Thrombosis; Ticlopidine; Treatment Outcome | 2016 |
Changes in platelet function independent of pharmacotherapy following coronary intervention in non-ST-elevation myocardial infarction patients.
Topics: 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Blood Platelets; Chromatography, Liquid; Clopidogrel; Electrodes; Female; Flow Cytometry; Humans; Luminescence; Male; Mass Spectrometry; Middle Aged; Myocardial Infarction; P-Selectin; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Tandem Mass Spectrometry; Ticlopidine | 2015 |
Advanced age and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
Topics: Adenosine; Adenosine Diphosphate; Age Factors; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Female; Humans; Male; Middle Aged; Odds Ratio; Patient Discharge; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prevalence; Thrombosis; Ticagrelor; Ticlopidine; Time Factors | 2016 |
Comparison of VerifyNow P2Y12 and thrombelastography for assessing clopidogrel response in stroke patients in China.
Topics: Adenosine Diphosphate; Aged; Brain Ischemia; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Stroke; Thrombelastography; Ticlopidine | 2016 |
The Antiplatelet Effect of Clopidogrel Decreases With Patient Age.
Topics: Adenosine Diphosphate; Age Factors; Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Flow Cytometry; Humans; P-Selectin; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Ticlopidine; Treatment Outcome | 2016 |
Dabigatran and rivaroxaban do not affect AA- and ADP-induced platelet aggregation in patients receiving concomitant platelet inhibitors.
Topics: Adenosine Diphosphate; Antithrombins; Arachidonic Acid; Clopidogrel; Dabigatran; Drug Therapy, Combination; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Rivaroxaban; Ticlopidine | 2016 |
Parathyroid Hormone Levels and High-Residual Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy With Acetylsalicylic Acid and Clopidogrel or Ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Databases, Factual; Drug Resistance; Drug Therapy, Combination; Female; Homeodomain Proteins; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Risk Factors; Ticagrelor; Ticlopidine; Time Factors; Transcription Factors; Treatment Outcome; Up-Regulation | 2016 |
Significant Improvement of Metabolic Characteristics and Bioactivities of Clopidogrel and Analogs by Selective Deuteration.
Topics: Adenosine Diphosphate; Animals; Clopidogrel; Hydrolysis; Male; Metabolic Networks and Pathways; Models, Molecular; Molecular Conformation; Phenylacetates; Platelet Aggregation; Platelet Aggregation Inhibitors; Rats; Thiophenes; Ticlopidine | 2016 |
Comparing Inverse Probability of Treatment Weighting and Instrumental Variable Methods for the Evaluation of Adenosine Diphosphate Receptor Inhibitors After Percutaneous Coronary Intervention.
Topics: Adenosine Diphosphate; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticlopidine; Treatment Outcome | 2016 |
Vitamin D levels and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
Topics: Adenosine; Adenosine Diphosphate; Aged; Aged, 80 and over; Biomarkers; Blood Platelets; Clopidogrel; Comorbidity; Coronary Angiography; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Odds Ratio; Platelet Activation; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine; Vitamin D | 2016 |
Activated platelets inhibit hepatocellular carcinoma cell differentiation and promote tumor progression via platelet-tumor cell binding.
Topics: Adenosine Diphosphate; Aged; Animals; Blood Platelets; Carcinogenesis; Carcinoma, Hepatocellular; Cell Differentiation; Clopidogrel; Female; Hep G2 Cells; Humans; Intercellular Junctions; Liver Neoplasms; Male; Mice; Mice, SCID; Middle Aged; P-Selectin; Platelet Activation; Protein Binding; RNA, Small Interfering; Ticlopidine; Transcription Factor 4; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2016 |
Platelet Activation and Clopidogrel Effects on ADP-Induced Platelet Activation in Cats with or without the A31P Mutation in MYBPC3.
Topics: Adenosine Diphosphate; Animals; Carrier Proteins; Cat Diseases; Cats; Clopidogrel; Gene Expression Regulation; Genetic Predisposition to Disease; Genotype; Mutation; Platelet Activation; Platelet Aggregation Inhibitors; Thrombosis; Ticlopidine | 2016 |
Head to Head Comparison of Two Point-of-care Platelet Function Tests Used for Assessment of On-clopidogrel Platelet Reactivity in Chinese Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention.
Topics: Adenosine Diphosphate; Aged; Aspirin; Blood Platelets; China; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Point-of-Care Systems; Receptors, Purinergic P2Y12; Thrombelastography; Ticlopidine | 2016 |
Underlying mechanism and specific prevention of hemolysis-induced platelet activation.
Topics: Adenosine Diphosphate; Adult; Aged; Apyrase; Blood Group Incompatibility; Blood Platelets; Clopidogrel; Female; Hemolysis; Humans; Male; Middle Aged; Platelet Activation; Platelet Glycoprotein GPIIb-IIIa Complex; Receptors, Purinergic P2Y12; Ticlopidine | 2017 |
Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients: Insights from the Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after
Topics: Adenosine; Adenosine Diphosphate; Aged; Cardiovascular Diseases; Clopidogrel; Drug Substitution; Female; Hemorrhage; Humans; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Patient Discharge; Patient Preference; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P1 Receptor Antagonists; Ticagrelor; Ticlopidine | 2017 |
High On-Treatment Platelet Reactivity to Adenosine Diphosphate Predicts Ischemic Events of Minor Stroke and Transient Ischemic Attack.
Topics: Adenosine Diphosphate; Adult; Aged; Aspirin; Blood Platelets; Brain Ischemia; Clopidogrel; Drug Resistance; Drug Therapy, Combination; Female; Humans; Ischemic Attack, Transient; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Aggregation Inhibitors; Predictive Value of Tests; Prospective Studies; Recurrence; Risk Factors; Stroke; Thrombelastography; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Impact of Test Conditions on ADP-Induced Platelet Function Results With the Multiplate Assay: Is Further Standardization Required?
Topics: Adenosine Diphosphate; Aged; Anticoagulants; Blood Platelets; Clopidogrel; Drug Monitoring; Drug Stability; Enoxaparin; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Prospective Studies; Purinergic P2Y Receptor Agonists; Purinergic P2Y Receptor Antagonists; Reproducibility of Results; Specimen Handling; Time Factors | 2018 |
Decreased platelet inhibition by P2Y12 receptor blockers in anaemia.
Topics: Adenosine; Adenosine Diphosphate; Aged; Anemia; Angioplasty; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Monocytes; P-Selectin; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Ticagrelor; Ticlopidine | 2018 |
Impact of Proton-pump Inhibitors on the Pharmacodynamic Effect and Clinical Outcomes in Patients Receiving Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: A Propensity Score Analysis.
Topics: Adenosine Diphosphate; Aged; Aspirin; Clopidogrel; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Proton Pump Inhibitors; Thrombelastography; Ticlopidine | 2017 |
Synthesis of a Novel Series of Amino Acid Prodrugs Based on Thienopyridine Scaffolds and Evaluation of Their Antiplatelet Activity.
Topics: Adenosine Diphosphate; Animals; Bleeding Time; Clopidogrel; Disease Models, Animal; Dose-Response Relationship, Drug; Male; Molecular Structure; Platelet Aggregation; Prasugrel Hydrochloride; Prodrugs; Rats; Thienopyridines; Ticlopidine | 2018 |
Leukocyte miR-223-3p is not associated with
altered platelet responses to clopidogrel in patients with coronary artery disease.
Topics: Adenosine Diphosphate; Blood Platelets; Clopidogrel; Coronary Artery Disease; Humans; Leukocytes; MicroRNAs; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticlopidine | 2018 |
Effect of Physical Exercise on Platelet Reactivity in Patients with Dual Antiplatelet Therapy.
Topics: Adenosine Diphosphate; Aspirin; Chromogranin A; Clopidogrel; Coronary Artery Disease; Electrocardiography; Exercise; Exercise Tolerance; Humans; P-Selectin; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Count; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Thrombosis; Ticlopidine | 2018 |
Comparison of factors affecting platelet reactivity in various platelet function tests.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Clopidogrel; Cross-Sectional Studies; Female; Humans; Male; Middle Aged; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Ticlopidine | 2019 |
Residual platelet reactivity is preferred over platelet inhibition rate in monitoring antiplatelet efficacy: insights using thrombelastography.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Thrombelastography | 2020 |
Ticagrelor and prasugrel are independent predictors of improved long-term survival in ACS patients.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Cardiovascular Diseases; Clopidogrel; Dual Anti-Platelet Therapy; Female; Humans; Male; Middle Aged; Mortality; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prognosis; Proportional Hazards Models; Prospective Studies; Secondary Prevention; Stroke; Survival Rate; Ticagrelor | 2020 |
Adenosine Diphosphate Receptor Inhibitors: Balancing Perioperative Bleeding and Protection From Adverse Coronary Events.
Topics: Adenosine Diphosphate; Clopidogrel; Hemorrhage; Humans; Purinergic P2Y Receptor Antagonists; Ticlopidine | 2021 |
Correlation Between the VerifyNow P2Y
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Blood Coagulation Tests; Blood Platelets; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests | 2020 |
Decreased Platelet Inhibition by Thienopyridines in Hyperuricemia.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty; Clopidogrel; Comorbidity; Cytochrome P-450 CYP2C9; Female; Genotype; Humans; Hyperuricemia; Male; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Stents; Thienopyridines; Ticagrelor; Ticlopidine; Uric Acid | 2021 |
Comparison of acetylsalicylic acid and clopidogrel non-responsiveness assessed by light transmittance aggregometry and PFA-100® in patients undergoing neuroendovascular procedures.
Topics: Adenosine Diphosphate; Aged; Alprostadil; Aspirin; Blood Coagulation Tests; Blood Platelets; Clopidogrel; Collagen; Epinephrine; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Reference Values; Reproducibility of Results; Stents; Technology Assessment, Biomedical; Thrombosis; Time Factors | 2020 |
Cilostazol increases adenosine plasma concentration in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Aged; Aspirin; China; Cilostazol; Clopidogrel; Cyclic AMP; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Function Tests | 2021 |
Elevated Serum Levels of Alkaline Phosphatase and the Risk of Low Responsiveness to Clopidogrel.
Topics: Adenosine Diphosphate; Aged; Alkaline Phosphatase; Aspirin; Clopidogrel; Dual Anti-Platelet Therapy; Female; Humans; Logistic Models; Male; Middle Aged; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thrombelastography; Treatment Outcome | 2020 |
Inhibitory Effects of P2Y12 Receptor Antagonist on PAR1- and PAR4-AP-Induced Platelet Aggregation in Patients with Stroke or TIA.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Adult; Aged; Aged, 80 and over; Blood Platelets; Case-Control Studies; Clopidogrel; Female; Humans; Ischemic Attack, Transient; Ischemic Stroke; Male; Middle Aged; Oligopeptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Treatment Outcome | 2021 |
Platelet aggregometry for hip fracture surgery in patients treated with clopidogrel: a pilot study.
Topics: Adenosine Diphosphate; Blood Platelets; Clopidogrel; Hip Fractures; Humans; Pilot Projects; Platelet Aggregation Inhibitors; Ticlopidine | 2022 |
Clinical validation of AggreGuide A-100 ADP, a novel assay for assessing the antiplatelet effect of oral P2Y
Topics: Adenosine; Adenosine Diphosphate; Blood Platelets; Clopidogrel; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2021 |
Being Overweight or Obese Is Associated with an Increased Platelet Reactivity Despite Dual Antiplatelet Therapy with Aspirin and Clopidogrel.
Topics: Adenosine; Adenosine Diphosphate; Aspirin; Blood Platelets; Clopidogrel; Humans; Obesity; Overweight; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticagrelor; Ticlopidine | 2023 |
Does thromboelastography predict bleeding in patients treated with clopidogrel or ticagrelor in off-pump coronary artery bypass grafting?
Topics: Adenosine Diphosphate; Adult; Aspirin; Clopidogrel; Coronary Artery Bypass; Humans; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Prospective Studies; Thrombelastography; Ticagrelor | 2022 |
A study of microRNA-223 in evaluating platelet reactivity in patients with acute ischemic stroke.
Topics: Adenosine Diphosphate; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Ischemic Stroke; MicroRNAs; Platelet Aggregation Inhibitors; Ticlopidine | 2022 |
Impact of the
Topics: Adenosine Diphosphate; Aspirin; Cardiovascular Diseases; China; Clopidogrel; Humans; Hyperglycemia; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Receptors, Cell Surface | 2022 |
Effectiveness of aspirin vs. clopidogrel in dogs with immune mediated haemolytic anaemia evaluated by serial thromboelastography and platelet mapping.
Topics: Adenosine Diphosphate; Anemia, Hemolytic, Autoimmune; Animals; Aspirin; Blood Platelets; Clopidogrel; Dog Diseases; Dogs; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Thrombelastography; Thromboxanes | 2022 |
Elevated serum C1q is an independent predictor of high residual platelet reactivity in CAD patients receiving clopidogrel therapy.
Topics: Adenosine; Adenosine Diphosphate; Clopidogrel; Complement C1q; Coronary Artery Disease; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Thrombosis; Ticagrelor; Ticlopidine | 2022 |
Time from blood draw to multiple electrode aggregometry and association with platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Blood Platelets; Clopidogrel; Cohort Studies; Electrodes; Female; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticlopidine | 2023 |
Ticagrelor versus Clopidogrel in the Dual Antiplatelet Regimen for Unruptured Intracranial Aneurysm Treated with Stent-Assisted Coil Embolization: A Single-Center Cohort Study.
Topics: Adenosine Diphosphate; Clopidogrel; Cohort Studies; Embolization, Therapeutic; Fibrinogen; Humans; Intracranial Aneurysm; Platelet Aggregation Inhibitors; Stents; Ticagrelor; Treatment Outcome | 2023 |